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ABSTRACT

DEVELOPMENT OF BINARY COMPOSITE SOLID MICROPARTICLES
FOR IMPROVED INTRANASAL ABSORPTION OF LOW PERMEATION
DRUG MOLECULES

By
Dipy M. Vasa
May 2017

Dissertation supervised by: Peter L.D. Wildfong, Ph.D.
The objective of this work was to introduce a novel formulation strategy for
intranasal

delivery of

two

low

permeation

candidates:

levodopa

(L-DOPA;

antiparkinsonism drug) and ribavirin (RBVN; an antiviral drug). The central hypothesis
states that preparation of binary composite microparticles with Pluronic® triblock
copolymers (polyethylene glycol-polypropylene glycol-polyethylene glycol) should allow
increased drug transport across nasal mucosal tissue relative to drug alone. Testing the
hypothesis necessitated execution of specific aims directed to addressing issues inherent
to the proposed approach. The work herein is presented with respect to two separate
subjects: (1) material understanding and (2) formulation development. In the first two
chapters, the feasibility of direct deposition of dry, solid drug microparticles on intranasal

iv

permeation was explored. Further, specific emphasis was placed on selection of the most
suitable solid form which can sustain the stresses of the chosen manufacturing processes.
The concluding part of this work is devoted to illustrating the use of binary
composite polymeric microparticles, ultimately stemming from the materials and
methodologies developed in the initial stages. The rate and extent of ribavirin transport
was significantly higher from solid polymeric microparticles compared to standalone
drug powder and its aqueous solution. Increased drug transport was attributable to
permeation enhancement afforded by Pluronic® accompanied with a high initial
concentration gradient established across the model tissue.

v

FOR MUMMA AND PAPA

vi

ACKNOWLEDGEMENT

Imagine being 21 and confronted with the toughest decision of your life – move
half way across the world to pursue the dream of doctoral studies at the cost of leaving
behind family, friends and familiarity. That was me seven years ago….When I set foot on
this adventurous journey and came to Duquesne University, I did not have the faintest
idea of the challenges ahead. Navigating through the success and failure in graduate
school while grappling with the responsibilities of adulthood was difficult, at best.
Fortunately, I was surrounded by many influential individuals who helped me get through
the various stages of graduate school. I want to take this opportunity to acknowledge
them for their phenomenal contribution.
I express sincere gratitude:
To my advisor - Dr. Peter L.D. Wildfong. Without his vision and unwavering
trust, this dissertation would not have been possible. He took me under his wings and
mentored me every step of way. Whatever I am today in terms of a researcher, presenter
or author; is all attributed to his efforts and undivided attention towards his students. He
always maintained a collaborative environment in the lab where I could share my
research ideas and opinions without hesitation. Thank you for all your help and guidance
through these years.
To my co-advisor - Dr. Ira S. Buckner. His extensive feedback, astute observation
and critical assessment were integral to my growth as a scientist. I am also thankful to
him for giving a strong foundation of physical pharmacy, which has been truly helpful in
my professional endeavors.
To my dissertation committee members - Drs. Wilson Meng, Lauren O’Donnell
and Maureen Donovan; for the genuine interest in my research. The support, external
conversations and inputs provided by them have been valuable.

vii

To the faculty of Pharmaceutics discipline – Drs. James K. Drennen III, Carl
Anderson, Jelena Janjic, Lawrence Block, Robert Stratford and Devika Maneckam for
sharing their knowledge and wisdom through the diverse coursework and milestone
evaluations.
To the funding provided by Hunkele Dreaded Disease Award, BoehringerIngelheim and the National Institute for Pharmaceutical Technology and Education for
making a large portion of my work possible.
To my colleague Kevin DeBoyace. I am constantly inspired by his hard work,
focus and determination. He brought good energy and positive attitude to the lab, which
was truly vital to my success.
To the members of Buckner lab – Drs. Namita Dalal, Rahul Roopwani, Jeffrey
Katz and Akshata Nevrekar for helping me develop analytical skills. The technical
discussions during the group meetings have been instrumental to this work.
To the AAPS Duquesne University Student Chapter, especially, Sravan Patel,
Anik Alam, and Shikhar Mohan. Thank you for the numerous scientifically stimulating
conversations and valuable input during mock seminar and ORP sessions.
To my fellow graduate students – Mayur, Ravi, Priya, Negin, Christina, Khushbu,
Shruti for the lifelong friendship.
To my dear friend Apurva for accepting my eccentricities and allowing me to
freely express my emotions. He was a constant support through all the highs and lows,
both professionally and personally.
To my parents and family for all the sacrifices that have made to ensure that I
complete this journey. This would not have been possible without their motivation, care
and love.
To my husband, Anil, who truly represents my “better half”. He is my biggest
source of strength, stability and sanity. Every day, I strive to mirror his benevolence but I
know it a long way to go…
viii

TABLE OF CONTENTS
Page
Abstract .............................................................................................................................. iv
Dedication .......................................................................................................................... vi
Acknowledgement ............................................................................................................ vii
List of Tables .....................................................................................................................xv
List of Figures .................................................................................................................. xvi
List of Abbreviations ...................................................................................................... xxii
Chapter 1: Introduction…………………………………………………………………1
1.1. Statement of Problem……………………………………………………………..1
1.2. Hypothesis and Research objectives……………………………………………...5
1.3. Nasal cavity……………………………………………………………………….6
1.3.1. Respiratory region…………………………………………………………7
1.3.2. Olfactory region…………………………………………………………...8
1.3.3. Evidence of nose-to-CNS pathway………………………………………10
1.4. Factors influencing nasal absorption……………………………………………11
1.4.1. Physiological considerations……………………………………………..11
1.4.1.1. Targeted deposition………………………………………………….11
1.4.1.2. Mucociliary clearance……………………………………………….12
1.4.1.3. Enzymatic degradation………………………………………………14
1.4.1.4. Nasal permeation……………...…………………………………….15
1.4.2. Formulation / Dosage form considerations………………………………16
1.4.2.1. Nasal drops and sprays………………………………………………16

ix

1.4.2.2. Nasal powders……………………………………………………….17
1.4.2.3. Physical properties…………………………………………………..19
1.4.2.4. Mucoadhesives………………………………………………………21
1.4.2.5. Permeation Enhancers……………………………………………….23
1.4.3. Delivery device considerations………………………………..…………25
1.5. Chemical profiles………………………………………………………………..30
1.5.1. Levodopa…………………………………………………………………30
1.5.2. Ribavirin…………………………………………………………………33
1.5.3. Poloxamers……………………………………………………………...36
1.6. Summary………………………………………………………………………...39
1.7. Acknowledgments……………………………………………………………….39
Chapter 2: Improved flux of levodopa via direct deposition of solid microparticles
on nasal tissue ………………………………………………………………………….40
2.1. Introduction…………………………………………………………...…………40
2.2. Experimental Section……………………………………………………………42
2.2.1. Chemicals and Reagents…………………………………………………..42
2.2.2. L-DOPA solid microparticles……………………………………………..43
2.2.2.1. Solid-state characterization…………………………………………43
2.2.2.2. Particle Size analysis………………………………………………..44
2.2.3. L-DOPA solution…………………………………………………………44
2.2.3.1. Assessment of chemical stability……………………………………44
2.2.3.2. Measurement of L-DOPA saturation solubility…………………….45
2.2.4. L-DOPA Transport in Nasal Mucosa……………………………………..46
2.3. Results and Discussion………………………………………………………….48

x

2.3.1. L-DOPA Solid…………………………………………………………….48
2.3.2. L-DOPA Solution…………………………………………………………53
2.3.3. L-DOPA transport studies…………………………………………………56
2.4. Conclusion………………………………………………………………………62
2.5. Acknowledgments…………………………………………………..……………….63
Chapter 3: Solid-state transformations of ribavirin as a result of high shear
mechanical processing………………………………………………………………….64
3.1. Introduction…………………………….………………………………..………64
3.2. Materials and Methods…...……………………………………………………..67
3.2.1. Recrystallization of Ribavirin Polymorphs………………………………..67
3.2.2. Generation of Amorphous Ribavirin……………………………………...68
3.2.3. Isothermal heating experiments…………………………………………...68
3.2.4. Milling experiments…………………………………….…………………68
3.2.5. Influence of storage conditions……………………………………………69
3.2.6. Characterization…………………………………………………………..70
3.2.6.1. Thermogravimetric Analysis (TGA)………………………………...70
3.2.6.2. Differential Scanning Calorimetry (DSC)…………………………..70
3.2.6.3. X-ray powder diffraction (PXRD)…………………………………..71
3.2.6.4. Solution Calorimetry………………………………………………...72
3.2.6.5. Measurement of aqueous solubility…………………………………72
3.2.6.6. Surface area determination (BET)…………………………………..73
3.2.6.7. High performance liquid chromatography (HPLC)…………………73
3.3. Results and Discussion………………………………………………………….74
3.3.1. Physical characterization of ribavirin polymorphs……………………….74

xi

3.3.2. Estimation of transition temperature (Ttr) and enthalpy (ΔHtr)…………..79
3.3.3. Exposure of R-II to T > Ttr..........................................................................84
3.3.4. Exposure of R-II to high-shear mechanical energy……………………….85
3.3.5. Recrystallization and kinetic irreversibility……………………………….97
3.4. Conclusion..……………………………………………………………………..98
3.5. Acknowledgments..…………………………………………………………….100
Chapter 4: Preparation, characterization and evaluation of ribavirin loaded
polymer microparticles for intranasal uptake………………………………………101
4.1. Introduction…………………………………………………………………….101
4.2. Experimental Section…………………………………………………………..104
4.2.1. Determination of RBVN solubility in POX188…………………………..104
4.2.2. Preparation of binary composite microparticles…………………………..105
4.2.3. Characterization…………………………………………………………....106
4.2.3.1. Ribavirin solid phase purity…………………………………………..106
4.2.3.2. Assessment of Particle properties……………………………………..107
4.2.3.3. Microparticle Drug content and Content uniformity………….……..108
4.2.4. Evaluation of Microparticle Performance………………………………….109
4.2.4.1. in vitro Drug Release…………………………………………………..109
4.2.4.2. in vitro Nasal Cell Toxicity……………………………………………110
4.2.4.3. in vitro Permeation Measurements……………………………………111
4.3. Results and Discussion…………………………………………..……………112
4.3.1. Preparation of Binary composite microparticles…………….…………….112
4.3.2. Characterization of Microparticles………………………….…………….117
4.3.2.1. Solid state properties…………………………………….……………117

xii

4.3.2.2. Particle properties……………………………………………………..119
4.3.2.3. Drug content and uniformity………………………………………….121
4.3.3. Evaluation of formulation…………………………………………………122
4.3.3.1. in vitro Drug Release…………………………………………………..122
4.3.3.2. in vitro Cytotoxicity……………………………………………………125
4.3.3.3. in vitro Permeation…………………………………………………….129
4.4. Conclusion……………………………………………………………………..136
Chapter 5: Summary…………………………………………………………………137
Appendix A: Physical characterization of drug and polymer dispersion behavior in
PEG 4000 solid dispersions using a suite of complementary analytical
techniques……………………………………………………………………………...140
A.1. Introduction……………………………………………………………………140
A.2. Materials and Methods…...……………………………………………………142
A.2.1. Materials….……………………………………………………………...142
A.2.2. Co-solidification of API:PEG4000 Mixtures …………………………...144
A.2.3. Differential Scanning Calorimetry (DSC)………………………….…...145
A.2.4. Optical Hot Stage Microscopy (HSM)…..…….………………………..146
A.2.5. Powder X-ray Diffraction (PXRD)……………………………………...146
A.2.6. Pair Distribution Function (PDF) analyses of PXRD data ……………..147
A.3. Results and Discussion…..….…………………………………………………149
A.3.1. API:PEG4000 library …………………………………………………...149
A.3.2. Inferences from PXRD data….………………………………………….149
A.3.3. Inferences from PDF-transformed PXRD data………………………….154
A.3.4. Inferences from DSC data ………………………………………………158

xiii

A.3.5. Inferences from HSM data ……………………………………………...162
A.3.6. Combined inferences from physicochemical characterization suite….....169
A.4. Conclusion..…………………………………………………………………...173
A.5. Acknowledgments..……………………………………………………………174
Bibliography…………………………………………………………………………...175

xiv

LIST OF TABLES
Page
Table 1.1. Drugs used in nose-to-CNS drug transport studies in man…………….11
Table 1.2. Pathological conditions and their impact in nasal mucociliary clearance..13
Table 1.3: Comparison of liquid and powder formulations for nasal deposition and
clearance……………………………………………………………………………..19
Table 2.1. Particle size distribution of L-DOPA determined by sieve analysis…….50
Table 2.2. Pseudo 1st order rate constants for degradation of L-DOPA in solution...54
Table 2.3. Comparison of average in vitro nasal epithelial flux of L-DOPA from
aqueous solution and solid microparticles………………………………………...…57
Table 3.1. Summary of crystallographic and thermal properties of ribavirin solid
forms…..……………………………………………………………………………..78
Table 3.2. Comparison of full width half maximum (FWHM) between diffraction
patterns of R-II as a function of milling time in vibratory impact ball mill…………87
Table 4.1. Properties of BCM prepared using 2x2 full factorial design of experiments
(DoE) with % w/w drug loading (as factor 1) and milling time (as factor 2)………116
Table A.1. Molecular structures for model drugs and polymer used in this study...143
Table A.2. Summary of PXRD analyses. Cambridge Structural Database (CSD)
reference codes for each API are indicated parenthetically below the compound name.
CSD structures were used to identify diffraction peaks for crystalline API in
API:polymer mixtures……………………………………………………………...151
Table A.3. Summary of PDF analyses. R-values were minimized by artificially
scaling API:polymer w/w concentrations used to generate theoretical PDF………156
Table A.4. Summary of DSC analyses…………………………………………….163
Table A.5. Summary of inferences from individual techniques compared with
inferences made by collective consideration of all techniques (Combined
Inference)…………………………………………………………………………...170

xv

LIST OF FIGURES
Page
Figure 1.1. Schematic representation of the lateral wall of the human nasal cavity.
The boxed region delineates the olfactory region……………………………………7
Figure 1.2. Anatomical representation of olfactory epithelium. Yellow dashed line (---) indicates the paracellular pathway, purple dashed line (---) indicates the
transcellular pathway and the red dashed line (---) represents the transneuronal
pathway……………………………………………………………………………….9
Figure 1.3. Tres for each formulation averaged over the whole test group. Error bars
represent the S.E.M., n = 12. There was no statistical difference between the average
Tres values for each polymer formulation. Reprinted from European Journal of
Pharmaceutical Sciences, 30, S. Charlton, N.S. Jones, S.S. Davis, L. Illum,
Distribution and clearance of bioadhesive formulations from the olfactory region in
man: Effect of polymer type and nasal delivery device, pp:295-302, Copyright 2007,
with permission from Elsevier………………………………………………………22
Figure 1.4. Gamma camera image information from the nasal cavity is superimposed
on the corresponding sagittal MRI section. The images are from the same subject and
present deposition 2 min after delivery using (a) a traditional liquid spray, (b) the
breath-powered Opti-Nose™ powder device, and (c) the breath-powered Opti-Mist™
liquid spray device incorporating the same spray pump as used in a. The initial
deposition following traditional spray was greatest in the lower anterior regions of the
nose, whereas deposition with the breath-powered delivery devices was greatest in the
upper posterior regions of the nose. The less broad distribution in b following breathpowered Opti-Nose™ powder device is believed to be due to the slower clearance for
powder the first 6–8 min, reflecting the dissolution of the powder into the mucosal
layer.23………………………………………………………………………………..28
Figure 1.5. Chemical reaction showing (a) conversion of L-DOPA to dopamine (b)
oxidation of L-DOPA to L-dopaquinone and (c) zwitterionic nature of L-DOPA
between pH of 3 to 9.107……………………………………………………………..30
Figure 1.6. Time courses of plasma and brain l-dopa concentrations following
intranasal administration of l-dopa (2.5 mg/kg) in the presence and absence of C-dopa
(0.63 mg/kg) (mean ± SD, n = 6). Reprinted from European Journal of
Pharmaceutical Sciences, 38, Tae Kyung Kim, Wonku Kang, In Koo Chun, Seaung
Youl Oh, Yeon Hong Lee, Hye Sun Gwak, Pharmacokinetic evaluation and modeling
of formulated levodopa intranasal delivery systems, pp:525-523, Copyright 2009,
with permission from Elsevier………………………………………………………32
Figure 1.7. Chemical structure of Ribavirin………………………………………...33

xvi

Figure 1.8. (a) Ribavirin brain concentrations after in vivo nasal administration of an
aqueous solution (white bars) versus intravenous injection (gray bars). (b) Ribavirin
brain concentrations after in vivo nasal administration of an aqueous solution (white
bars) versus ribavirin powder (black bars). The measured values were normalized by
the dose administered. OB: olfactory bulb; CTX Ant and CTX Post: anterior and
posterior cerebral cortex; BG: basal ganglia; Hip: hippocampus; CSF: Cerebrospinal
fluid. Reprinted from Antiviral Research, 92(3), Gaia Colombo, Luca Lorenzini,
Elisa Zironi, Viola Galligioni, Fabio Sonvico, Anna Giulia Balducci, Giampiero
Pagliuca, Alessandro Giuliani, Laura Calzà, Alessandra Scagliarini, Brain
distribution of ribavirin after intranasal administration, pp: 408–414, Copyright 2011,
with permission from Elsevier………………………………………………………35
Figure 1.9. General chemical structure of Poloxamers®…………………………….36
Figure 1.10. in vivo mucociliary transit time recorded for curcumin loaded in aqueous
solution and poloxamer containing hydrogel. Reprinted from Journal of Pharmacy
and Pharmacology, 65, Xi Chen, Feng Zhi, Xuefeng Jia, Xiang Zhang, Rohan
Ambardekar, Zhengjie Meng, Anant R. Paradkar, Yiqiao Hu, Yilin Yang, Enhanced
brain targeting of curcumin by intranasal administration of a thermosensitive
poloxamer hydrogel, pp:807-816, Copyright 2013, with permission from John Wiley
and Sons……………………………………………………………………………..37
Figure 2.1. Experimental PXRD pattern for vendor-supplied L-DOPA powder (black
solid line) is compared with simulated diffraction pattern (ICDD reference code:
LDOPAS03 grey solid line). The data indicate that the powder sample is comprised
of a single phase solid form…………………………………………………………49
Figure 2.2. Experimental DSC thermogram of L-DOPA (solid line) showing Tm =
276.6 oC. Post-melting baseline is indicative of rapid thermal degradation.
Superimposed TGA thermogram (dashed line) represents 12.90% weight loss
beginning immediately at Td, confirming degradation at T>Tm……………………..50
Figure 2.3. (a) Micrograph depicting morphology of L-DOPA primary particles
immersed in oil, observed through a 25× objective; (b,c) typical micrographs used to
measure Feret diameter (n = 300); (d) particle size distribution of primary particles
observed in (b and c)………………………………………………………………...52
Figure 2.4. Effect of temperature and presence of antioxidant on the concentration of
L-DOPA in aqueous solution. Data are shown as mean + SD. Bonferroni multiple
comparison (α = 0.05) between groups is shown to denote the extent of loss in LDOPA concentration on day 7. The rate constants for degradation are summarized in
Table 2.2…………………………………………………………………………......53
Figure 2.5. Saturation solubility of L-DOPA microparticles. Closed grey squares (■)
and closed black circles (●) represent solubility profile at 25° and 37°C, respectively.

xvii

In 12 h, the measured saturation concentration (Cs) of L-DOPA was almost 1.6 times
higher at 37°C (p <0.001, Student’s t-test)………………………………………….55
Figure 2.6. in vitro permeation profiles of L-DOPA across bovine olfactory mucosa
from an aqueous solution (empty circles, n = 3) and solid particles (filled
circles, n = 2). (a) Data are expressed as cumulative L-DOPA permeated with time
(mean ± SD). The solid connecting line represents the initial steady-state portion that
was chosen to calculate Jss according to Eq. 1; (b) data normalized with respect to
initially loaded mass of L-DOPA i.e., 0.75 mg in 1 mL donor solution and 1.5 mg as
solid microparticles………………………………………………………………….58
Figure 2.7. Schematic representation of the L-DOPA permeation of nasal epithelial
cells. Green closed circles represent directly deposited L-DOPA microparticles on the
donor side of tissue, which saturate the mucus layer (Cs = 2.77 mg/mL). This
contrasts the dark blue shaded region denoting L-DOPA solution contact with the
mucus layer at a constant concentration throughout the entire donor chamber (0.75
mg/mL). As depicted, saturation of the mucus layer by L-DOPA dissolved from solid
microparticles results in a much higher steady-state concentration gradient that
explains the 3-fold increase in flux relative to L-DOPA solution experiments……..61
Figure 3.1. The experimental PXRD pattern for vendor-supplied ribavirin powder RRW (red) is compared with recrystallized ribavirin R-I (green) and recrystallized
ribavirin R-II (blue). Simulated diffraction patterns for R-I (CSD reference code:
VIRAZL, in grey) and R-II (CSD reference code: VIRAZL01, in black) are also
provided. The data indicate that R-RW corresponded entirely with the R-II pattern,
and did not contain discernable quantities of R-I……………………………………75
Figure 3.2. Comparison of DSC thermograms of R-RW (red) with recrystallized
phase pure samples of R-I (green) and R-II (blue). R-RW melted at 166 °C consistent
with R-II (Tm = 168.1 + 0.7 °C) followed by recrystallization and subsequent melting
at 174 °C, consistent with R-I (Tm = 177.4 + 0.2 °C). The superimposed TGA
thermogram (dashed line) shows no weight loss until approximately Tm R-I + 30 °C,
confirming that both solid forms of ribavirin were thermally stable, and essentially
devoid of residual solvent……………………………………………………………77
Figure 3.3. (a) Reversible heat capacity as a function of temperature for crystalline
forms of ribavirin; R-II in blue and R-I in green, respectively. Amorphous ribavirin is
shown in black. (b) Configurational heat capacity for R-I and R-II shown in green and
blue respectively………………………………………………………………….….80
Figure 3.4. Configurational free energy (Gc) phase diagram for ribavirin polymorphs.
Gc of R-I is denoted by green dashed line and of R-II is denoted by blue solid line.
Intersection (T = 341.6 K) represents Ttr = 68.4 oC…………………………………81

xviii

Figure 3.5. Aqueous saturation solubility of ribavirin polymorphs. Closed green
circles (●) and open blue circles (○) represent solubility profile of R-I and R-II,
respectively. Data are represented as mean + standard deviation, n = 3…………..83
Figure 3.6. PXRD patterns of R-II milled for various time intervals in a vibratory
impact ball mill. Note: Eventual conversion from R-II to R-I at 270 min of milling..86
Figure 3.7. (a) DSC thermogram of R-II milled for 60 min a vibratory impact ball
mill is compared with the untreated polymorph samples. The dotted circle highlights
the endotherm associated with R-II to R-I transition in situ (See inset). (b) DSC
thermograms of 60 min milled R-II, recorded at various heating rates……………...89
Figure 3.8. DSC thermograms of 270 min milled R-II measured at different heating
rates. Complete R-II R-I conversion can be seen based on the single melting
endotherm attributable to high Tm enantiotrope (R-I). DSC data recorded at 2 and 20
°C/min are not shown………………………………………………………………..92
Figure 3.9. (a) PXRD patterns of R-II milled for various time intervals in a cryogenic
impact mill. Note the halo pattern following 120 min cryomilling, suggestive of
complete loss of lattice periodicity (b) DSC thermogram of R-II milled for 60 and 120
min a cryogenic impact mill is compared with the unprocessed starting material (i.e.
R-II). The inset shows observed glass transition of ribavirin after 120 min of
cryomilling, confirming transformation to persistent amorphous ribavirin. Data was
recorded at 20 °C/min………………………………………………………………..94
Figure 3.10. Schematic representation of solid state transformation in R-II……....100
Figure 4.1. (a) DSC thermograms of physical mixtures of RBVN and POX188 in
varying proportions of polymer measured at the heating rate of 2 °C/min. (b)
Extrapolated onset of melting plotted as a function of polymer composition…….114
Figure 4.2. Schematic representation of RBVN : POX188 (1:1) binary composite
preparation…………………………………………………………………………115
Figure 4.3. PXRD patterns of 1 : 1 RBVN and POX188 product as it progresses
through the different stages of manufacturing scheme, PM – physical mixture, SS –
solid suspension post cooling in ice water, BCM – Binary composite microparticles
after sieve fractionation. PXRD patterns of pure components are provided for
comparison…………………………………………………………………………117
Figure 4.4. DSC thermograms of pure RBVN, pure POX188 and the milled + sieve
fractionated composite microparticle drug product at 2 °C/min heating rate………119

xix

Figure 4.5. (a and b) Micrograph depicting particle size distribution of 1:1 RBVN :
POX188 binary composite microparticles. The particles were not immersed in oil,
observed through a 10× objective. These micrographs were used to measure Feret
diameter (n = 300) particles; (c) particle size distribution of primary particles
observed in (a and b)……………………………………………………………….120
Figure 4.6. Scanning electron micrographs: (A) unprocessed ribavirin, (B) poloxamer
188 and (C) 1:1 (w/w) milled + sieved fractionated composite microparticles……121
Figure 4.7. The apparent cumulative RBVN release from standalone solid drug
particles (black circles) and binary composite microparticles (grey circles)………124
Figure 4.8. Cytotoxicity assay using CellTiter Glo® reagent (reported as mean ± SD,
n ≥ 3): RPMI 2650 cells were incubated with varying concentrations of POX188
only, RBVN only and RBVN: POX188 (1:1) mixture for 24 h at 37 °C and 5%
CO2 humidified atmosphere. 2 mg/mL stock solutions prepared in high-grade sterile
water was sterile filtered and serially diluted with media to generate the spectrum of
concentrations used here. For 1:1 physical mixtures, appropriate dose adjustment was
done (i.e. 4 mg/mL stock) was prepared to obtain concentrations upon dilution that
are comparable to the other test groups. Statistical differences within the same group
are denoted as; **P < 0.01; ***P < 0.001 and between groups are denoted as #P <
0.05…………………………………………………………………………………127
Figure 4.9. (a) A representation of permeation barrier produced with RPMI 2650
nasal cell line uniformily grown at an air-liquid interface within the cell inserts.
Reprinted from International Journal of Pharmaceutics, 515, Vanessa S.S. Gonçalves,
Ana A. Matias, Joana Poejo, Ana T. Serra, Catarina M.M. Duarte, Application of
RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of
drugs, pp:1-10, Copyright 2016, with permission from Elsevier. (b) A microscopic
image of RPMI 2650 cells growing as clusters on the inserts, as observed on day 10
from the day of seeding. Media was changed on the basolateral side every 48 hours.
Reprinted from Journal of Pharmaceutical Sciences, 97, Shuhua Bai, Tianzhi Yang,
Thomas J. Abbruscato, Fakhrul Ahsan, Evaluation of human nasal RPMI 2650 cells
grown at an air–liquid interface as a model for nasal drug transport studies, pp:11651178, Copyright 2008, with permission from Elsevier……………………………129
Figure 4.10. in vitro permeation profile of RBVN across bovine olfactory tissue,
when loaded as aqueous solution. Data are expressed as mean + SD, n=3. The dashed
line denoted steady state region……………………………………………………130
Figure 4.11. in vitro permeation profiles of RBVN across bovine olfactory tissue
when loaded as pure component drug particles (open diamonds) and 1:1 RBVN :
POX188 composite microparticles (closed diamonds). Data are expressed as mean +
SD, n = 3…………………………………………………………………………...132

xx

Figure 4.12. Schematic representation of RBVN (blue closed circles) transport across
the olfactory epithelium……………………………………………………………135
Figure A.1. Overlay of PXRD patterns. (a) Pure ibuprofen (IBPRAC01) is indicated
in blue; co-solidified 3:1 w/w ibuprofen:PEG4000 is shown in black; pure PEG4000
is shown in red. Select characteristic diffraction peaks attributable to API and
polymer are indicated as blue stars and red closed circles, respectively. (b) Pure
cimetidine (CIMETD) is indicated in blue; co-solidified 3:1 w/w
cimetidine:PEG4000 is shown in black; pure PEG4000 is shown in red.
Characteristic diffraction from neither drug nor polymer was observed, suggesting no
crystalline content………………………………………………………………….152
Figure A.2a and A.2b. PDF analysis of 3:1 w/w co-solidified cimetidine:PEG4000
sample (as labeled).…………………………………………………………………157
Figure A.3. Initial room temperature polarized light microscopy images of cosolidified 3:1 w/w samples containing PEG4000 and (a) chlorpropamide (b)
cimetidine (c) cloperastine·HCl (d) griseofulvin (e) ibuprofen (f) indomethacin (g)
itraconazole (h) ketoconazole (i) melatonin (j) nifedipine (k) propranolol·HCl (l)
quinidine (m) sulfanilamide (n) terfenadine (o) tolbutamide. Image (p) represents
only PEG4000 at room temperature. All scale bars (in yellow) correspond to 50
µm………………………………………………………………………………….159
Figure A.4. Overlay of DSC thermograms. Pure ibuprofen is indicated in blue, cosolidified 3:1 w/w ibuprofen:PEG4000 is shown in black; pure PEG4000 is shown in
red. No Tg was observed; only melt endotherms consistent with Tm,p and
Tm,API……………………………………………………………………………….164
Figure A.5. Overlay of Tg regions in DSC thermograms from top to bottom: Pure
cimetidine (in blue), co-solidified 3:1 w/w cimetidine:PEG4000 (in black) and pure
PEG4000 (in red). A single Tg was measured for the mixture, which fell intermediate
to Tg,p and Tg,API……………………………………………………………………165
Figure A.6. Overlay of Tg regions in DSC thermograms from top to bottom: Pure
terfenadine (in blue), co-solidified 3:1 w/w terfenadine:PEG4000 (in black) and pure
PEG4000 (in red). Panel a) a single Tg was measured for the mixture (-28.16oC in this
replicate; mean -30.79oC; n=2), which fell intermediate to Tg,p and Tg,API. Panel b)
two Tg values were measured (7.96oC and 61.32oC) indicating plasticization and
antiplasticization, respectively for Tg,API and Tg,p…………………………………..169

xxi

LIST OF ABBREVIATIONS

API

Active pharmaceutical ingredients

BBB

Blood-Brain Barrier

BCRP

Breast Cancer Resistant Proteins

BCS

Biopharmaceutics Classification System

BET

Brunauer, Emmett and Teller

CM

Cryogenic milling

CNS

Central Nervous System

CSF

Cerebrospinal Fluid

DSC

Differential Scanning Calorimetry

FDA

Food and Drug Administration

HSM

Hot-stage Polarized-light microscopy

IC

Intracranial

IM

Intramuscular

IN

Intranasal

IV

Intravenous

L-DOPA

Levodopa

MRP

Multidrug Resistance-associated Protein

NCE

New Chemical Entity

PDF

Pair distribution function

PEG4000

Polyethylene glycol 4000

POX188

Poloxamer 188

xxii

PSD

Particle Size Distribution

PXRD

Powder X-ray Diffraction

RBVN

Ribavirin

SEM

Scanning Electron Microscope

TGA

Thermogravimetric Analysis

VM

Vibratory impact Milling

WHO

World Health Organization

xxiii

Chapter 1: Introduction
1.1. Introduction
The selectively permeable nature of the blood-brain barrier (BBB) presents a
considerable challenge for effective delivery of drug molecules to the central nervous
system (CNS). According to one estimate, < 2% of all small molecules and virtually no
large molecules reach the CNS after systemic administration.1 Several potential neurotherapeutic drug candidates that are efficacious in vitro fail during the clinical phase
owing to the inability to enter the CNS. In general, the BBB limits substrate transport
based on lipophilicity, molecular size, and specificity for a variety of ATP-dependent
transport systems. Although there is a positive correlation between lipophilicity and the
BBB permeability,2 many of these substrates and their metabolites are removed almost
instantly by the efflux transporters (such as P-glycoprotein; P-gp) expressed in the
endothelial cells of the BBB. In addition to Pgp, the ATP binding cassette transporters of
the multidrug resistance protein (MRP) family and the breast cancer resistance protein
(BCRP) have a role in central drug uptake.3-5
Early assessment of the ability of a drug candidate to cross the BBB is critical.
Over the past several years, academia and industry have invested significant effort in the
development and optimization of screening procedures, including in vitro assays and
computational models to evaluate CNS penetration. This information can be used to
discover new chemical entities (NCEs) amenable to BBB transport, however, the
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financial burden that it puts on a pharmaceutical company often questions the feasibility
of this seemingly straightforward choice. The decline of “blockbuster” drug development
over the last decade further echoes the increasing need for exploring alternate routes of
administration and/or innovative formulations to effectively deliver extant therapeutic
molecules to the brain.
A key focus of intranasal (IN) drug delivery research is to afford direct entry of
drug molecules into the CNS using the unique anatomy and physiology of the nasal
cavity.6-10 The olfactory bulb is the only region of the CNS in direct contact with the
nasal cavity, which potentially allows molecules to bypass the BBB. Additionally, IN
delivery offers avoidance of first-pass hepatic metabolism along with local intestinal
metabolism/toxicity/efflux/degradation. Recent patents detailing IN delivery for the
treatment of Parkinson’s disease, multiple sclerosis, Alzheimer’s disease,11-14 dementia15
and migraine16 support ongoing interest in this route of administration. Large biomolecules, including cytokines and growth factors,17 have also shown promise for CNS
entry through IN administration. From a quantitative standpoint, however, IN
administration has shown relatively poor accumulation of drug in the CNS.6,18,19
According to recent reports, the average fraction of nasally administered dose that
reached the CNS was < 1 %.20,21,22 This is primarily attributed to (1) inadequate drug
deposition in the desired region of the nasal cavity which facilitates direct CNS access
i.e., the olfactory region and (2) rapid removal of drug from the site of deposition via
mucociliary clearance.
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Optimizing drug deposition in the olfactory region for targeted nose-to-CNS
delivery is rather complicated. The convoluted geometry and narrow passages of the
nasal cavity make access to the olfactory region challenging. Nonetheless, there are some
unique delivery devices, such as OptiNose® and ViaNaseTM that have effectively
administered drugs deep into the nasal cavity, with considerable exposure in the olfactory
region.23,24 Impel NeuroPharma® has also designed a novel nasal delivery technology to
provide targeted olfactory deposition via a pressurized aerosol device.24 These reports
represent an important step towards the ultimate goal of nose-to-CNS delivery and
invigorate pharmaceutical investment in this area.
Conversely, mucociliary clearance, which leads to rapid elimination of INadministered products in the gastroinstential tract (GIT), cannot be effectively addressed
via change of delivery device. Briefly, the nasal mucus layer is renewed every 10-20
min,25 which reduces total absorption of the deposited drug. To overcome this limitation,
an increased residence time (tres) of drug preparations in the nasal cavity is desirable.
This, in turn, is heavily dependent on the selection of formulation design and the
components. Reports suggest that drug administered as solid powder is likely retained at
the deposition site longer than corresponding aqueous solution. Prolonged tres increases
the contact time between the formulation and the nasal mucosa, which can result in
increased absorption and enhanced bioavailability. Use of mucoadhesive polymers has
also shown promise in increasing nasal retention time. The cross-linking between
polymer and components of nasal mucus presumably increases the viscosity of the
mucus, and eventually decreases the rate of clearance. This, in turn, may enhance noseto-CNS drug uptake.26-29
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Several mucoadhesive polymers are commonly used as permeation enhancers.
These can act by one or more of the following mechanisms:


Alteration of the physical properties of the olfactory membrane



Transient opening of tight junctions between epithelial cells



Inhibition of P-gp drug efflux transporters



Increasing membrane fluidity by extraction by creating disorder in the
phospholipid domains of the membrane

For targeted nose-to-CNS delivery, these excipients may be most favorable for the
molecules that lack adequate permeability (BCS Class III, IV) and are often dismissed as
viable development candidates.
Other than increase in the residence time, nasal powders offer the advantages of
stability (chemical and microbiological) and patient safety (lack of preservatives). There
is a great deal of interest in the pharmaceutical industry to develop solid dosage forms
that can be administered nasally with a state-of-the-art delivery device. Currently, we are
far from having a well-optimized solid drug product with exclusive delivery to the
olfactory region. But some underlying trends suggest that specific control over particle
size distribution (PSD) could be significant. Typically, microparticles in the size range of
10 – 45 m provide nasal deposition profiles favorable for nose-to-CNS delivery.30
Proper identification of manufacturing processes which can easily and reproducibly
generate microparticles in the desired size range is crucial to the success of this
formulation platform.
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Traditionally, dry powder formulations with nasal or pulmonary therapeutic
application are prepared by mixing micronized drug particles (1 – 5 m) with larger
carrier particles.31 The inter-particle force is relatively weak which may promote
segregation of components upon insufflation. To avoid this, it is imperative to combine
the ingredients of the formulation as solid composites that can potentially withstand the
agitation of pressurized delivery. Often, binary solid composites such as eutectics and
amorphous solid dispersions, are considered as enabling technologies for low solubility
drug candidates.32 However, with adequate modifications, the application of these solid
composites can be expanded to low permeation molecules that necessitate specialized
route of administration.

1.2. Hypothesis and research objectives
The central hypothesis of this dissertation is that direct deposition of solid
microparticles containing a low permeation drug alone or as a composite with a
permeation-enhancing polymer, will enhance mass transport across olfactory
epithelial tissue relative to aqueous drug solution.
In order to test this hypothesis, the following research objectives were proposed and
executed:
1.

An excised epithelial tissue permeation model that is simple yet translatable to
humans was identified. To test the usability of this model, L-DOPA epithelial
transport was measured when given as aqueous solution and standalone solid
microparticles.
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2.

Consistent with regulatory guidance on the use of polymorphic solid materials
in drug products,33 a thorough characterization of the relevant solid forms of
ribavirin was undertaken. It was expected that this would enable selection of
appropriate micronization equipment and procedures to avoid process-induced
polymorphic conversion during composite microparticle preparation.

3.

Binary composite solid microparticles of ribavirin and a permeationenhancing polymer were prepared, characterized and evaluated for toxicity,
drug release and permeation in vitro. Collectively, these data provided
sufficient evidence regarding effective IN delivery of ribavirin.

1.3. Nasal cavity
Drug deposition and clearance are heavily influenced by nasal anatomy and
physiology. The anatomical features of the olfactory mucosa important for nose-to-CNS
delivery are detailed throughout the literature.6,9,18
The mammalian nasal cavity has three distinct functional regions: vestibular,
respiratory, and olfactory. The vestibular region opens to the outside at the nares and
provides protection by filtration of airborne particles. The respiratory region constitutes
the inner part of each nasal cavity, including three lateral turbinates (or conchae) on the
lateral sides of the cavity and the nasal septum on the medial side of each nostril (Figure
1.1).
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Figure 1.1. Schematic representation of the lateral wall of the human nasal cavity. The
boxed region delineates the olfactory region.30

1.3.1 Respiratory region
The respiratory epithelium covers approximately 50% of the nasal cavity in rats
and 80–90% in humans.34 The human respiratory epithelium is comprised of goblet cells,
ciliated cells, intermediate cells, and basal cells. Primarily, goblet cells secrete mucus,
which covers the entire respiratory region (~10 µm thick) with a lower sol layer and an
upper gel layer. The normal pH range of nasal mucus is approximately 5.5-6.5; however,
the nasal mucosa tolerates solutions having a pH range of 3-10.35 The ciliated cells
project hair-like protrusions from the surface, which beat very rapidly in synchronized
fashion. In humans, the ciliary beat frequency is 1000 strokes per minute resulting in an
average nasal clearance rate of 8 mm/min.36 Consequently, nasal mucus is propelled
towards the nasopharynx where it is either swallowed or expectorated. The presence of
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dense microvilli on the epithelial cells, combined with high vascularization of this region,
makes it suitable for systemic drug absorption.

1.3.2 Olfactory region
The olfactory region (also known as the olfactory mucosa) is located within the
recesses of the skull, just under the cribriform plate of the ethmoid bone, approximately 7
cm from the nostril, at the roof of the nasal cavity, lying partly on the nasal septum and
partly on the superior turbinate (delineated in Figure 1.1). The surface area of the
olfactory mucosa in humans is estimated at 10 cm2.37 Conversely in dogs, this region
constitutes 150 cm2, indicating the importance of olfaction in the daily functions of dogs,
unlike humans.
The olfactory mucosa is comprised of three cell types: olfactory receptor cells
(also called olfactory receptor neurons, or ORN), supporting epithelial cells, and basal
cells (Figure 1.2). The ORN are bipolar neurons with a spherical cell body. A single
dendritic process extends from the cell body to the free apical surface (lumen of the nasal
cavity) where it terminates as a small knob-like swelling. This, in turn, bifurcates into
numerous long fibers and modified cilia. On the end of CNS, the ORN taper into an
unmyelinated axon, which penetrates the basal membrane to join other axons and form
large bundles in the lamina propria. The axons cross into the cranial cavity through small
holes in the cribriform plate and synapse in the olfactory bulb, thereby establishing a
direct anatomical connection between these two regions.

8

Figure 1.2. Anatomical representation of olfactory epithelium. Yellow dashed line (----)
indicates the paracellular pathway, purple dashed line (---) indicates the transcellular
pathway and the red dashed line (---) represents the transneuronal pathway.30
The cilia on the ORN are different from those on the respiratory epithelium,36 and
exist as three distinct, ciliated sub-regions: mobile, non-mobile, and intermingled. The
combination of ciliated sub-regions disturbs the systematic beating of the cilia, thereby
reducing the mucus clearance rate to 1-2 mm/h, which is ~240 times slower relative to
the respiratory region.9,36 This potentially allows for greater retention of IN formulations
in the olfactory region.
Previously, it was believed that drug transport from the nasal cavity to the CNS
was mediated directly by the ORNs (neuronal pathway), through the supporting epithelial
cells (epithelial pathway), or between the epithelial cells in the olfactory region
(paracellular pathway) (Figure 1.2). However, CNS entry may also occur through cells
outside of the olfactory region, such as the trigeminal nerves that innervate different
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regions of the nasal mucosa. It has also been shown that transporter systems in the
olfactory region have a role in drug uptake. Co-administration of transporter-efflux
inhibitors resulted in enhancement of drug absorption in the CNS.38,39 Other plausible
mechanisms for nose-to-CNS transport are discussed in the comprehensive work by
Dhuria et.al.9 It is likely that multiple pathways are responsible for drug uptake into the
CNS, although one pathway may predominate depending on the properties of the
therapeutic, characteristics of the formulation, and delivery device used.

1.3.3. Evidence of nose-to-CNS pathway
It is well known that the euphoria derived from sniffing cocaine occurs rapidly
(within 3–5 min). It has been suggested that the reason, apart from a rapid nasal
absorption, is the presence of a direct pathway from the nasal cavity to the CNS and the
ability of the drug to concentrate selectively in specific regions in the brain. Various
animal studies have confirmed that, at early time points after nasal administration, the
concentration of cocaine in the brain was higher with IN administration relative to IV,
thereby showing the existence of the pathway from nose-to-brain.40,41
Okuyama42 was the first to attempt a direct assessment of nose-to-brain transport
of

compounds

in

humans.

Using

a

radiotracer

99

m-technetium-labelled

diethylenetriamine-penta acetic acid (99mTC-DTPA) mixed with hyaluronidase sprayed
deep into the nasal cavity; gamma-scintigraphy was used to record the amount of activity
appearing in the intracranial space. A significant rise in cerebral radioactivity was
observed 5 min after introduction of the nasal spray. In another example, it was shown
that 27-times higher [3H]-dopamine reached the olfactory lobe after nasal administration
relative to intravenous injection in rodent model.43 Fehm44 reported a significant
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accumulation of insulin in the CSF after a single nasal administration of 40 IU insulin,
whereas no increase was seen in insulin plasma levels.
Evidence of direct nose-to-brain transport of drugs has also been gathered in
humans, mostly in terms of pharmacodynamic effects on the CNS, comparing drug
administration via nasal and intravenous routes of delivery.45 A list of the drugs studied
in humans is given in Table 1.1.
Table 1.1. Drugs used in nose-to-CNS drug transport studies in humans.45
Functional evidence in man of facilitated transport to the brain was provided by changes
in event related potential during performance of an oddball task
Arginin-vasopressin (n=15)
Cholecystokinin-8 (n=20)
Angiotensin II (n=12)
Adrenocorticotropin 4-10 (n=54)
Insulin (n=12)

1.4. Factors influencing nasal absorption
Whether a drug is nasally administered to induce systemic or CNS effects,
absorption from the nasal mucosa is a pre-requisite for successful delivery. Several
physiological and physicochemical factors play a crucial role in determining the rate and
extent of nasal absorption.

1.4.1. Physiological considerations
1.4.1.1. Targeted deposition
For desirable therapeutic outcomes, it is essential to target an appropriate
deposition site for inhaled particles. Locally acting drugs are best targeted to the middle
meatus,46 while the turbinates and septum wall are best for systemic delivery owing to
efficient drug absorption.6 Deposition on the anterior portion of the nose typically
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provides a longer nasal residence time; however, this region is not amenable to
permeation and thereby nasal absorption. In contrast, deposition of formulations in the
posterior chamber of the nasal cavity enables greater uptake but is subjected to rapid
mucociliary clearance, which ultimately limits nasal absorption. For direct nose-to-CNS
transport, the olfactory region is the best target.47
From a mechanistic standpoint, inertial impaction and gravitational sedimentation
predominantly govern deposition of pharmaceutical materials.48-52 Briefly, turbulent
airflow is needed to displace the relatively stagnant air volume in the upper nasal cavity
in order to allow impaction of mucosa with drug particles.53 Reports suggest that the
choice of dosage form (drops versus sprays) and the physical properties (particle size and
size distribution, plume angle, and plume velocity) play a crucial role in determining the
extent of nasal deposition targeted specifically to the olfactory region. These are
discussed in later sections.

1.4.1.2. Mucociliary clearance
Mucociliary clearance is a natural phenomenon that protects the lungs from
foreign particles. When allergens, microbes, toxins, etc. adhere to, or dissolve in the
mucus of the nasal cavity, they are transported towards the nasopharynx for eventual
discharge into the gastrointestinal tract (GIT). Mucociliary clearance results from the
coordination between the overlying mucus and the wavelike movement of the cilia,
therefore, the efficiency depends on the length, density and beat frequency of cilia as well
as the amount and viscoelastic properties of the mucus. Clearance rates may vary owing
to any environmental or pathological factor that alters mucus production, mucus viscosity
or ciliary beat frequency. Increase in body temperature and cigarette smoking has shown
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decrease in clearance rates possibly from dehydration of mucus layer and/or impaired
cilia.54 The effects of disease conditions on normal mucociliary clearance rates are
summarized in Table 1.2.
Table 1.2. Pathological conditions and their impact in nasal mucociliary
clearance.54,55
Pathological conditions
Ciliary dyskinesia
Asthma
Cystic fibrosis
Viral and bacterial
infections
Diabetes mellitus

Effect on mucociliary clearance and reason
Impaired: absence or dyskinetic beating cilia
Increased: inflammatory process and irritation
Decreased: epithelial damage
Decreased: dehydration of mucus
Impaired: loss of cilia and change of mucus properties
Decreased: dehydration and microvascular damage

Theoretically, the mucus layer is transported at 5 mm/s and renewed every 10-20 min,37
which can reduce total absorption of the intranasally deposited drug. Slow clearance
allows increased time of contact between drug molecules and the mucosal layer and
subsequently enhances nasal absorption.
Clearance of a drug formulation can be influenced by its deposition site.
Fortunately, ciliated epithelium is not uniformly located across the nasal cavity. While
the middle and posterior turbinates are covered with ciliated epithelium, cilia are mostly
absent from the anterior regions. Differences in ciliation significantly changes the
clearance kinetics for particles deposited in different regions, and in turn alters tres. This is
perhaps the reason for the biphasic clearance pattern observed for inhaled particles in
human studies.49,56,57 Initially, particles deposited in the ciliated regions of the posterior
nasal cavity were rapidly cleared, followed by a comparatively slower secondary
clearance attributable to particles deposited on the non-ciliated anterior region of the
nose. While ciliary movement is the primary mechanism for clearance from the

13

respiratory region, the presence of non-mobile cilia in the olfactory region makes it most
likely that the upright position of the human head results in the removal of mucus in this
region due to gravity.26 This may provide an opportunity for decreased mucociliary
clearance and enhanced direct nose-to-CNS uptake for a drug formulation targeted for
deposition in the olfactory region.

1.4.1.3. Enzymatic degradation
Even though nasally administered drugs are thought to avoid first-pass heaptic
metabolism, the bioavailability of nasally administered drug molecules and proteins can
be limited by a spectrum of metabolic enzymes localized in the nasal mucosa.
Carboxyl esterases, aldehyde dehydrogenases, epoxide hydrolases and glutathione Stransferases have been found in nasal epithelial cells.58,59 Cytochrome P450 isoenzymes
expressed in the nasal mucosa are also reported to limit absorption of drugs such as
cocaine, nicotine, alcohols, progesterone and decongestants.59 Likewise, proteolytic
enzymes (aminopeptidases and proteases) reported to impede intestinal uptake of
peptides such as calcitonin, insulin and desmopressin are also expressed in nasal cells.59
Xenobiotic

metabolizing

enzymes

may

affect

the

pharmacokinetic

pharmacodynamic profiles of drugs administered intranasally.

and

It is important to

acknowledge that several pathological conditions, including the common cold, nasal
polyps, and rhinitis may alter the relative expression of xenobiotic enzyme, thereby
influencing nasal absorption.
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1.4.1.4. Nasal permeation
For successful nose-to-CNS delivery, it is of utmost importance that the drug
molecule demonstrates a balanace of solubility in the mucus layer and permeation across
the olfactory epithelium. Lipophilic drugs such as propranolol, progesterone and fentanyl
are, in general, well absorbed from the nasal cavity, presenting pharmacokinetic profiles
similar to those obtained after intravenous administration with a nasal-to-systemic uptake
near to 100%.60 However, it is important to note that this is predominantly true for
lipophilic compounds presenting a molecular weight <1 kDa. The extent of nasal
absorption for lipophilic drugs >1 kDa is significantly reduced.61 The nasal membrane is
predominantly lipophilic, hence, drug absorption is expected to diminish with a decrease
in lipophilicity. The rate and degree of nasal absorption of polar drugs with molecular
weight higher than 300 Da is notoriously low.38,61
For some small polar molecules, a bioavailability of only 10% may result.
Furthermore, polar drugs are more likely to be affected by mucociliary clearance, owing
to greater solubility in the nasal fluid. Thus, it is evident that polar drugs are not easily
transported across nasal mucosa, and necessitate formulation strategies that reduce
clearance rates. The apparent distribution coefficient (K’) is also an important factor
influencing the permeability through nasal mucosa. This depends on both the drug pKa
and the pH at the absorption site (estimated to be 5.0-6.5 in human nasal fluid).
According to the pH-partition theory, a biological membrane is more permeable to the
non-ionized fraction of a drug relative to the ionized fraction, therefore, it can be assumed
that the nasal absorption of weak electrolytes depends on the extent of their ionization,
with the most rapid absorption occurring for the unionized species. It is notable, however,
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that drugs such as acetylsalicylic acid and bucolome have been observed to be well
absorbed across the nasal membrane, even in environments in which they were expected
to be primarily ionized.62,

63

Further, multidrug resistance transporters have been

identified in human nasal respiratory and olfactory mucosa, which may be involved in the
transport of a wide variety of hydrophilic and amphiphilic drugs.60

1.4.2. Formulation / Dosage form considerations
1.4.2.1. Nasal drops and sprays
Liquid formulations are commonly used for IN delivery. Common drawbacks
associated with liquid formulations, such as drug substance aqueous solubility, chemical
stability in a liquid vehicle, and formulation sterility should, however, be considered.
Additionally, most liquid formulations require preservatives, which have demonstrated
ciliotoxic effects in animal models following chronic use.64,65 Nonetheless, controlled
volumes of formulated solutions can be easily delivered into the nasal cavity as sprays or
drops, making them attractive as a delivery system. The differences in deposition pattern
and clearance kinetics for these dosage forms merit particular attention.
The type of liquid dosage form selected heavily influences deposition and
clearance. Drops are one of the oldest delivery methods for nasal administration of
liquids. Despite being relatively inexpensive and easy to manufacture, their main
disadvantage stems from the complex maneuvers of the delivery device for effective
administration. Several papers have highlighted the difficulty of identifying a single “best
technique” for the administration of nasal drops.66-68 There is tremendous variability in
deposition and clearance owing to varied administration procedures, anatomy, and head
position. Generally, drops tend to be deposited in the posterior region over a larger area
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in the respiratory epithelium, with minimal (or no) deposition in the olfactory region. As
a result, drops are cleared more rapidly than sprays.56,69-71 Moreover, slight changes in
dosing volume in nasal drops can lead to erratic pharmacokinetic profiles and strict
patient compliance becomes necessary.67
Given the advantages of dosing precision and reproducible droplet size
characteristics, nasal sprays are most widely used for IN delivery of solutions and
suspensions. The diversity of pump choices and actuator fittings makes these sprays
suitable for targeted, region-specific nasal delivery. Mechanistically, metered sprays
build hydraulic pressure in the metering chamber upon compression of the pump, which
when it reaches an adequate level, pushes the liquid formulation out of the small orifice at
the tip of the actuator. Shear forces and surface tension act upon the formulation,
converting the liquid stream into a plume with unique geometric and droplet properties.

1.4.2.2. Nasal powders
Although dry powders benefit from improved chemical and microbiological
stability relative to solutions, they are less frequently used for IN drug delivery. In
addition to better stability, nasally administered solid particles may also result in better
patient compliance, especially for children if the smell and taste of the drug in solution or
suspension is unacceptable. Most powder formulations do not require preservatives,
which have demonstrated ciliotoxic effects in animal models following chronic use.64,65
Furthermore, powders allow delivery of the highest mass of active ingredient without the
necessity of a liquid vehicle or propellant, making for simpler formulations. Nonetheless,
nasal powder formulations should allow for reproducible dose delivery, which is
ultimately governed by several physical attributes such as particle shape, particle size and
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size distribution, bulk density, hygroscopicity and flow properties. Furthermore, these
formulations should also be appropriate for aerosolization to allow targeted nasal
deposition and distribution.
Through in vitro and in vivo comparisons of IN delivered dry powder and liquid
formulations, it is generally held that solid particles deposit locally in the nasal cavity,
providing higher concentrations at the deposition loci, which combined with improved
residence time, affords higher bioavailability relative to liquids. The reason for this
advantage may be associated with the un-hydrated state of any solid dosage form.57 At
the deposition sites, the powder is hydrated owing to the presence of water in the nasal
mucus, but at the cost of dehydration of the latter. Consequently, sporadic regions having
increased local viscosity are generated, which may increase resistance to the ciliary beat,
in comparison to an equivalent solution form. Results of studies comparing drug
uptake/bioavailabilities from different dosage forms are summarized in Table 1.3. Since
most of these studies were pursued for systemic delivery, additional research efforts
focusing on nose-to-CNS transport are warranted to determine full potential of solid nasal
carriers.
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Table 1.3: Comparison of liquid and powder formulations for nasal deposition and
clearance.
Drug of interest
Insulin72

Model
Observation and inference
Beagle dogs Crystalline insulin provided higher
hypoglycemic effect relative to insulin
suspension (pH 5.8) at a similar dose of 5 IU/kg

Insulin + dimethyl-βcyclodextrin
(permeation enhancer –
1.9 µmol/dose) 73

Rabbits

Use of freeze dried powder formulation resulted
in higher systemic bioavailability of insulin (~
13%) compared to same formulation as solution
(~ 1%) at a consistent dose of 4 IU/rabbit

Calcitonin and
Glucagon74

Human

Administration of spray solution and powder did
not give significantly different (p < 0.001)
absorption profiles

Dihydroergotamine
(DHE) combined with
randomly methylatedβ-cyclodextrin
(solubilizer – 10
mg/kg)75
Ribavirin22

Rabbit

DHE serum bioavailability with nasal powder
(56%) was not significantly enhanced (p > 0.05)
relative to liquid spray form (44 - 50%). DHE
was administered at 0.1 mg/kg for all
formulations

Rat

Concentration in the olfactory bulb was > 3-fold
higher for dry powder relative to aqueous
solution

Cromoglycolate loaded
in polymeric
microsphere system76

Human

Small volumes of liquid or powder particles
have almost the same clearance rate in the
absence of bioadhesive excipients. However, in
the presence of bioadhesive excipients, solid
formulations cleared slower.

Chitosan57

Sheep

Clearance time of chitosan solution and chitosan
microspheres was 43 min and 115 min
respectively.

1.4.2.3. Physical properties
Although estimates of particle sizes (PS) have shown that droplets or particles
having aerodynamic diameters of ~5 µm typically deposit in the upper respiratory tract,
the latest FDA guidance for nasal devices recommends minimizing the fraction of

19

respirable particles below 9 μm in order to avoid lung inhalation.77 With PS increased
>10 µm, total nasal deposition was shown to effectively increased to ~100%.78 More
detailed analyses of sub-regional nasal deposition (especially olfactory region) are less
common, but can be helpful for optimizing drug product characteristics.
Physical properties of IN liquid formulations, particularly droplet size, have a
significant influence on the deposition pattern, with droplet diameters >20 µm resulting
in ~100% nasal deposition.70,79 Analysis of sub-regional deposition suggests that larger
droplets primarily deposit in the anterior or vestibular regions (Dv50 = 40 µm),79 leaving a
significant portion of the nasal cavity unexposed to the drug. Among other relevant
physical properties, plume angle and spray velocities have shown to heavily influence
sub-regional nasal deposition.80,81
For powder formulations, a study was attempted to identify the optimum particle
size range needed to maximize total and regional deposition in the nasal cavity. Briefly,
different size ranges of β-cyclodextrin powder were released in the silicone nasal cast and
evaluated for distribution upon aerosolization.82 In these experiments, particles up to 45
µm provided a more uniform covering of the nasal surface, whereas larger diameter
particles (125-250 µm) were found to be sparsely distributed.
Computational fluid dynamic (CFD) modeling has been used to augment inertial
impaction and gravitational sedimentation, and help identify factors that potentially affect
nasal deposition. Garcia and Kimbell83 developed a CFD model of a rat nose for
quantifying the deposition of inhaled nanoparticles into the rat olfactory region at
different particle sizes (1-100 nm) and airflow rates. The simulations indicated a strong
influence on PS with a 6-9% of the inhaled dose as the maximum deposition achieved in
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the olfactory region for 3-4 nm particles. Although this study focused on
pharmaceutically impractical PS range, this study suggests that human CFD models could
be generated for predicting the fraction of olfactory deposition as a factor of physical
properties.

1.4.2.4. Mucoadhesives
As discussed earlier, MCC is one of the most important factors limiting nasal
absorption owing to reduction in the time allowed for drug uptake. Intuitively, therefore,
nasal absorption can be improved by prolonging the contact time between drug and
mucosal membrane. In this regard, mucoadhesive drug delivery systems have been
developed for IN delivery. Use of polymeric ingredients, among others, in the dosage
form markedly reduces the rate of MCC. Several theories have been proposed to explain
the mechanism of polymer–mucus interactions that lead to mucoadhesion.84 The most
commonly accepted theory includes intimate contact between polymer and the biological
tissue followed by wetting of the polymer chains. Subsequently, cross-linking between
polymer and mucus occurs. This increases the viscosity of the mucus, and eventually
decreases the rate of mucociliary clearance. Therefore, it is logical that changes in
polymer properties, such as surface roughness, work of adhesion, hydration potential,
molecular mass, cross-linking density, ionic strength, pH, and surface charge can
considerably alter the extent of mucoadhesion.
In an recent example, Charlton et al. compared the abilities of several polymeric
formulations to reach the olfactory region and increase the residence time on the
epithelium.26 Different bioadhesive formulations were prepared using polymers such as
pectin and chitosan, the amount of which was determined based on ease of delivery of the
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final solution from the nasal delivery devices and adequate gelling characteristics at nasal
physiological conditions. Distribution and clearance of the formulation from the olfactory
region was assessed by taking photographs over time using endoscopy. From these
studies, the authors concluded that all bioadhesive formulations were retained on the
olfactory epithelium for more than four times longer than relative control solutions (See
Figure 1.3).

Figure 1.3. Tres for each formulation averaged over the whole test group. Error bars
represent the S.E.M., n = 12. There was no statistical difference between the average T res
values for each polymer formulation. Reprinted from European Journal of
Pharmaceutical Sciences, 30, S. Charlton, N.S. Jones, S.S. Davis, L. Illum, Distribution
and clearance of bioadhesive formulations from the olfactory region in man: Effect of
polymer type and nasal delivery device, pp:295-302, Copyright 2007, with permission
from Elsevier.
Likewise for polymeric solid microparticles, Tafaghodi et al. compared the
clearance rates to highlight the importance of selecting the correct polymer for an
optimum nasal absorption. Briefly, technetium-labeled microspheres of PLGA, alginate,
Sephadex® and lactose were prepared and administered to healthy human volunteers. The
clearance rates were compared using two regions of interest; the initial site of deposition
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and the nasopharynx. Alginate and PLGA microspheres showed the lowest clearance rate
compared to lactose powder (p < 0.0001 and p < 0.001) respectively.85
In a recent clinical study, the plasma area under the curve (AUC) of desmopressin
acetate following administration of a nasal powder formulation was increased 3-fold in
the presence of sodium starch glycolate (SSG).86 The drug was homogenously distributed
on SSG microparticles and, owing to complete hydration of this carrier material,
increased release and absorption of the active drug was expected. In another study, it was
concluded that a lyophilized insulin powder combined with Carbopol® 934 resulted in the
highest systemic absorption of insulin relative to other formulations.87 The authors
explained that the gelling of Carbopol® 934 following hydration may have led to longer
adhesion with the nasal mucosa, thereby allowing more time for enhanced insulin
absorption.

1.4.2.5. Permeation enhancers
The key to successful nose-to-CNS delivery, however, is not only an increase in
nasal residence time but also increased CNS uptake of drugs. Hydrophilic drug molecules
may poorly permeate the nasal epithelium and, thereby, exhibit insufficient
bioavailability. It is possible to greatly improve their absorption by combination with
absorption enhancers which induce transient modifications on the structure of epithelial
barrier. In IN delivery, the most widely used absorption enhancers include surfactants
(laureth-9), bile salts, fatty acids (taurodihydrofusidate) and polymers (chitosan,
cyclodextrins, poly-L-arginine, polyethylene glycol and polyoxyethylene).26,88-90 The
mechanism of action of these permeation enhancers is not well known but they typically
alter the permeability of epithelial cell layer by modifying the phospholipidic bilayer,
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increasing membrane fluidity or opening tight junctions between epithelial cells and,
thus, increasing paracellular transport.91 Although the absorption promoters enhance drug
bioavailability, chronic use may damage the integrity of the olfactory membrane which
should not be overlooked.
Recently, Vaka et al. demonstrated that formulations containing chitosan
glutamate enhanced the hippocampal bioavailability of IN administered nerve growth
factor (NGF) solution up to 14-fold.92 This observation was attributable to the permeation
enhancement of chitosan, which transiently opens tight junctions between the olfactory
epithelial cells. In another study, an alternative strategy involved conjugation of
therapeutic agents with receptor-targeting moieties, which showed promising results for
direct CNS uptake.93 For example, the olfactory bulb concentration of 1.0% horseradish
peroxidase (HRP) protein was almost 700 times (p < 0.001) higher when conjugated with
wheat germ agglutinin (WGA) relative to HRP itself. It was hypothesized that WGA
conjugation provided accessibility to receptor mediated endocytosis into olfactory
sensory neurons. Subsequently, a fraction of the internalized protein transcytosed to axon
terminals in the olfactory bulb. Such strategies can open possibilities of nose-to-CNS
transport for other therapeutic agents used in neurodegenerative diseases. Use of chitosan
glutamate (CG) as both a mucoadhesive agent and a permeation enhancer has shown
exciting results for nose-to-CNS delivery of zolmitriptan, an anti-migraine drug.
Microparticles (2.7 – 9.4 µm) of 1:1 drug:polymer ratio were prepared through spray
drying process and assessed for ex vivo permeation enhancement and adhesiveness.94
Although, the formulation showed comparable mucoashesion relative to drug alone (p <
0.05), the drug permeation was increased by 28% for the CG containing microparticles as
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compared to the spray dried drug (p < 0.05). When the authors compared the CSF
concentrations of zolmitriptan following nasal administration as suspension versus drugloaded chitosan-based microparticles, the solid formulation resulted in a modest 1.6-fold
increase in drug in the CSF, verifying that polymers helped enable CNS targeting of the
drug. In a similar study, the CSF-to-blood ratio of an anti-ischemic agent was
respectively 4.3 and 57.5 for mannitol-lecithin and chitosan-loaded microparticles. The
CSF concentration of the same drug through nasal suspension, however, was
undetectable at the same dose.95

1.4.3. Delivery device considerations
There are a wide variety of delivery devices available for IN delivery of powders.
Correct choice of delivery device is important because differences in actuation pressure
and device tip dimensions can affect both the volume of the emitted dose and its nasal
deposition pattern.96-100 Pringels et al. studied the effect of delivery devices on deposition
patterns of dry powder formulations.101 In their work, a silicone human nose model was
insufflated with freeze-dried, radiolabeled lactose powder from three different devices:
the Monopowder P® system, the Pfeiffer system, and an experimental device developed
in-house. Of these, the Monopowder P® system showed the greatest deposition near the
upper turbinate region, whereas the experimental device resulted in highest deposition in
the anterior regions of the nasal cavity. Administration using the Pfeiffer system resulted
in homogenous distribution throughout the nose, which led to faster clearance. The
authors controlled both size fraction and bulk density of the powders; however, devicespecific comparisons of airflow velocity at the time of actuation, administration angle,
and device insertion depth were less clear. Additionally, an explanation for the
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differences in deposition behavior between delivery devices was not provided, making it
difficult to identify the particular device attributes that favor site-specific deposition.
Such parameters can alter the deposition site, as described in a study investigating overall
nasal deposition of budesonide powder from a unique breath actuated delivery device
(Turbuhaler®).102
In 2006, Djupesland et al.97 developed the OptiMistTM device, a modified version
of the traditional nasal spray that allowed penetration of the emitted dose beyond the
anterior region of the nasal cavity, which had previously been a substantial challenge.
This device utilizes the positive dynamic pressure of exhalation, which expands the
narrow nasal passages, allowing the inhaled particles to reach the posterior regions of the
nasal cavity. The results of a study comparing nasal deposition and clearance of drug
administered from the OptiMistTM device with a traditional nasal spray were highly
promising. Human volunteers were administered technetium labeled saline using both
devices on separate days. The devices were characterized for the reproducible dose
volume and droplet size (48 μm). Both delivery technique and head position of the
volunteers were kept constant for all administrations. Regional deposition analysis
indicated that the OptiMistTM device delivered more than 70–80 % of the dose beyond the
anterior region when compared with the traditional nasal spray device. Additionally, the
OptiMistTM device provided ∼3× more deposition in the upper posterior region of the
nasal cavity, which houses the olfactory region (p < 0.004). Although a major fraction
(about 50%) of the OptiMistTM deposited in this region was cleared within 6 min of
administration, it can be anticipated that the use of bioadhesive components in the

26

formulation will increase the residence time in the olfactory region to improve CNS
uptake.
Recently, the regional human nasal deposition and clearance patterns of lactose
powder delivered by the breath actuated bi-directional powder device (OptiNoseTM) were
compared with those from a traditional liquid nasal spray (droplet size = 48.5 μm).103
Radiolabeled lactose powder (d10 = 3 μm, d50 = 15 μm, d90 = 38 μm) was delivered
through the breath-actuated powder device. The method of administration and head
position of the volunteers were kept consistent between two methods. Upon
administration, gamma scintigraphy images were collected for studying nasal deposition
and clearance. Results showed that both powder and spray were distributed to all nasal
regions. However, in the upper posterior region, which is of concern to nose-to-CNS
transport, the initial deposition of OptiNoseTM powder was approximately nine times
higher than the traditional spray (See figure 1.4).
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Figure 1.4. Gamma camera image information from the nasal cavity is superimposed on the corresponding sagittal MRI section. The
images are from the same subject and present deposition 2 min after delivery using (a) a traditional liquid spray, (b) the breathpowered Opti-Nose™ powder device, and (c) the breath-powered Opti-Mist™ liquid spray device incorporating the same spray pump
as used in a. The initial deposition following traditional spray was greatest in the lower anterior regions of the nose, whereas
deposition with the breath-powered delivery devices was greatest in the upper posterior regions of the nose. The less broad distribution
in b following breath-powered Opti-Nose™ powder device is believed to be due to the slower clearance for powder the first 6–8 min,
reflecting the dissolution of the powder into the mucosal layer.23

Currently, it is difficult to make conclusions regarding the relative performance of
breath-actuated novel devices, namely, OptiMistTM and OptiNoseTM, despite similar
underlying mechanisms. Due to the inconsistency of formulation ingredients and
essential physical properties such as particle size and particle density in the present data,
supplementary studies to overcome these differences can greatly substantiate it.
Nevertheless, it is encouraging to observe that the remarkable influence of delivery
devices on olfactory deposition. Presently, this novel device is being studied for delivery
of sumatriptan and fluticasone for migraine and chronic rhinosinusitis, respectively.
In another study, a pressurized olfactory device (POD) consistently delivered a
majority of its dose to the olfactory region of adult rats.104 Pressurized nitrogen was
mixed with a dye solution to create an energetic aerosol directed towards the roof of the
nasal cavity. The insertion depth and dose volumes were well controlled from animal-toanimal. Qualitative deposition analysis suggested that the POD results in preferential
localization in the olfactory region. To monitor nose-to-brain delivery, the dye solution
was replaced with either radiolabeled mannitol (hydrophilic) or radiolabeled nelfinavir
(lipophilic) liquid as model solutions. Following nasal administration, the radioactivity of
samples was determined in excised brain tissues and blood. Using the POD, mannitol
concentrations increased 25.6-fold (p < 0.05) in the olfactory bulb when compared with
administration of drops. Similarly, nelfinavir concentrations were increased at the
olfactory bulb (5.8-fold) and cortex (13.8-fold, p < 0.05). Further, the cortex-to-blood
ratio for mannitol (3.6-fold, p < 0.05) and nelfinavir (13.6-fold, p < 0.05) increased with
POD administration. These results support the possibility of enhanced nose-to-brain
transport with increased deposition in the olfactory region.
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1.5. Chemical profile
1.5.1. Levodopa
Levodopa (L-DOPA; L-3,4-dihydroxyphenylalanine) is an amino acid and
precursor of dopamine, which remains the mainstay of treatment for Parkinson’s disease
(PD). The molecular formula of L-DOPA is C9H11NO4 and its molecular weight is 197.2
g/mol. L-dopa exists as zwitterions in solution, owing to the presence of an amine group
(pKa 8.11) and a carboxylic acid group (pKa 2.30). The cLogP of L-DOPA105 is -2.19 and
this molecule demonstrates good aqueous solubility at 1.65 mg/ml (20 °C).106
L-DOPA crosses the BBB and is rapidly taken up by dopaminergic neurons and
converted to dopamine (Figure 1.5) by the enzyme aromatic L-amino acid decarboxylase
(DOPA decarboxylase). Consequently, moderate increases in the levels of dopamine
alleviate the complications associated with PD.

Figure 1.5. Chemical reaction showing (a) conversion of L-DOPA to dopamine (b)
oxidation of L-DOPA to L-dopaquinone and (c) zwitterionic nature of L-DOPA between
pH of 3 to 9.107
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Traditional peroral L-DOPA therapy is limited by poor relative bioavailability of
approximately 5-15%, with less than 1% of the administered dose reaching the brain.108
For this reason, large peroral doses of L-DOPA are required for adequate therapeutic
effect, which may often be accompanied with painful side effects such as motor
fluctuations, dyskinesia, nausea and vomiting, some of which are attributable to
dopamine formed in extracerebral tissues.109,110 Potential reasons for the low
bioavailability of orally administered L-DOPA therapy include site-specific absorption of
the drug in the duodenum, carrier-mediated active transport from the gut wall, extensive
metabolism in the gastrointestinal tract and inter-individual variability in the degree of
first-pass metabolism.108,111
Recently, CNS targeting of L-DOPA was investigated in an aqueous solution
through IN versus IV administration (Figure 1.6).20 The pharmacokinetic analysis
showed that the amount of L-DOPA that reached the CNS was therapeutically
ineffective.
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Figure 1.6. Time courses of plasma and brain l-dopa concentrations following intranasal
administration of l-dopa (2.5 mg/kg) in the presence and absence of C-dopa (0.63 mg/kg)
(mean ± SD, n = 6). Reprinted from European Journal of Pharmaceutical Sciences, 38,
Tae Kyung Kim, Wonku Kang, In Koo Chun, Seaung Youl Oh, Yeon Hong Lee, Hye
Sun Gwak, Pharmacokinetic evaluation and modeling of formulated levodopa intranasal
delivery systems, pp:525-523, Copyright 2009, with permission from Elsevier.
This was attributable to the low aqueous solubility of L-DOPA, which restricted
the amount of drug that could be loaded per dose volume. Furthermore, the fluctuations
in CNS concentration of the drug suggested inconsistent delivery from liquid vehicles
potentially due to rapid removal of the drug from the absorption site initiated by mucus
turnover. In another study, water-soluble prodrugs of L-DOPA in liquid vehicles were
formulated and the issue of solubility was minimized,106 however, IN administration of
the prodrugs showed nearly complete absorption of the drug in the systemic circulation,
defeating the purpose of nose-to-brain transport. This study also suggested the potential
role of mucociliary clearance in limiting the nasal retention of aqueous formulations.
Additionally, the chemical instability of the prodrugs in aqueous media, similar to the
drug itself, limited the usefulness of this strategy. Based on these observations, it can be
speculated that the use of solid platforms for intranasal delivery of this drug may be
beneficial in addressing the aforementioned issues.
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1.5.2. Ribavirin
Ribavirin (1-β-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide), an anti-viral
drug, is a synthetic nucleoside analog structurally related to guanine. The molecular
formula of ribavirin is C8H12N4O5 and molecular weight is 244.2 g/mol. The structure of
ribavirin is shown in figure 1.7.

Figure 1.7. Chemical structure of Ribavirin

Ribavirin is a polar compound with clogP of -3.23 and an experimental logP
(MlogP) reported as -1.85.112 Ribavirin is an ampholyte having both an acidic and a basic
group, the pKa values of which are reported as 12.95 and 1.00 respectively for the acid
and base.112 These values indicate that at most physiologically relevant pH values, the
compound is unionized.
Ribavirin is typically administered orally in doses of 400, 500, or 600 mg twice
daily. It is rapidly absorbed into the systemic circulation, with the uptake mechanism
being active transport by the human concentrative nucleoside transporter 2 (hCNT2) in
the proximal small bowel. Saturable uptake of ribavirin in the human intestine is the most
likely explanation for the observation that, at very high doses (1200-2400 mg), the
maximal plasma concentration of ribavirin after oral administration of the drug does not
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increase in proportion with the dose.113,114 The combined use of ribavirin and pegylated
interferon-α is approved by the US Food and Drugs Administration (FDA) for treatment
of hepatitis C in normal and HIV-infected individuals.115 According to the Essential
Medicines List of the World Health Organization, ribavirin can also be used to treat viral
hemorrhagic infections, such as Lassa fever and Crimean-Congo fever.116 Further, it is
also used to treat respiratory syncytial virus infections in moderately to severely
immunocompromised patients.117
Despite demonstrating high antiviral activity in vitro against CNS-borne
pathogens,118-120 the in vivo effectiveness of RBVN is restricted by its inability to cross
the BBB. Studies reveal that intraperitoneal (IP), subcutaneous (SC) and intramuscular
(IM) injections of RBVN were ineffective against several encephalitis viruses in
mice.121,122 The drug improved the survival of subacute sclerosing panencephalitis
(SSPE) in measles virus-infected hamsters only when administered intracranially (IC),122
which, though effective, is not a route of administration amenable to patient selfadministration. For this reason, alternative means of administering RBVN or innovative
formulation strategies are sought in order to increase the extent of drug that reaches the
CNS.
A recent study investigated distribution of ribavirin in the CNS after IN
administration in the form of aqueous solution or powder at the same dose. IV solution
was used as control group.

It was found that 20 min after administration, the

accumulation of ribavirin in olfactory bulb was comparable between IV and IN solutions,
whereas the powder led to significantly higher levels (figure 1.8).22 The extent of drug
accumulation, however, was not enough to be efficacious. This supports the rationale that
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solid nasal dosage forms have the ability to potentially deliver therapeutic quantities of
drug to the CNS if formulated appropriately with permeation enhancing excipients.

Figure 1.8. (a) Ribavirin brain concentrations after in vivo nasal administration of an
aqueous solution (white bars) versus intravenous injection (gray bars). (b) Ribavirin brain
concentrations after in vivo nasal administration of an aqueous solution (white bars)
versus ribavirin powder (black bars). The measured values were normalized by the dose
administered. OB: olfactory bulb; CTX Ant and CTX Post: anterior and posterior
cerebral cortex; BG: basal ganglia; Hip: hippocampus; CSF: Cerebrospinal fluid.
Reprinted from Antiviral Research, 92(3), Gaia Colombo, Luca Lorenzini, Elisa Zironi,
Viola Galligioni, Fabio Sonvico, Anna Giulia Balducci, Giampiero Pagliuca,
Alessandro Giuliani, Laura Calzà, Alessandra Scagliarini, Brain distribution of ribavirin
after intranasal administration, pp: 408–414, Copyright 2011, with permission from
Elsevier.
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1.5.3. Poloxamers
Poloxamers, also known by trade names Pluronics® or Kolliphor®, are tri-block
copolymers of poly(oxyethylene)–poly(oxypropylene)–poly(oxyethylene). They are
predominantly used as surfactants, solubilisers, wetting agent for microemulions and as
drug reservoir post micellization. All Pluronics® have similar chemical structures but
with different molecular weights and composition of the hydrophilic PEO block (a) and
hydrophobic PPO block (b) (shown in figure 1.9).

Figure 1.9. General chemical structure of Poloxamers® or Pluronics®.

For pharmaceutical applications, two of the most commonly used grades of
Pluronics® are F-68 (also referred as Poloxamer 188; a=80, b=27) having an average
molecular weight of 8400 Da, and F-127 (or Poloxamer 407; a=101, b=56) having an
average

molecular

weight

of

12200

Da.

These

polymers

exhibit

inverse

thermosensitivity; therefore, they are soluble in aqueous solutions at low temperature, but
gel at higher temperatures.
Pluronics® are widely used in drug delivery owing to the relatively low toxicity
and potential for permeation enhancement. For hydrophilic drug molecules, these
copolymers have been shown to promote permeation via inhibition of the P-gp and MRP
mediated efflux.123-6 For lipophilic molecules, however, the process of permeation may
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be facilitated by adsorption of copolymer on the cell membrane, followed by
translocation of drugs molecules across lipid membranes.127 Pluronics® in this regard,
offer universal applicability of BCS class II, III and IV molecules.
According to a recent report,128 CNS delivery of curcumin (a form of turmeric and
naturally occurring food color) was significantly enhanced in the presence of poloxamers.
In the rodent model, nasal in-situ hydrogels comprising of Pluronic F-68 and F-127
exhibited higher nasal retention time resulting from possible gelation at the physiological
temperature, thereby promoting curcumin uptake into the CNS. Results from in vivo
mucoadhesion tests revealed that yellow color in the oropharynx appeared 67 min after
IN administration of hydrogels. This was almost 10-fold longer than the mucociliary
transit time recorded for curcumin aqueous solution (see figure 1.10).

Figure 1.10. in vivo mucociliary transit time recorded for curcumin loaded in aqueous
solution and poloxamer containing hydrogel. Reprinted from Journal of Pharmacy and
Pharmacology, 65, Xi Chen, Feng Zhi, Xuefeng Jia, Xiang Zhang, Rohan Ambardekar,
Zhengjie Meng, Anant R. Paradkar, Yiqiao Hu, Yilin Yang, Enhanced brain targeting of
curcumin by intranasal administration of a thermosensitive poloxamer hydrogel, pp:807816, Copyright 2013, with permission from John Wiley and Sons.
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The superiority of intranasally administered curcumin hydrogels was also reflected
in the pharmacokinetic evaluations where the drug targeting efficiency (DTE; calculated
as AUCbrain

part/AUCplasma)

in the olfactory bulb, cerebellum and hippocampus was

significantly higher (p < 0.01) than the equivalent dose of i.v. solution. Authors deduced
that curcumin may be absorbed in the cerebral tissues via olfactory pathway.
In another study,129 the use of Pluronics® improved the delivery of zidovudine to the
brain. This is an antiviral drug which chemically resembles the structure of ribavirin.
Briefly, a 20% w/v solution of F-127 was prepared in phosphate buffer (pH 5.5). The
solution exhibited desired gelation characteristics between 27–30 °C. In vitro permeation
experiments performed in rabbit nasal mucosa using side-by-side diffusion cells showed
a 53% rise through incorporation of copolymers. These results also confirmed that
entrapment of zidovudine in a hydrogel network does not inhibit the diffusivity of the
molecule. It was concluded that the absorption of zidovudine may not be limited by the
rate of drug release from the gel rather governed by the rate of drug diffusion through the
biological membrane. The pharmacokinetic and brain distribution studies further
supported the observation in vitro.

Almost 56 times higher amounts of zidovudin

accumulated in the brain and cerebrospinal fluid (CSF) from nasal application of the in
situ gelling formulation when compared with i.v. dose. At any rate, this study shows
promise that IN administration of a polar compound such as zidovudine could also
preferentially enter into the CNS possibly via the olfactory route.
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1.6. Summary
Intranasal drug delivery systems have shown variable and limited success in direct
CNS uptake. Hence, the clinical usefulness of this pathway is a topic of current
discussion. Targeted olfactory deposition and adequate residence time of the
formulation within this region are essential to successful IN delivery. Currently, an
ideal formulation or delivery device that enables exclusive drug delivery to the
olfactory region has yet to be identified; however, research continues to maximize the
fraction of dose delivered to this location. Generally, solid powder dosage forms show
greater site-specific nasal deposition and reduced clearance relative to liquid dosage
forms. Combining a well-optimized solid drug product with a state-of-the-art nasal
delivery device can provide adequate drug targeting to the olfactory epithelium. Even
though there are a number of challenges in IN delivery, the potential of this route to
provide direct access to the CNS continues to encourage academic and
industrial research. Exciting developments in formulation design and delivery device
can enhance clinical developments and eventually time-to-market of new products.
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Chapter 2: Improved flux of levodopa via direct
deposition of solid microparticles on nasal tissue
2.1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder resulting in
tremors, physical rigidity, and difficulty with walking, balance and coordination.
Currently, 1 million Americans are affected with PD, with an estimated 60,000 new
diagnoses each year.130 As of 2012, the Center for Disease Control (CDC) ranks the
complications of PD as the 14th leading cause of death in the United States.130 Although
the average age of onset is 60, the Parkinson’s Disease Foundation estimated that 4% of
PD patients experienced "early-onset," prior to age 50.131 The US Census Bureau
indicates that the fastest growing segment of the U.S. population is individuals over the
age of 65, suggesting the potential for a commensurate increase in the incidence of PD in
the near future.
Descriptions of the origin and progression of PD are reviewed in detail
elsewhere.132-134 In brief, PD motor symptoms manifest when approximately 60–80% of
the dopamine-producing cells are damaged in the substantia nigra. If left untreated, PD
progresses to the point at which the patient becomes totally disabled, leading to a decline
in all brain functions and an early death. Direct dopamine supplementation as an
approach for symptomatic relief in PD patients is ineffective owing to the high
ionizability of the molecule, which limits transport across the blood-brain-barrier (BBB).
Therefore, oral administration of the metabolic precursor of dopamine i.e., levodopa (LDOPA, L-3,4-dihydroxyphenylalanine) has been the mainstay of PD management for
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decades.133-136 Currently marketed peroral formulations contain carbidopa (SINEMET ®
and STALEVO®), a DOPA decarboxylase enzyme inhibitor which has shown remarkable
improvement in the oral bioavailability of L-DOPA (> 70%).137 However, the problems
associated with erratic absorption, pulsatile delivery, and rapid rise and fall in CNS levels
of the drug still persist.137,138
Innovation in L-DOPA formulations and delivery is an active area of research,
aimed at accumulating consistent drug concentration in the brain. Although continuous
intravenous infusion of L-DOPA alone or in combination with a decarboxylase inhibitor
demonstrably reduces the frequency of motor fluctuations,139 and provides significant
improvement in mobility,140 it is impractical and inconvenient for routine patient selfadministration. Solution-based IN administration of both dopamine141 and many water
soluble prodrugs, including L-DOPA has been demonstrated.20,106 Unfortunately, low
brain levels of L-DOPA accompanied with dramatic fluctuations in drug concentration
suggest inconsistent delivery from liquid vehicles. Further, these formulations were
confronted with the issue of rapid mucociliary clearance and oxidation of L-DOPA in
solution limiting the effective dose delivered.
While liquid formulations offer a potentially easy method of IN delivery (via
nasal pump or spray), it is well established that liquid vehicles are most likely to have to
contend with rapid clearance from the nasal cavity, highlighting one of the major factors
that limits direct nose-to-CNS drug uptake. Normal mucociliary transit time in humans
has been reported to be between 10–20 min, during which the mucus lining moves
towards the nasopharynx for eventual drainage to the gastrointestinal tract. As a
consequence, the majority of the administered dose is cleared from the nasal mucosa,
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which is exacerbated by the drainage of solution droplets via the same channel owing to
gravity. In contrast, semisolid platforms (such as gels) and direct deposition of solid
particles (via insufflation) provide longer retention times in the nasal cavity, making them
increasingly favorable approaches for IN delivery. It is anticipated that these dosage
forms increase the viscosity of nasal mucus, leading to reduced clearance rate. At the
very least, they are less prone to gravitational drainage than their liquid counterparts.
To take advantage of IN delivery, while circumventing stability and clearance
issues, this work evaluates permeation of L-DOPA from solid microparticles placed in
direct contact with nasal epithelial tissue relative to permeation from solution
formulation. It is expected that IN delivered solid particles will be retained on olfactory
epithelial tissue longer relative to solution droplets, resulting in greater cumulative mass
transport. Further, it is hypothesized that L-DOPA molecules delivered from solid
particles deposited directly in contact with the mucosal membrane will result in more
rapid flux relative to L-DOPA in solution, due to an increase in localized concentration in
nasal fluid, resulting in a higher concentration gradient, which leads to a more rapid
diffusion rate.

Ultimately, this research finding can provide a foundation for

development of innovative sustained release solid dosage forms for IN application and
potentially minimize problems associated with fluctuations in drug levels, in PD patients.

2.2. Experimental Section
2.2.1. Chemicals and Reagents
L-DOPA, > 99% pure, was obtained from Acros OrganicsTM, (New Jersey, USA)
and stored in a low relative humidity desiccator over anhydrous CaSO4 (DrieriteTM) prior
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to experimentation. Solubility studies were conducted by preparation of simulated nasal
electrolyte solution (SNES), which combined 8.77 g NaCl, 2.98 g KCl, 0.59 g CaCl 2
anhydrous in 1000 mL of deionized water.142 The pH of the solutions was adjusted
between 5.5 and 6.0 with 1N HCl to simulate the pH of nasal fluid. Kreb’s Ringer Buffer
(KRB) was used for permeation studies, and was prepared by adding 0.05 g MgCl 2, 0.34
g KCl, 7.0 g NaCl, 0.18 g Na2HPO4, 0.1 g NaH2PO4, 1.8 g D-Glucose, 0.28 g CaCl2, and
1.26 g NaHCO3 to 1000 mL deionized water. Both buffer solutions contained 0.021 g/L
sodium metabisulphite to control oxidation of L-DOPA.143 All reagents were purchased
from Sigma Aldrich (Saint Louis, MO, USA).

2.2.2. L-DOPA solid microparticles
2.2.2.1. Solid-state characterization
Powder X-ray diffraction (PXRD) patterns were obtained using an X’Pert Pro
MPD system (PANalytical B.V., Almelo, the Netherlands), equipped with a copper anode
(Cu Kα, λ = 1.5406 Å), an auxiliary elliptical mirror, and X’Celerator TM detector. LDOPA powder was loaded between two layers of Kapton ® film (ChemPlex, Palm City,
FL) and spun in a vertical sample stage; consistent irradiation times of 135 s per step with
an angular step size of 0.017 °2 were used for all diffraction experiments. PXRD data
were collected over the range of 5–50 °2θ, using an operating voltage and amperage set,
respectively, to 45.0 kV and 40.0 mA.
Thermogravimetric analysis (TGA) was performed in an open Pt pan using a TA
instruments TGA (Model Q50, New Castle, DE). Approximately, 10 mg of sample was
accurately weighed and placed in the pan. The furnace temperature was increased at a
constant rate of 5 °C/min from 40 °C to 400 °C, as precise sample weights were recorded.
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Differential scanning calorimetry (DSC) was performed using a TA instruments DSC
(Model Q100, New Castle, DE). Accurately weighed samples (4.0–5.0 mg) were
hermetically sealed in Al pans, and the furnace temperature was increased at a constant
rate of 5 °C/min from 0 °C to 350 °C under constant 50 mL/min dry N2 gas purge. A
three-point enthalpy-temperature calibration was performed at 10 °C/min using oterphenyl, In, and Sn standards. Measurements were performed in triplicate and the mean
+ standard deviation is reported.

2.2.2.2. Particle Size analysis
Sieve fractionation (Performer III Model: SS-3, Gilson Company, Lewis Center,
OH) was used to separate different size fractions of 5 g L-DOPA powder (Table 3.1).
Collected fractions were weighed at intervals ranging from 15–30 min until the measured
weight change was less than 0.1 g. The fine sieve cut representing 20–53 μm of L-DOPA
was retained and stored for use in subsequent experimentation. Additionally, L-DOPA
fines were analyzed using an Olympus BX-51 optical microscope equipped with
polarizing filter, under 10x and 25x magnification. Photomicrographs were obtained to
evaluate morphology and measure Feret diameter for approximately 300 particles.

2.2.3. L-DOPA solution
2.2.3.1. Assessment of chemical stability
To ensure chemical integrity during the course of tissue experiments, the
concentration of L-DOPA in aqueous solution was determined using HPLC. Briefly,
solid L-DOPA was dissolved in water and vortexed until no undissolved particles were
observed. The solutions were analyzed for decreased potency under the conditions
summarized in Section 2.3.2. Triplicate samples of each test combination were removed
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from stock solutions following storage for 0, 1, 2, 3 and 7 days, and L-DOPA
concentration was assayed in every sample. Previous reports indicate that aqueous
stability of L-DOPA is unaffected by light,144 however, care was taken to avoid overexposure, and all samples were stored in the dark.
L-DOPA concentration in all samples was determined using a Waters Alliance
2690 HPLC system (Millford, MA) equipped with photo diode array (PDA) detector
using a Lichrospher 100 RP-18 column (25 cm x 4 mm with 5 µm particle size).
Previously filtered and degassed mobile phase comprising of 97:3 mixture of monobasic
potassium phosphate (0.01 M, pH = 2 adjusted with phosphoric acid) and acetonitrile was
used. It has been previously demonstrated that L-DOPA remains chemically stable in the
presence of strong acids.145 The mobile phase was pumped continuously at a flow rate of
1.0 mL/min with an injection volume of 20 µL. Standard solutions and test samples were
analyzed at the detector wavelength of 280 nm. All solutions were diluted in mobile
phase. Data were analyzed using one way analysis of variance (ANOVA) model. Posthoc comparisons of individual time points were conducted using paired t-test statistics
with a Bonferroni corrected significance level of 0.05 (two-tailed).

2.2.3.2. Measurement of L-DOPA saturation solubility
Equilibrium solubility of L-DOPA was determined by placing excess solid in
SNES containing antioxidant in glass vial enclosures. Vials were stirred mechanically
(200 rpm) in an orbital water bath shaker (Lab-Line instruments Inc., Melrose Park, IL,
Model No. 3540) maintained at a constant temperature (25 °C or 37 °C). At predetermined time intervals, aliquots of 10 mL were withdrawn, filtered using 0.45 µm
nylon filter (Millipore), and measured spectrophotometrically (UV Spectrophotometer
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8453, Hewlett Packard, Germany) at λ = 280 nm. Experiments were carried out in
triplicate; therefore, only mean values with S.D. error bars are reported.

2.2.4. L-DOPA Transport in Nasal Mucosa
Bovine olfactory mucosa was used as a model tissue for permeation studies,
where L-DOPA permeability was measured by adapting the methods published by
Chemuturi et al.143 Briefly, cow heads were obtained from Bud’s Custom Meats
(Riverside, IA). The olfactory turbinates, which were covered by a pale yellow olfactory
mucosa, were removed within 15 min of decapitation. The excised tissues were
thoroughly rinsed with KRB and transported in fresh KRB maintained on ice; all studies
were conducted within 4 h of procurement to ensure tissue viability.
The permeability of L-DOPA molecules through the bovine olfactory mucosa was
measured during experiments that used NaviCyte vertical chambers (Harvard Apparatus,
South Natick, MA). Tissue was carefully removed from the underlying cartilage and
affixed with the mucosal side facing the donor compartment, between the opposing faces
of the two half-chambers (donor and receiver), using a series of pins that surrounded the
opening. L-DOPA was loaded into the donor compartment either as a solution in KRB (1
mL of 0.75 mg/mL) or as solid microparticles (1.5 mg L-DOPA powder), which were
evenly sprinkled directly on the mucosal side of the tissue during apparatus assembly. It
should be noted that the mass of L-DOPA microparticles deposited on tissues was 2-fold
greater than that in solution samples to enable accurate weighing of the solid and
reproducible transfer, while minimizing powder loss. The temperature of the diffusion
cells was maintained using a heating block (Brinkmann Instruments Co., New York,
NY). Tissue samples were equilibrated for 30 min in KRB at 37°C, followed by
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replacement of donor and receiver with L-DOPA solution and fresh KRB, respectively.
Alternatively, the equilibration step was performed prior to assembly of the chambers
that were loaded with L-DOPA microparticles. The cells were aerated by constant
carbogen flow (95% O2 + 5% CO2) at a rate of 3–4 bubbles/s. The pH of the donor and
receiver solutions was adjusted to 5.7 + 0.2 with 1 N HCl. Every 15 min, 200 µL samples
were withdrawn from the receiver compartment and replaced with fresh, pre-warmed
KRB. L-DOPA permeation was measured from the receiver compartment aliquots using
the previously described HPLC method. Tests were performed in triplicate; results are
expressed as mean + SEM. At the end of each transport study, tissue viability was
confirmed by measurement of the electrical resistance across the mucosal membrane,
where non-viable tissue samples were considered those having measured control transepithelial resistance values (approximately 180 ohm/cm2) that dropped by more than
20%. Based on the TEER measurements, the viability of all tissue explants was
maintained during the course of all transport studies. It is noted, however, that a
paracellular transport marker (Lucifer yellow, LY) or histopathology tests could be used
as an additional tool to verify tissue integrity.
Calculations of steady-state and apparent permeability coefficients were based on
Fick’s First Law of diffusion. Steady-state flux (Jss) was calculated according to
Equation 2.1:

𝐉𝐒𝐒 =

𝐝𝐌 𝟏

(2.1)

𝐝𝐭 𝐀

where M is the cumulative amount of drug in the receiver cell at time t, dM/dt is the mass
transport rate obtained from linear regression of the initial steady-state portion (µg/min)
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and A is the area of the exposed membrane, i.e., diffusion area (0.64 cm2). The apparent
permeability coefficients (Papp) were calculated using Equation 2.2:

𝐏𝐚𝐩𝐩 =

𝐉𝐬𝐬
𝐂𝟎

𝐱 𝟔𝟎

(2.2)

where Co is the initial donor concentration (µg/mL), resulting in units for Papp of cm/s.
The underlying assumption of these equations is that the donor concentration of analyte
remains constant for the period of steady state.

2.3. Results and Discussion
2.3.1. L-DOPA Solid
As with many other dosage forms involving crystalline particles, solid state
characterization of the drug substance is necessary for development of dry powder
inhalation products. In that regard, it is important to identify the presence of
ordered/disordered phases that may significantly impact the reproducibility of
manufacturing and therapeutic performance. L-DOPA powder was characterized using
PXRD, DSC and TGA. The PXRD pattern of the vendor-supplied L-DOPA is shown in
Figure 2.1, and corresponds well with the respective calculated reference pattern
(Cambridge Structural Database refcode: LDOPAS03) indicating the presence of a single
solid phase.146
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Figure 2.1. Experimental PXRD pattern for vendor-supplied L-DOPA powder (black
solid line) is compared with simulated diffraction pattern (ICDD reference code:
LDOPAS03 grey solid line).146 The data indicate that the powder sample is comprised of
a single phase solid form.
In Figure 2.2, the DSC data show a single endotherm attributable to melting with
an onset temperature (Tm) of 276.6 (1.3) oC, n = 3, which agrees closely with reported
values (30, 31). Melting was followed immediately by rapid thermal degradation of LDOPA at approximately 298.3 (3.8) oC (Td), n = 3, which was consistent with the rapid
12.90% weight-loss observed in the TGA data. This suggested that proper care should be
taken in all preparation and experimental procedures to avoid temperatures exceeding Td.
Neither TGA nor DSC data showed signal consistent with desorption of water,
suggesting that the applied storage conditions were appropriate for solid L-DOPA.
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Figure 2.2. Experimental DSC thermogram of L-DOPA (solid line) showing Tm = 276.6
o
C. Post-melting baseline is indicative of rapid thermal degradation. Superimposed TGA
thermogram (dashed line) represents 12.90% weight loss beginning immediately at Td,
confirming degradation at T>Tm.

Particle size (PS) is an important parameter that is known to influence nasal
delivery, therefore, sieve fractionation of L-DOPA powder was performed and the
particle size distribution (PSD) was represented as cumulative percent undersize (Table
2.1).
Table 2.1. Particle size distribution of L-DOPA determined by sieve analysis.
Particle size distribution for levodopa by sieve analysis
Cumulative Percentage Undersize
< 20 µm
< 53 µm
< 75 µm
< 125 µm
L-DOPA
4.2
47.0
54.8
79.3
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< 180 µm
97.2

< 250 µm
99.8

< 500 µm
100.0

Recognizing that optimum in vivo olfactory deposition requires particles sized
approximately 10–45 µm, the fraction of L-DOPA fines collected on the 20 µm sieve
were retained for mass transport studies involving solid microparticles. It is
acknowledged that, although sieve fractionation yielded a sufficient quantity of L-DOPA
fines for the present studies, larger scales, and undoubtedly, manufacturing, would likely
require comminution to homogenize L-DOPA particle size to this specification. In those
cases, solid state characterization would be essential to ensure that the much harsher
processing did not deleteriously change the L-DOPA solid. In the present study, the
selected sieve fraction was characterized for surface and bulk morphology, with
photomicrographs showing that the majority of L-DOPA crystallites exhibited a platelike morphology (Figure 2.3a – 2.3c). The median primary particle size (d50) was 20.93
µm, with d10 and d90 respectively measuring 9.5 µm and 43.7 µm (See Fig. 2.3d).
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Figure 2.3. (a) Micrograph depicting morphology of L-DOPA primary particles
immersed in oil, observed through a 25× objective; (b,c) typical micrographs used to
measure Feret diameter (n = 300), 4x objective; (d) particle size distribution of primary
particles observed in (b and c).
Although the morphology of particles obtained from analytical samples may not
be particularly favorable for reproducibly emitted doses from nasal devices, it is expected
that the size reduction step necessary at larger scales will likely make the particle
morphology more regular; making it suitable for insufflation and nasal deposition.
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2.3.2. L-DOPA Solution
The potency of L-DOPA solutions was evaluated when stored in combination
with an antioxidant (0.021 g/L sodium metabisulphite). To simulate both storage and
physiological conditions, 0.4 mg/mL L-DOPA solutions were held at 25 oC and 37 oC,
respectively. The % recovery vs. time profiles of L-DOPA, subjected to experimental
conditions are shown in Figure 2.4.

Figure 2.4. Effect of temperature and presence of antioxidant on the concentration of LDOPA in aqueous solution. Data are shown as mean + SD. Bonferroni multiple
comparison (α = 0.05) between groups is shown to denote the extent of loss in L-DOPA
concentration on day 7. The rate constants for degradation are summarized in Table 2.2.
Generally, it was noted that the extent of L-DOPA degradation increased with
experimental temperature, as expected. In the solutions containing antioxidant, however,
the L-DOPA content was less significantly reduced at both temperatures, suggesting that
the sodium metabisulfite inhibited oxidative degradation in solution. After 7 days, a
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maximum of 3.8% and 7.7% decrease in the amount of L-DOPA was recorded
respectively for solutions maintained at 25 oC at 37 oC. In contrast, solutions without
antioxidant resulted in greater L-DOPA degradations of 18.3 % (at 25 oC) and 31.4 % (at
37 oC). A moderate green discoloration in these samples was observed, suggesting
solution-mediated oxidation of L-DOPA to L-dopaquinone as a primary degradation
pathway.147 The data are in agreement with earlier reports and show goodness of fit to
pseudo first-order kinetics.144,147,148
The degradation rate constants were determined using Equation 2.3:

−

𝒅𝑪
𝒅𝒕

= 𝒌(𝑪) ↔ 𝒍𝒏

𝑪𝟎
𝑪

= 𝒌𝒕

(2.3)

where k is the pseudo first-order rate constant and C0 and C represent L-DOPA
concentrations at time zero and t, respectively. If the results of Figure 2.4 are plotted in
the form of Equation 2.3, k values can be computed from the slopes of the straight lines,
which is summarized in Table 2.2.

Table 2.2. Pseudo 1st order rate constants for degradation of L-DOPA in solution.
L-DOPA aqueous solution (0.4 mg/mL)
Conditions
Rate constant (k) min-1
25 °C with antioxidant
0.7 x 10-2
25 °C without antioxidant
3.4 x 10-2
37 °C with antioxidant
1.5 x 10-2
37 °C without antioxidant
9.7 x 10-2
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R2
0.99
0.99
0.99
0.99

These results were important in deciding a rigorous timeline for the permeation
studies and subsequent quantitative analyses. Accordingly, L-DOPA solutions containing
antioxidant were prepared on the day of permeation tests, thereby minimizing
degradation to < 1%. Although it is recognized that chronic use of metabisulphites can
result in cellular injury,149 the time of antioxidant exposure in these permeation tests is
not expected to be particularly damaging to the nasal olfactory tissue.
The saturation solubility of L-DOPA microparticles isolated through sieve
fractionation (see Section 2.3.1) was evaluated prior to tissue permeation experiments.
Figure 2.5 plots the concentrations obtained in the dissolution medium for crystalline LDOPA microparticles as a function of time, in the presence of excess solid phase.

Figure 2.5. Saturation solubility of L-DOPA microparticles. Closed grey squares (■) and
closed black circles (●) represent solubility profile at 25° and 37°C, respectively. In 12 h,
the measured saturation concentration (Cs) of L-DOPA was almost 1.6 times higher at
37°C (p <0.001, Student’s t-test).
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At equilibrium, the measured saturation concentration (Cs) of L-DOPA was,
respectively, 1.73 + 0.15 mg/mL and 2.77 + 0.16 mg/mL at 25 oC and 37 oC. The data
corroborated earlier reports indicating slight solubility of L-DOPA in aqueous
medium.150,151 These measurements were not atypical, owing to the zwitterionic nature of
the L-DOPA molecule at pH values between 3–9, having an amine group (pKa 8.11) and
a carboxylic acid (pKa 2.30). Consequently, increased solution potencies are possible only
when the pH of the solution is altered dramatically. For example, the solubility of LDOPA is reported to be 10 mg/mL in 0.01 M maleic acid (pH = 2).20 Considering that
such extreme conditions do not accurately simulate the physiological environment of the
nasal cavity, and could potentially affect the integrity of nasal tissue, using dissolution
media having such a low pH is not recommended. In the present experiments, PXRD data
obtained for solid residue in contact with KRB at either 25 oC or 37 oC was consistent
with the L-DOPA Cambridge Structural Database powder pattern, suggesting that that the
solid phase remained unchanged during the experiments (data not shown).

2.3.3. L-DOPA transport studies
Permeation of L-DOPA through bovine olfactory tissue was evaluated in vitro.
Since liquid formulations are the most commonly developed dosage forms for IN
delivery, 1 mL of a 0.75 mg/mL L-DOPA solution in KRB was chosen as a comparator
for mass transport resulting from the 1.5 mg of L-DOPA solid microparticles directly
deposited on the epithelial tissue surface. The amount of L-DOPA measured in the
receiver compartment over time was used to calculate Jss and Papp as described above
(Equations 2.1 and 2.2). Figure 2.6(a) demonstrates the permeation profiles across nasal
mucosa, when L-DOPA was loaded as either solution or solid microparticles. After 120
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min of contact with nasal mucosa, the cumulative amount of L-DOPA that permeated
from solution, per unit area tissue, was 225.13 ± 38.31 µg cm-2 (n = 3). In contrast, a
maximum of 501.07 ± 105.63 µg cm-2 mass transport was measured when the donor side
was loaded with L-DOPA solid microparticles (n = 2).
This was also reflected in the average Jss values, where approximately 3-fold
higher flux was measured in the diffusion cells loaded with L-DOPA solid when
compared with those containing L-DOPA solution (See Table 2.3). The linear region in
all permeation profiles, chosen based on goodness-of-fit (R2 >0.97), was used to estimate
mass transport under steady-state conditions (shown in dashed line).
Table 2.3. Comparison of average in vitro nasal epithelial flux of L-DOPA from aqueous
solution and solid microparticles.
Average steady state flux (Jss)
µg.cm-2.min-1 (correlation) + SD
L-DOPA
aqueous solution a
solid microparticles b
2.13 (0.95) 0.97
6.08 (0.97) 0.69
a
b

number of replicates = 3
number of replicates = 2
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Figure 2.6. in vitro permeation profiles of L-DOPA across bovine olfactory mucosa from an aqueous solution (empty circles, n = 3)
and solid particles (filled circles, n = 2). (a) Data are expressed as cumulative L-DOPA permeated with time (mean ± SD). The solid
connecting line represents the initial steady-state portion that was chosen to calculate Jss according to Eq. 1; (b) data normalized with
respect to initially loaded mass of L-DOPA i.e., 0.75 mg in 1 mL donor solution and 1.5 mg as solid microparticles.

It should be noted that no additional dissolution medium was added to the donor
compartments containing the solid microparticles, which were directly deposited on
tissue surfaces. It was expected that dissolution of the L-DOPA in the naturally moist
surface of olfactory mucosal membrane in these experiments would occur similarly in
vivo following insufflation.
Despite a low hydration volume, the relatively rapid dissolution of L-DOPA from
microparticles in the nasal mucus is proposed to occur by two mechanisms. Given that
the average size of the primary L-DOPA microparticles was approximately 20 µm, a
fraction of the solid was expected to rapidly dissolve in the small volume of nasal fluid,
owing to an increase in the surface energy and thereby improved wettability.152 The
other contribution to rapid dissolution includes favorable interactions forming between
the overall negative charge, typical of nasal cell surfaces (resulting from the presence of
sialic acid in nasal mucin), and the positively charged L-DOPA molecules expected at
experimental pH.153 As a consequence, the L-DOPA microparticles were expected to
saturate the mucus layer, the concentration of which was expected to be close to C s (2.77
+ 0.16 mg/mL at 37oC). Such a strong driving-force can potentially justify the rapid mass
transport observed within the first 60–75 min of contact with nasal mucosa. The
subsequent reduction in L-DOPA flux may be attributed to removal of fine solid particles
away from the diffusion area under gravity.
The average apparent permeability coefficient (Papp) of L-DOPA was calculated
to be 4.73 x 10-5 cm/s from solution samples. As the chemical structure of the molecule
was not altered in this study, it was assumed that Papp should remain consistent for LDOPA solid samples, even when the measured membrane flux (Jss) was considerably
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different. Using Equation 2.2, the apparent initial concentration (Co) for solid samples
was calculated to be 2.14 + 0.24 mg/mL. The closeness of this value to the
experimentally measured Cs (2.77 mg/mL) supports that the claim the L-DOPA solid
particles saturated the nasal mucus (refer to Figure 2.7).
To caluclate Papp, it was taken the donor concentration remains constant for the
steady state region (dashed line). In order to test the validity of this assumption for the
solid microparticle group, the cumulative L-DOPA transport at 60 min is used as an
example. The mean cumulative L-DOPA permeated at 60 min is 220.31 + 50.98 μg. If LDOPA trapped within the olfactory tissue is insignificant, the amount of drug remaining
on the donor side is about 1280 μg which is still expected to saturate the nasal mucus.
Therefore, it supports the assumption of steady donor concentration. Beyond this time
point, it can be seen that the permeation profile levels off which may be attributable to
slow drifting away of particles from the diffusion area under gravity.
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Figure 2.7. Schematic representation of the L-DOPA permeation of nasal epithelial cells. Green closed circles represent directly
deposited L-DOPA microparticles on the donor side of tissue, which saturate the mucus layer (Cs = 2.77 mg/mL). This contrasts the
dark blue shaded region denoting L-DOPA solution contact with the mucus layer at a constant concentration throughout the entire
donor chamber (0.75 mg/mL). As depicted, saturation of the mucus layer by L-DOPA dissolved from solid microparticles results in a
much higher steady-state concentration gradient that explains the 3-fold increase in flux relative to L-DOPA solution experiments.

It is acknowledged that the starting mass of L-DOPA solid was almost double the
quantity loaded in solution, which was necessitated in order to minimize weighing errors.
Therefore, the comparison between the mass transport from either physical form is
incomplete if the cumulative L-DOPA transport values are not normalized with respect to
initial concentration. The adjusted data showed that approximately 11.79% of the initial
amount was permeated from L-DOPA microparticles within 30 min. In contrast, only
about 7.84% of the initial concentration of L-DOPA was permeated from molecules in
solution, as shown in figure 2.6(b). It is clear that, despite normalization of mass
transport values, the solid microparticles demonstrated greater L-DOPA permeation (up
to 75 min), which can be related to the higher concentration gradient across the epithelial
tissue. Notably, the maximum % of L-DOPA transported after 120 min was comparable,
with 30.1% and 33.4% respectively for the solution and powder samples, however, the
present data still represent a significant finding in that the delivery of L-DOPA from solid
microparticles will not be restricted by low dissolution volume in the nasal cavity.
Moreover, the residence time for solid microparticles is expected to be much greater
relative to solution, which is rapidly drained away from the delivery site by normal
mucocilliary clearance and flow due to gravity. As such, the more extensive initial
permeation from the microparticles suggests that delivery in this physical form may
provide the opportunity for greater drug absorption.

2.4 Conclusions
Deposition of solid microparticles on nasal mucosa via insufflation is a potentially
viable, yet relatively unexplored means of IN drug delivery. These data showed that total
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in vitro nasal permeation of L-DOPA dissolved from solid miroparticles was comparable
with aqueous solution. Almost three-fold greater nasal epithelial steady-state flux was
observed for L-DOPA absorbed from powder experiments, indicating rapid mass
transport. Furthermore, well known issues related to chemical stability of aqueous
solution of L-DOPA as well as potential tissue injury owing to the use of sodium
metabisulfite in solution formulations were successfully avoided by deposition of solid
microparticles, which required neither an aqueous vehicle nor antioxidant. Collectively,
the data demonstrated that dry, solid powder dosage forms could be developed for IN
delivery of L-DOPA. In the pharmaceutical field, such evidence could be particularly
important in treatment of other neurological disorders where no straightforward, noninvasive therapies exist in current clinical practice.
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Chapter 3: Solid-state transformations of ribavirin
as a result of high shear mechanical processing
3.1. Introduction
Ribavirin is predominantly administered via solid oral dosage forms. Some
marketed products include Copegus® (200 mg film coated tablets; Hoffman La-Roche),
Rebetol® (200 mg hard capsules and 40 mg/mL oral solution; Merck), Ribasphere® (200,
400 and 600 mg hard capsules; Three Rivers Pharmaceuticals), and ModeribaTM (200,
400, 600 mg film coated tablets, AbbVie).154 Additionally, it is also given as a powder for
inhalation solution (Virazole® 6 g vials; Valeant Pharmaceuticals). Regardless of the
delivery system, it is likely that solid ribavirin will be subject to some degree of highshear mechanical processing, including milling, granulation and compaction, making
unanticipated solid-state transformations, including crystal-to-crystal and crystal-toglassy solids, a possibility during manufacturing.
Over the last few decades, numerous examples of process-induced phase changes
of pharmaceutically relevant materials have been reported.154-160 Some estimates suggest
that approximately 30% of active pharmaceutical ingredients (API) are susceptible to
solid form changes during mechanical processing.159 The impetus to identify potential
process-induced

transformations

during

processing,

followed

by

thorough

characterization and elucidation of the underlying mechanisms is important for product
development, and consistent with the materials understanding at the heart of worldwide
regulatory guidances.
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Ribavirin was previously reported as solidifying as one of two unique crystalline
polymorphs,161,162 conventionally named R-I and R-II, which respectively represent the
high-melting and low-melting temperature enantiotropes.163 Careful selection of a
consistent solid form during pre-formulation, which persists in the final drug product, is,
therefore, warranted. In addition, the impalpable nature of ribavirin powder, accompanied
with low and variable tapped densities (reported range 0.32-0.45 g/mL)164 pose
considerable challenges to material handling. While flow properties and processability of
ribavirin can be improved through secondary manufacturing procedures, such as
pelletization,165 roller compaction164 and wet granulation;166 the potential for concurrent
solid-state transformations during manufacturing has not been investigated. It seems
likely that, consistent with other small molecule crystalline materials, unanticipated
partial or complete phase conversions can alter the mechanical properties, processability,
and performance attributes of the drug substance in the final drug product.
Polymorphic transformations of pharmaceutically relevant solid materials are a
known potential consequence of milling, which can affect the quality and performance of
the final drug product.157,167-169 When a crystalline API is milled, the excessive shear
stress accompanied by other manifestations of very high mechanical energy (such as
heat), elicit structural changes to the crystal, while introducing substantial lattice defects
that alter the physical and chemical properties of the solid. While empirical models of
mechanical activation potential exist,170,171 their utility is restricted to specific
experimental conditions such as temperature, equipment dimensions, and sample size,
making universal predictions elusive. Experimental observation of mechanically induced
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transformations, therefore, remains important, especially if a range of temperatures,
processing stresses and other conditions are expected.
In the present work, the influence of thermal and mechanical stresses on ribavirin
was investigated as they pertained to the potential to induce solid-state phase
transformations as a consequence of processing. Following the observation that the
kinetics of a temperature-mediated enantiotropic conversion was prohibitive for
unprocessed ribavirin, it was hypothesized that transitions between polymorphs could be
observed in shorter timeframes when defects resulting from pulverization enabled more
rapid transformations at elevated temperatures. To test the hypothesis, phase pure
samples of each ribavirin enantiotrope were generated, and the enantiotropic transition
temperature (Ttr) was determined. Samples were milled, with and without temperature
control, and the outcomes of mechanical and/or thermal stimuli were recorded. Particle
size reduction, commensurate with increased specific surface area, and the extent of
crystal damage were measured to identify which of these factors predominate in the
observed phase transformations. This additional effort was expected to provide a better
understanding of the likelihood of phase conversion during other manufacturing steps
(such as compaction, which also involves particle fracture and crystal damage).
Reversibility of the polymorphic transition (R-I  R-II) was also investigated by
isothermal exposure of the phase-pure metastable polymorphic form to varied conditions
of relative humidity. Ultimately, these observations serve as a reference for materials that
may be similarly susceptible to mechanically induced phase changes.
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3.2. Materials and Methods
Ribavirin was purchased from Jinan Jiaquan Chemicals Co. Ltd. (Jinan, China,
Lot number 02110330). Samples were stored in a desiccator containing phosphorous
pentoxide (P2O5) at ambient temperature prior to use.

3.2.1. Recrystallization of Ribavirin Polymorphs
Phase-pure samples of ribavirin polymorphs were prepared by recrystallization
from solvents, using previously reported methods with slight modification.161,162 To
obtain pure R-II, a slight excess of vendor supplied ribavirin (R-RW) was dissolved in
water at 80 °C to form a supersaturated solution. The suspension was filtered and left to
cool slowly to room temperature. The resulting crystals were vacuum dried at 25 °C
overnight and stored for further characterization.
Pure R-I was prepared by fractional recrystallization, where a supersaturated
solution of R-RW was formed in methanol (> 99% HPLC grade, Fisher Scientific) at 60
°C and filtered. The filtrate was dried under a current of air, which facilitated rapid
crystallization, owing to rapid evaporation of organic solvent, accompanied by a
temperature drop. Upon appearance of the first few crystals, the mother liquor was refiltered to harvest pure R-I; phase purity was confirmed by rapid differential scanning
calorimetry (DSC) and peak-by-peak comparison of powder X-ray diffraction (PXRD)
patterns with the known crystal structure (CSD refcode: VIRAZL). Experimentation
demonstrated that the re-filtration to harvest R-I crystals was required to prevent
recrystallization of a mixture of phases. Isolated R-I crystals were dried in a vacuum
oven, and used as seeds for producing subsequent batches (0.5-1.0 g) of pure R-I.
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3.2.2. Generation of Amorphous Ribavirin
Amorphous ribavirin was prepared in situ during DSC experiments. An accurately
weighed sample of R-II was heated to Tm + 10 °C at a rate of 5 °C/min, and held
isothermally for 10 min. The molten sample was rapidly cooled at 40 °C/min, with no
observation of recrystallization, and the Tg was determined during the subsequent DSC
heating cycle.

3.2.3. Isothermal heating experiments
Conversion to the high-temperature stable enantiotrope, R-I, was attempted using
a method similar to that reported for chlorpropamide enantiotropes.172 Approximately
500 mg of R-II powder was placed in glass petri dishes, which were held isothermally at
150°C (T < Tm for either polymorph) in an Isotemp 13-246-506GA gravity convection
oven (Fisher Scientific, Dubuque, IA). Thermal exposure was maintained as long as the
sample did not exhibit signs of thermal degradation. Samples were periodically
characterized to identify the emergence of the R-I phase, by comparison of experimental
diffraction patterns with the calculated PXRD patterns of each enantiotrope.

3.2.4. Milling experiments
R-II was milled at frequency of 30 Hz in a vibratory impact ball mill (Mixer Mill
MM200, Retsch GmbH & Co., Germany) for milling durations of 60, 180 and 270 min.
A 0.5 g powder sample was placed in a 25 mL volume stainless steel jar containing one
12 mm diameter stainless steel ball. Milled samples were immediately characterized
using PXRD and DSC. Although care was taken to avoid excess heat accumulation, by
intermittently opening the milling jar for short time intervals, it is acknowledged that the
procedure does not allow rigorous temperature control.
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In contrast, cryogenic grinding of R-II was accomplished using a SPEX Certiprep
6750 Freezer Mill (SPEX Certiprep, Metuchen, NJ) in which powder samples weighing
approximately 1.0 g were placed in a polycarbonate milling vessel. A stainless steel
cylindrical milling rod was placed in the vessel, and samples were allowed to equilibrate
for 3 min following immersion in a liquid nitrogen bath prior to milling. Temperature
control during processing was enabled by consistently maintaining the liquid nitrogen
bath during the experiments, allowing continuous immersion of the samples and milling
medium throughout comminution. Similar to a previously published method,167 materials
were ground for 2 min intervals at a frequency of 10 Hz, separated by 2 min cool-down
periods, allowing minimization of local sample temperature increases during
experimentation. Upon completion of milling, triplicate samples were analyzed using
PXRD and DSC.
The particle size and size distributions of unmilled R-II and all milled samples
were determined using an Olympus BX-51 optical microscope equipped with polarizing
filter, at 10x magnification. Primary particles were separated by preparing a dilute
suspension in immersion oil, which was placed between microscope slides and a
coverslip. Photomicrographs for each sample were collected to measure the Feret
diameter for approximately 300 particles.

3.2.5. Influence of storage conditions
Recrystallized R-I was observed for re-conversion to the stable polymorph under
varied conditions of relative humidity at ambient room temperature (22 + 2°C). Each 300
mg sample was equilibrated at 0% RH by storage in a desiccator with P2O5, or at % RH
of 33%, 60%, and 75% by equilibration over saturated solutions, respectively containing
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MgCl2, NaBr, or NaCl. Repeated hygrometer measurements ensured that each humidity
condition was maintained at + 3% of the desired values. Samples were evaluated for
phase changes using PXRD at regular intervals for up to 60 days.

3.2.6. Characterization
3.2.6.1. Thermogravimetric Analysis (TGA)
Samples were evaluated for the possibility of solvate formation using a
thermogravimetric analyzer (Model Q500, TA Instruments, New Castle, DE). Samples
weighing approximately 10 mg were placed on an open platinum pan and heated at
2°C/min under constant nitrogen purge at 60 mL/min. Subsequent thermograms were
examined for stepwise weight loss commensurate with desolvation.

3.2.6.2. Differential Scanning Calorimetry (DSC)
Conventional and modulated temperature DSC analyses were performed using a
TA Instruments Q100 differential scanning calorimeter (TA Instruments, New Castle,
DE) with an attached refrigerated cooling accessory. Dry nitrogen gas (50 mL/min) was
allowed to constantly purge the DSC cell during all experiments, while a three-point
temperature and enthalpy calibration was accomplished using Sn (Tm 231.9 oC), In (Tm
156.6 oC), and o-terphenyl (Tm 55-56 oC) standards. Conventional DSC measurements
were made to determine the melting temperatures (Tm) of ribavirin polymorphs.
Accurately weighed samples (5.0 + 0.5 mg) were hermetically sealed in an Al sample pan
and heated at constant rates of 0.5, 2, 5, 10, 20, or 40°C/min to a temperature beyond the
reported Tm.162,163 All measurements were performed in triplicate and reported as mean
values + standard deviation.
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The heat capacities of R-I, R-II and amorphous ribavirin were determined in the
MDSC (modulated temperature) mode, using experimental parameters carefully selected
to produce accurate and artifact-free data.173 A modulation amplitude of + 0.256 °C,
period of 100 s, and an underlying heating rate of 1 °C/min were used to allow 4-5
modulation cycles over the critical temperature range of transition (55-65 °C) while
minimizing the thermal gradient across the sample. Samples weighing approximately 10
mg were loaded and tightly packed in standard Al pans, which were subsequently
crimped to ensure good sample-to-pan contact. Background noise was minimized by
ensuring that sample and reference pan weights matched within + 0.02 mg. Sample heat
capacities were then obtained by deconvoluting the non-reversing and reversing signals
from the total heat flow, using instrument software (Universal Analysis 2.0, TA
Instruments). The heat capacities of both the crystalline and amorphous forms of ribavirin
were measured over temperatures ranging from Tg – 50 °C to Tg + 50 °C. The heat
capacity constant (KCp) was previously calibrated using a sapphire disc weighing
approximately 25 mg. Additionally, vacuum dried samples of crystalline sucrose were
used as external standard to verify the precision of the instrument, and measured heat
capacities were compared with the literature reported values.174

3.2.6.3. X-ray powder diffraction (PXRD)
Powder X-ray diffraction (PXRD) patterns were obtained using an X’Pert Pro
MPD diffractometer (PANalytical B.V., Almelo, the Netherlands), equipped with an
auxiliary elliptical mirror and X’CeleratorTM detector. Powder samples were placed
between two layers of Kapton® film (ChemPlex, Palm City, FL) and spun in a vertical
sample transmission stage. Irradiation with X-rays from a copper source (Cu Kα, λ =
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1.5406 Å) for a duration of 135 s per step, and incremental angular steps of 0.017 °2
were used for all diffraction experiments. PXRD data were collected over the range of 5–
50 °2θ, using an operating voltage and amperage set, respectively, to 45.0 kV and 40.0
mA.

3.2.6.4. Solution Calorimetry
The heats of solution (ΔHsol) at 25 °C were determined for ribavirin polymorphs
using an isothermal heat-conduction microcalorimeter (Model 7211, Calorimetry
Sciences Corp., Lindon, UT). Solid samples of phase pure polymorphs were accurately
weighed (25+1 mg), and the integral heat of solution was measured as each was dissolved
into 25.0 mL of distilled water. The dissolution medium was stirred at 50 rpm by a
paddle. Triplicate measurements were made and reported as an average + standard
deviation.

3.2.6.5. Measurement of aqueous solubility
The aqueous solubility of ribavirin polymorphs was determined by placing excess
solid in screw-capped glass vials containing distilled water. Vials were stirred
mechanically in an orbital water bath shaker (Model 3540, Lab-Line Instruments Inc.,
Melrose Park, IL) maintained at a constant temperature of 25°C and 200 rpm speed. At
appropriate time intervals, 10 mL aliquots were withdrawn, filtered using 0.45 µm nylon
filter and measured spectrophotometrically (UV Spectrophotometer 8453, Hewlett
Packard, Germany) at λ = 207 nm. Experiments were carried out in triplicate; therefore
only mean values with S.D. error bars are reported.
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3.2.6.6. Surface area determination (BET)
Brunauer, Emmett and Teller (BET) surface area quantification was performed
using a Flow Sorb II 2300 (Micromeritics Corp., Norcross, GA) instrument and a fivepoint BET N2 adsorption protocol. Samples weighing approximately 200 mg were
degassed under dry nitrogen for 12 h prior to analysis. Room temperature was used to try
and avoid any possible phase transformation. Replicate measurements were performed to
verify the precision of each measurement.

3.2.6.7. High performance liquid chromatography (HPLC)
Ribavirin was assayed using a published stability-indicating HPLC method with
slight modifications.175 The analysis employed a Hypersil C18 reverse phase column
(5 μm, 250 mm × 4.6 mm i.d., Waters, MA, USA) and a Waters 2690 LC system
equipped with a Waters 996 photodiode array detector and an autosampler (Waters Corp.,
MA, USA). The mobile phase, comprised of 0.01 M potassium dihydrogen phosphate
solution and pure methanol (95:5, v/v), was eluted isocratically at a flow rate of
1 mL/min, while the detector response was set at  = 207 nm. Ribavirin was eluted as a
single peak in the chromatogram at approximately 4.55–4.65 min.
R-RW, R-II and R-I samples were separately dissolved in distilled water to a final
concentration of 50 µg/ml, of which 20 L was injected into the column. A calibration
curve constructed using standard ribavirin solutions within the appropriate concentration
range (10 – 90 µg/ml) displayed excellent linearity with an R2 larger than 0.99. All
measurements were performed in triplicate.
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3.3. Results and Discussion
3.3.1. Physical characterization of ribavirin polymorphs
The PXRD pattern for ribavirin obtained from the vendor (R-RW) was compared
with simulated reference patterns obtained from the Cambridge Crystallographic Data
Centre (Figure 3.1). All peaks for R-RW corresponded with the reference pattern for R-II
(CSD refcode: VIRAZL01) with no discernable peaks attributable to R-I (CSD refcode:
VIRAZL).176
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Figure 3.1. The experimental PXRD pattern for vendor-supplied ribavirin powder R-RW (red) is compared with recrystallized
ribavirin R-I (green) and recrystallized ribavirin R-II (blue). Simulated diffraction patterns for R-I (CSD reference code: VIRAZL, in
grey) and R-II (CSD reference code: VIRAZL01, in black) are also provided. The data indicate that R-RW corresponded entirely with
the R-II pattern, and did not contain discernable quantities of R-I.

DSC thermograms for R-RW collected at 2 °C/min exhibited a melting endotherm
at 166.05 °C for R-II; followed by partial recrystallization and subsequent melting at
174.9 °C for R-I (Figure 3.2). This thermal behavior was in close agreement with that
reported in the literature,162,163 and not unexpected for enantiotropes characterized by
DSC. To ensure phase purity of the starting materials used for subsequent
experimentation, ribavirin polymorphs were recrystallizaed from solvent, as described in
Section 3.2.1. As shown in Figure 3.2b, the DSC thermograms of the isolated samples
of R-I and R-II exhibited no thermal features identifiable with the other solid form,
suggesting that recrystallization had resulted in pure phases. Additionally, PXRD patterns
for samples of R-I and R-II recrystallized from solvent (Figure 3.1), were consistent with
the respective calculated reference patterns obtained from the CCDC. TGA data for each
recrystallized sample did not show weight loss prior to melting, suggesting that residual
solvent from recrystallization was removed during vacuum drying, and confirmed that
neither crystalline form was solvated.

76

77
Figure 3.2. Comparison of DSC thermograms of R-RW (red) with recrystallized phase pure samples of R-I (green) and R-II (blue). RRW melted at 166 °C consistent with R-II (Tm = 168.1 + 0.7 °C) followed by recrystallization and subsequent melting at 174 °C,
consistent with R-I (Tm = 177.4 + 0.2 °C). The superimposed TGA thermogram (dashed line) shows no weight loss until
approximately Tm R-I + 30 °C, confirming that both solid forms of ribavirin were thermally stable, and essentially devoid of residual
solvent.

Comparison of relevant crystallographic and thermal properties of ribavirin
polymorphs, as listed in Table 3.1, revealed that the higher Tm form had a lower
enthalpy, indicating enantiotropic polymorphism, per the heat of fusion rule.177 The
reported crystallographic densities of R-I and R-II (at ambient temperature) appear to
violate the density rule;176 however, these observations are consistent with other small
molecule solids at room temperature, including hydroquinone178 and resorcinol.179

Table 3.1. Summary of crystallographic and thermal properties of ribavirin solid forms177
Properties

R-II

R-I

Crystallographic
properties

Unit cell dimensions (Å)

Unit cell dimensions (Å)

a = 25.034

a = 14.863

b = 7.719

b = 7.512

c = 5.289

c = 8.788

Density (g/cm3) = 1.587

Density (g/cm3) = 1.653

Space group = P212121

Space group = P212121

Z = 4, Z’ = 1

Z = 4, Z’ = 1

Melting temperature - Tm
168.1 + 0.7 °C

Melting temperature- Tm
177.4 + 0.2 °C

Enthalpy of melting – ΔHm
44.1 + 0.8 kJ/mol

Enthalpy of melting – ΔHm
41.3 + 0.1 kJ/mol

Thermal properties
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3.3.2. Estimation of transition temperature (Ttr) and enthalpy (Htr)
The determination of Ttr for ribavirin was important in order to identify the
circumstances under which its enantiotropes were subject to conversion. For
enantiotropically related systems, such as carbamazepine180,181 or sulfamerazine182,
identification of Ttr allowed assessment of the risks associated with conversions to
different forms by temperature excursions during processing.183 In the present work, two
independent methods were used to determine this value: 1) interpolation of a Gc phase
diagram and 2) solubility extrapolation.
1) Gc phase diagram method: Configurational thermodynamic quantities have
traditionally been used to estimate the molecular mobility and physical stability of
amorphous solid forms.184,185 More recently, however, this has been applied to estimate
Ttr.186,187 Calculations of thermodynamic parameters, such as configurational enthalpy
(Hc) and configurational entropy (Sc) were used to plot Gc versus T using the following
equations:
𝑻

𝑯𝒄 (𝑻) = 𝑯𝒂𝒎 (𝑻) − 𝑯𝒙𝒕𝒂𝒍 (𝑻) = ∆𝑯𝒎 + ∫𝑻 𝒎 𝑪𝒑𝒄𝒐𝒏𝒇 𝒅𝑻
𝑺𝒄 (𝑻) = 𝑺𝒂𝒎 (𝑻) − 𝑺𝒙𝒕𝒂𝒍 (𝑻) =

∆𝑯𝒎
𝑻

𝑻

+ ∫𝑻 𝒎

𝑪𝒑𝒄𝒐𝒏𝒇
𝑻

𝒅𝑻

(3.1)
(3.2)
(3.3)

𝑮𝑪 (𝑻) = 𝑯𝑪 (𝑻) − 𝑺𝑪 (𝑻) ∙ 𝑻

where 𝐶𝑝𝑐𝑜𝑛𝑓 is the reversing heat capacity (Rev Cp) difference between the amorphous
and crystalline forms (Refer Figure 3.3).
𝑹−𝑰
𝑪𝒑𝒄𝒐𝒏𝒇(𝑹−𝑰) = 𝑪𝒂𝒎
𝒑 − 𝑪𝒑

(3.4)

𝑹−𝑰𝑰
𝑪𝒑𝒄𝒐𝒏𝒇(𝑹−𝑰𝑰) = 𝑪𝒂𝒎
𝒑 − 𝑪𝒑

(3.5)
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Figure 3.3. (a) Reversible heat capacity as a function of temperature for crystalline forms of ribavirin; R-II in blue and R-I in green,
respectively. Amorphous ribavirin is shown in black. (b) Configurational heat capacity for R-I and R-II shown in green and blue
respectively.

The point of intersection of the Gc curves for the two ribavirin solid forms was
taken as the thermodynamic transition temperature (Ttr), which is shown in Figure 3.4
(Ttr = 68.4 °C).

Figure 3.4. Configurational free energy (Gc) phase diagram for ribavirin polymorphs. Gc
of R-I is denoted by green dashed line and of R-II is denoted by blue solid line.
Intersection (T = 341.6 K) represents Ttr = 68.4 oC.
Although this technique only provides an estimate of Ttr, the enthalpy associated
with the polymorphic transition (ΔHtr) was calculated from the difference between the
experimentally obtained heats of fusion,188 and determined to be 2.8 kJ/mol. While the
parameters of melting temperatures and heats of fusions derived from thermoanalytical
techniques are routinely used for estimation of Ttr, if concurrent thermal events occur
(e.g., commensurate melting and recrystallization or melting with decomposition), then
the reliability of the data may be questionable.
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2) Solubility extrapolation: Determination of solution enthalpies (Hsol) is also a
widely accepted technique used to differentiate between polymorphs.181,182,187 In order to
confirm the values obtained by interpolation of the Gc data, a complementary method that
used the heat of solution and solubility data was performed for estimation of Ttr
(Equation 3.6):

𝑻𝒕𝒓 = (

𝟐.𝟑𝟎𝟑 .𝑹 . (𝒍𝒐𝒈𝑺𝑰𝑰,𝑻 −𝒍𝒐𝒈𝑺𝑰,𝑻 )
∆𝑯𝒕𝒓,𝑻

𝟏

−𝟏

+ )
𝑻

(3.6)

Above, the logarithmic solubility of R-I and R-II were represented as 𝑙𝑜𝑔𝑆𝐼 and 𝑙𝑜𝑔𝑆𝐼𝐼 ,
respectively, at temperature T = 25 °C. ∆𝐻𝑡𝑟,𝑇 is the heat of transition corresponding to
the difference in the heat of solution at temperature, T = 25 °C. Although the heat of
solution varies with the choice of solvent, the heat of transition corresponding to the
difference in the heat of solution is theoretically equal. In distilled water, the heat of
solution for R-I and R-II was measured to be -29.4 + 0.8 kJ/mol and -31.2 + 0.1 kJ/mol,
respectively, while ∆𝐻𝑡,25 °𝐶 was estimated to be 1.8 + 0.35 kJ/mol.
Figure 3.5 plots the concentrations of each form of ribavirin in distilled water as a
function of time, in the presence of excess solid phase. As shown, both solid forms
reached a plateau of maximum solubility within 30 min, at which the measured saturation
concentrations at 25 oC of R-I and R-II were, respectively, 162.5 + 3.6 mg/mL and 149.0
+ 1.7 mg/mL.
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Figure 3.5. Aqueous saturation solubility of ribavirin polymorphs. Closed green circles
(●) and open blue circles (○) represent solubility profile of R-I and R-II, respectively.
Data are represented as mean + standard deviation, n = 3.
In all cases, it was confirmed by DSC and PXRD that the residue did not convert
to another solid form during the course of the experiment (data not shown), confirming
that these values are specific to R-I and R-II.

When these measured values were

substituted into Equation 3.6, the Ttr for R-I and R-II polymorphs was determined to be
71.3 °C, which agrees well with the value obtained by interpolation of the Gc diagram
(68.4 °C). The slight difference in values is likely attributable to the underlying
assumptions of each technique,182 but suggests a good approximation of the actual Ttr.
Both methods employed here assume that the heat capacity difference between the two
polymorphs is independent of temperature. Further, the melting method assumes that
enthalpy of fusion is independent of temperature. Likewise, the solubility – heat of
solution method assumes the difference between the activity coefficients of two
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polymorphs is negligible. Ultimately, since this polymorphic pair has a Ttr that is both
realistic (less than either of the melting points of the polymorphs), and mutually
supported by independent techniques, their enantiotropism was confirmed.

3.3.3. Exposure of R-II to T > Ttr
Following determination of R-I and R-II enantiotropism, and the Ttr, it was
reasonable to expect that temperature-mediated conversion directly from R-II to R-I
should be observed upon heating of R-II to T > Ttr without exceeding the Tm for either
form. R-II was heated in situ in DSC pans at different rates ranging from 2-40 °C/min;
ultimately the slowest DSC data were selected for their resolution, and the potentially
reduced likelihood of instrumental artifacts.189 Additionally, it was expected that the
slower heating rate would enable conversion of R-II to R-I without melting during the
experiments. However, all DSC thermograms for R-II showed only a single endothermic
event with an onset temperature of 169.29 + 2.72 °C and an enthalpy of 44.32 + 1.56
kJ/mol. The absence of any notable endothermic transition prior to melting, even at the
slowest heating rates, suggested that the kinetics of the R-II to R-I solid state conversion
were much slower than those afforded by even the slowest DSC experiment.
To address the need for longer exposure time at T > Ttr, R-II samples were held
isothermally at 150 °C, with care taken not to expose samples to temperatures that might
melt either polymorph. Against expectations, samples of R-II held at 150 °C for 7 days
persisted without conversion to R-I, as evidenced by characterization of these samples
using PXRD and DSC. It was also noted that isothermal storage at this temperature
beyond 7 days resulted in brown discoloration of portions of the samples, suggesting
thermal instability. This was confirmed via HPLC by a decrease in ribavirin potency to
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less than 70 % when compared with the USP standard, for samples held at 150 oC for
longer than 7 days. Unlike other examples of temperature induced solid-state
changes,180,190,191 the present work demonstrated that, although enantiotropically related
transitions are thermodynamically reversible with temperature and pressure, the kinetics
may prohibit interconversion within reasonable (or applicable timeframes). It is important
that new chemical entities (NCEs) demonstrating enantiotropism are also tested for
kinetics of thermally mediated transitions, as shown here.

3.3.4. Exposure of R-II to high-shear mechanical energy
Although the R-II to R-I conversion kinetics upon exposure to T > Ttr appear to be
much slower than the kinetics of chemical degradation at the same temperature, it is
anticipated that during typical manufacturing operations, ribavirin will be exposed to
mechanical stress conditions potentially capable of accelerating the kinetics of solid state
transformations.

Milling of R-II in a vibratory impact mill prior to isothermal

temperature experiments was expected to damage crystallite surfaces to the extent that a
commensurate increase in molecular mobility around damage sites would enable either a
sufficiently rapid polymorphic transformation that observation is possible prior to
extensive chemical degradation, or, potentially facilitating a direct conversion during
prolonged mechanical treatment.
Vibratory impact ball milling: Samples of R-II were extensively milled in a
vibratory impact mill without temperature control. In a previously published paper,163
bulk ribavirin that was ball milled for 50 min resulted in only 0.642 % w/w conversion to
R-I, as estimated using only DSC. Therefore, in the present work, R-II was milled for 60
min, with the intent of creating surface defects on ribavirin crystallites without causing
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detectable phase change. This was confirmed using PXRD patterns of milled R-II
samples, which showed that, even after 60 min milling, the crystallites still diffracted at
2 angles entirely consistent with the R-II reference pattern (Figure 3.6).

Figure 3.6. PXRD patterns of R-II milled for various time intervals in a vibratory impact
ball mill. Note: Eventual conversion from R-II to R-I at 270 min of milling.

The diffraction peaks were observed to broaden, relative to the starting material,
as evidenced in the full width at half maximum (FWHM) of characteristic peaks,
suggesting a potential reduction in R-II crystallinity as a consequence of impact milling
(See Table 3.2).
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Table 3.2. Comparison of full width half maximum (FWHM) between diffraction
patterns of R-II as a function of milling time in vibratory impact ball mill.
Miller
indices (hkl)

Position (°2)

Full width at Half Maximum – FWHM (°2)
R-II
R-II
R-II
(before milling) (milled 60 min) (milled 180 min)
(110)
11.92
0.0836
0.1840
0.2676
(210)
13.43
0.0836
0.2007
0.2676
(310)
15.59
0.0836
0.1673
0.2676
(201)
18.15
0.1171
0.1840
0.2676
(420)
27.12
0.1506
0.4015
0.2342
30.56
0.1171
0.4015*
0.3346*
30.82
0.1171
32.04
0.1506
0.2007*
0.5353*
32.35
0.1004
*double peaks merge into a single peak

Although particle size (PS) reduction can lead to similar PXRD pattern
broadening,192 optical microscopy of the R-II samples taken before milling (d10 = 8.1 µm;
d50 = 14.8 µm; d90 = 30.4 µm) and after milling (d10 = 5.4 µm; d50 = 11.2 µm; d90 = 32. 9
µm) did not show significant reduction in the PS of R-II primary particles. These data
suggest that much of the mechanical energy was used to induce defects, resulting in
dislocated molecules that are lost as contributors to diffracting planes, thereby broadening
the diffraction pattern.193 Similarly, the BET results for R-II exhibited a comparable
trend with PS data, in which the specific surface area (SSA) did not change significantly
for samples measured following milling (1.4 m2/g) relative to those measured prior to
milling (1.1 m2/g). These results are similar to those from a published study194 in which
it was reported that cryogenic grinding of ketoconazole particles caused nominal fracture,
which ceased after 5 min of milling time. In this same study, milling for 10 and 30 min
did not result in continuous particle size reduction, possibly due to sintering or fusion of
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fines onto larger particles, which was reflected in BET measurements for milled
ketoconazole in which the increase in SSA (relative to unmilled samples) after 30 min of
milling was < 1.0 m2/g. It is important to consider that a tiny fraction of amorphous
ribavirin (if formed) could remain undetected; hidden under the strong Bragg peaks of the
milled crystalline ribavirin. To eliminate this ambiguity, DSC analysis of ground R-II
was performed at multiple heating rates. Slow heating rates of up to 5 °C/min resulted in
thermograms having a single melting endotherm, attributable to R-I (Tm = 176.09 °C;
ΔHm = 38.4 KJ/mol) without a recrystallization exotherm or glass transition prior to this
event. At first, these data seemed to contradict the PXRD observations, which showed no
detectable R-I in the milled samples. Close inspection of the thermograms, however,
showed a small endotherm between 144–146 °C, having an enthalpy of 1.9 kJ/mol,
suggesting that the milled R-II converted to R-I in situ during DSC experiments, owing to
the imposition of a temperature ramp on the samples during the experiment (Figure
3.7a). In contrast, DSC measurements conducted at more rapid ramp rates (10, 20 and 40
°C/min), showed two endothermic events, corresponding to both R-II and R-I, where the
area of the peak attributable to R-II progressively increased with increasing experimental
heating rate, while the onset and peak temperatures for R-II showed a 15-20% decrease
with milling time (Figure 3.7b). These data suggested that the milled R-II samples
underwent partial in situ conversion to R-I during the DSC temperature ramp, to an
extent commensurate with longer times spent at higher temperatures. As before, the
PXRD data for milled R-II showed no R-I formation, while the DSC data for unmilled RII, showed no in situ conversion to R-I. The data collectively suggest that milling of R-II
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resulted in the induction of crystal defects, which facilitated rapid conversion to R-I when
those samples were exposed to T > Ttr.

Figure 3.7. (a) DSC thermogram of R-II milled for 60 min a vibratory impact ball mill is
compared with the untreated polymorph samples. The dotted circle highlights the
endotherm associated with R-II to R-I transition in situ (See inset). (b) DSC thermograms
of 60 min milled R-II, recorded at various heating rates.
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Solid-state transformations caused in situ during DSC experiments have been
reported for several pharmaceutically relevant materials.180,195,196 In the example of
carbamezapine enantiotropes, DSC measurements at 2 °C/min resulted in an endothermic
event attributable to form III  I transition, followed by melting of form I. It was only at
higher heating rates (10, 20, 30 and 40 °C/min) that the melting of form III prior to
melting of form I was observable. Furthermore, the melting of form III in every
experiment was immediately followed by a distinct exothermic event attributed to
formation of form I via sublimation. In the present case, the higher relative stability of RI near the melting temperature of R-II, and the apparent ease of nucleation and
crystallization of R-I make direct assessment of the extent of polymorphic conversion
impossible from a single DSC experiment, conducted at a single heating rate.
Use of PXRD to characterize processed ribavirin was particularly beneficial in the
present work. Had the conclusions been based only on DSC measurements, the data
recorded at slow heating rates might have suggested complete transition to R-I as a
consequence of milling, while those recorded at higher heating rates would have
suggested a partial enantiotropic conversion, despite a consistent milling duration. As it
turned out, neither interpretation would have been accurate, as demonstrated by the
PXRD data which showed no conversion to R-I during milling. To further examine the
effects of milling on the facilitation of R-II to R-I solid state conversion, milled R-II was
held isothermally at 150 °C in a convection oven. In contrast to the unmilled R-II, which
remained physically stable for 7 days before eventually chemically degrading, the milled
R-II samples completely converted to R-I within 15 min isothermal storage.

90

Additionally, when the milled R-II samples were annealed at T < Ttr (50 °C), no
conversion to R-I was observed. These data collectively suggest that the induction of
defects in R-II crystallites during milling is needed in order to accelerate the conversion
kinetics sufficiently that complete conversion to R-I at T > Ttr can be observed.
It seems likely that the commercially available ribavirin products (all of which
contain R-II), or any innovative new formulations will utilize pulverization during
primary and/or secondary manufacturing. If the milled R-II particles later experience
temperature excursions that exceed Ttr, during storage or transport, a relatively rapid
conversion to R-I becomes much more likely. Should such an unanticipated change result
in significant alterations in either dosage form performance or downstream material
handling, a company that is unaware of this possibility may run into major regulatory
challenges.197
Additional impact milling experiments were conducted, which involved durations
beyond 60 min. As shown in Figure 3.6, when R-II was comminuted for 270 min in the
uncontrolled temperature impact mill, complete conversion to R-I occurred in the milling
vessel, as evidenced by the PXRD data. The DSC data for the same samples, showed
only a single melting endotherm, observed at all experimental heating rates (Figure 3.8),
which was unambiguously attributable to R-I. Although there was no evidence in these
samples of persistent amorphous ribavirin, it is likely that regional disordering during
pulverization, by the accumulation of defects, provided sites of increased mobility that
allowed rapid recrystallization to R-I, driven by localized heating inside the milling jar to
temperatures potentially exceeding both Tg (~ 61 °C) and Ttr.
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Figure 3.8. DSC thermograms of 270 min milled R-II measured at different heating rates.
Complete R-II R-I conversion can be seen based on the single melting endotherm
attributable to high Tm enantiotrope (R-I). DSC data recorded at 2 and 20 °C/min are not
shown.
In order to evaluate whether extensive comminution caused any chemical
degradation, all milled ribavirin samples were analyzed using HPLC. Despite
simultaneous exposure to high-shear mechanical energy and likely increased localized
temperatures, the concentration of ribavirin recovered in all samples was >99%. These
data suggested that, although extensive processing under these conditions elicited a
physical change in the ribavirin solid, the molecules remained chemically unaltered.
Cryogenic impact milling: The observations described above starkly contrast the
results of temperature controlled, cryogenic milling, which maintained samples, medium,
and milling environment in a constant liquid nitrogen bath throughout processing. In
order to isolate, as best as possible, the role of mechanical energy in defect formation,
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from localized temperature build-up, the relative fraction of sample volume in the milling
jar was kept consistent relative to the vibratory ball milling experiments.
Characterization of cryomilled samples using PXRD and DSC showed
progressive reduction of long-range lattice periodicity, resulting in the formation of
completely disordered ribavirin after 120 min. As shown in Figure 3.9, diffraction
patterns for these milled samples have a prominent X-ray amorphous halo, while DSC
data showed an observable Tg (61-65 °C), consistent with the measured value for
ribavirin. These results suggest that the limited molecular mobility attributable to the
very low milling temperature (T << Tg) likely inhibited recrystallization of the ribavirin to
either crystalline solid form. Additionally, the difference in particle size and morphology
as a result of cryogenic grinding was negligible with all milled samples. Instead,
micrographs revealed considerable de-agglomeration, irregular morphology, and surface
crack formation, but little change in primary particle size.

This suggests that the

incoherent scattering of X-rays from the 120 min cryomilled samples was due to
complete loss of lattice periodicity, as opposed to a PS effect, confirming that the
mechanical energy was used to disorder the crystalline solid particles rather than
consumed by sequential fracture events.
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Figure 3.9. (a) PXRD patterns of R-II milled for various time intervals in a cryogenic
impact mill. Note the halo pattern following 120 min cryomilling, suggestive of complete
loss of lattice periodicity (b) DSC thermogram of R-II milled for 60 and 120 min a
cryogenic impact mill is compared with the unprocessed starting material (i.e. R-II). The
inset shows observed glass transition of ribavirin after 120 min of cryomilling,
confirming transformation to persistent amorphous ribavirin. Data was recorded at 20
°C/min.
The results of cryomilling ribavirin indicated that the solid form of the “end
product” was directly influenced by the temperature experienced during milling. These
data follow nicely with the published observations for fananserine,198 where the milling
temperature relative to the Tg of the material being milled determined the solid form of
the end product. Fananserine milled above Tg (19 °C) resulted in transformation to its
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metastable polymorph, while milling under liquid nitrogen temperatures resulted in
complete conversion to the amorphous phase. This is because the milling temperature
was well below Tg – 50 oC, a temperature at which mobility is expected to be too low to
support recrystallization. Even if localized temperatures exceeded cryogenic conditions,
continuous maintenance of the liquid nitrogen bath, accompanied by regular cool down
cycles during the milling protocol, are expected to keep the powder bed well below Tg for
the material.167 Based on the observations for fananserine and the Tg for ribavirin (61-65
°C), milling of R-II might have been expected to convert to the amorphous state as a
result of either technique used in the present work, given that both the milling
temperatures were < Tg. The characterization data, however, show that continuous
impaction without temperature control resulted in conversion to R-I, rather than
formation of a persistent amorphous solid. This seems likely to have been the result of
localized temperature excursions in the vibratory impact mill, which exceeded Tg and,
possibly even Ttr for ribavirin. This appears to be consistent with the results of Chieng et.
al.199 who, using a similar impact mill, observed that the average temperature of a powder
bed was increased by 30-35 °C within 60 min of milling and remained constant when
milling was continued for 180 min. Such a prolonged elevation of the bed temperature for
ribavirin would approach Tg, allowing for local heating at surfaces to exceed it. Although
persistent amorphous ribavirin was not observed in samples milled without temperature
control, it is plausible that R-II  R-I may have been the result of the formation of a
transient amorphous intermediate, which rapidly recrystallizes to R-I at T > Tg.
In the present work, the observed transformation of ribavirin is thought to be
initiated when the long range order of R-II crystals was disrupted via application of high-

95

shear stress, without substantial particle size reduction. The resulting defect accumulation
facilitated sufficient molecular mobility that, when exacerbated by temperatures
exceeding Tg, allowed collective reorganization of ribavirin molecules and direct crystalto-crystal transformation without the formation of a persistent amorphous intermediate.
This type of mechanism has been observed in cold worked metals200,201 and potentially
supports the observation of a solid-state change in R-II tablets when compressed at high
loads.164
There are several theories in support of formation of amorphous solids as a result
of milling. One hypothesis suggests that temperature elevation owing to continuous
impact and attrition may sufficiently induce local hot points that exceed the Tm of the
API, whereupon subsequent returns to ambient temperature would quench the material
allowing for formation of amorphous solid by a series of melt/quench events. In the
present work, however, the cryogenic environment rigorously maintains the experimental
temperature ~360 oC below the Tm of ribavirin, making this mechanism unlikely.
Alternatively, the model adapted by Wildfong et. al.,202 seems more potentially
relevant. In that work, the free energy required for incorporation of a critical dislocation
density was related to the free energy change needed to convert the crystalline material
into an amorphous solid. At this critical density, the accumulated dislocations were
thought to cause overall lattice perturbations such that the collective molecular bonds
required to maintain periodicity of the lattice were lost. As with the present work,
experiments conducted in the dislocation-based model, also rigorously controlled the
milling temperature to inhibit recrystallization of any amorphous solid formed during
milling, thereby facilitating persistence of the “end product” solid form.
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Additional support for a dislocation-mediated transformation of R-II to
amorphous ribavirin during cryogenic milling comes from considering the extension of
Wildfong’s work by Lin et al.,171 who showed that the potential to become completely
disordered as a result of continuous cryogenic milling was highly correlated to the
combination of the Tg of the material being milled and the molar volume (Mv) of the
molecules comprising the solid. According to their work, values of Tg and Mv that exceed
the bivariate decision boundary g(Tg,Mv) correspond to materials that are predicted to
form a persistent amorphous solid via continuous cryogenic milling. Calculation of the
Mv of R-II (147.64 cm3/mol), in combination with its Tg, and application to the decision
boundary function described in Lin et al.,171 results in a value that corresponds with a
material predicted to become completely amorphous during extensive cryomilling, which
was confirmed by characterization of the milled samples.

3.3.5. Recrystallization and kinetic irreversibility
The reversibility of enantiotropic polymorphism can be identified using DSC.189,203
Usually, the presence of an exothermic peak in a DSC thermogram occurring during the
cooling cycle at a temperature close to that at which an endothermic transition occurs
during heating, suggests that a reversible transition is observable. Accordingly, samples
of phase pure R-I were allowed to melt in situ in DSC pans, followed by subsequent
cooling at different rates (2 and 20 oC/min) in order to identify whether a distinct
exothermic transition associated with re-conversion to R-II could be observed. Neither
cooling rate, however, resulted in any observable thermal event surrounding the apparent
transition temperature, suggesting that the high-melting enantiotrope of ribavirin, R-I, is
kinetically irreversible, even if the temperature is decreased below the estimated Ttr. To

97

verify this observation, R-I samples were stored under various conditions of relative
humidity (0%, 33%, 60% and 75%) at room temperature (T << Ttr), for 60 days. Despite
much longer storage at conditions that should be favorable to the conversion from R-I to
R-II, the high temperature enantiotrope remained unchanged under all humidity
conditions, as evidenced by PXRD devoid of peaks attributable to R-II, and DSC
thermograms showing only melting associated with R-I. This is relevant to the scenario
described above, in which unanticipated conversion of R-II to R-I occur as a result of
applied high-shear stress and elevated temperatures during processing. The DSC data
suggest that R-I would be kinetically trapped, potentially resulting in batches that contain
a mixture of solid forms having variable performance characteristics. Although the high
aqueous solubility of either form of ribavirin would likely offset any potential differences
in bioavailability stemming from phase impurity induced during manufacturing,
differences in material handling and mechanical properties are more likely to be
impacted, potentially manifesting as product uniformity and other regulatory issues.
Given the results detailed herein, further investigation of this material seems warranted.

3.4. Conclusion
Process-induced transformations of solid materials have received a great deal of
attention in the pharmaceutical industry, where understanding the relationships and
pathways between different solid forms plays a role in determining the most suitable
solid phase for a formulation and manufacturing scheme. The enantiotropic relationship
between ribavirin polymorphs R-II and R-I was previously reported, however,
determination of the solid state transition temperature of ~70 oC, and characterization of
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the very slow kinetics of R-I  R-II reconversion are expected to provide more
information regarding how these polymorphs may interconvert. Additionally, solid-state
transformations of ribavirin were examined under different thermal and mechanical stress
conditions. Unprocessed R-II did not transform into R-I, at T > Ttr, even after 7 days,
however, following grinding, the same isothermal storage conditions resulted in rapid RII  R-I conversion. This suggested that the energy barrier required to produce the high
Tm enantiotrope was reduced by generating high mobility defects during milling.
Extensive milling also led to complete R-II  R-I conversion, when the milling
temperature was not controlled, likely proceeding via formation of a transient disordered
phase, which rapidly recrystallized at T > Tg (See figure 3.10). In contrast, high shear
cryogenic milling of R-II, conducted at T << Tg resulted in complete transformation to
persistent amorphous ribavirin.
These data suggest that the solid form that results from milling was determined by
the interplay of two processes: (1) regional disordering of the sample due to continuous
impact and attrition, and (2) thermally mediated recrystallization. Recrystallization to R-I
takes advantage of the higher molecular mobility afforded by amorphous regions, which
at T > Tg favors conversion to a crystalline phase. At T << Tg, however, continuous
regional disordering eventually spreads throughout the sample as milling continues, and a
completely disordered state can be achieved.
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Figure 3.10. Schematic representation of solid state transformation in R-II.
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Chapter 4: Preparation, characterization and
evaluation of ribavirin loaded polymer microparticles
for intranasal uptake
4.1. Introduction
Ribavirin [RBVN, 1-(-d-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide] is a
water-soluble synthetic nucleoside (BCS class III drug) having broad spectrum antiviral
properties.204 Although the activity of RBVN in vitro is promising,118-120 its in vivo
effectiveness in the treatment of viruses affecting the central nervous system is reduced
by its inability to cross the blood-brain-barrier (BBB). Previous studies reveal
administration of RBVN via intraperitoneal, subcutaneous, and intramuscular
injections121,122 proved ineffective against several encephalitis viruses in mice, and
showed improved survival against subacute sclerosing panencephalitis (SSPE) in virusinfected hamsters only when administered intracranially.122 Pursuit of alternative routes
of administration for RBVN that increases CNS bioavailability, with the potential for
patient self-care, requires further research.
Intranasal (IN) drug delivery holds promise for CNS targeting, given its potential
to bypass the BBB.7-10,17-19 Direct nose-to-CNS delivery occurs through the olfactory
region of the nasal cavity, offering several advantages, including avoidance of hepatic
first pass metabolism, rapid onset of action, and the potential for patient selfadministration. Nonetheless, targeted deposition and adequate residence time in the nasal
cavity remain as challenges. Currently, an ideal formulation or device enabling drug
deposition exclusively to the olfactory region is not known; however, ongoing research
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continues to improve the fraction of dose that is delivered to this location.24,30 The
deposition pattern for liquid IN formulations is influenced, in particular, by droplet size,
with diameters >20 m resulting in almost 100% nasal deposition.70,75,79 Additionally,
breath-actuated insufflation of solid particles (D90 <40 m) has indicated that preferential
deposition of drug occurs on the olfactory tissue, while promoting longer retention of
particles relative to liquid vehicle dosage forms such as metered sprays.98,103 This is
suggested to be the result of slow hydration of powder particles in contact with the nasal
mucus, which increases viscosity and provides greater resistance to mucociliary
clearance.
The key to successful nose-to-CNS delivery, is not only increased nasal residence
time, but also increased CNS uptake of the targeted drug. Certain polymers have
demonstrated utility in this regard,76,84 including poloxamers, which are tri-blockcopolymers consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO)
monomer units. Owing to the thermoreversible sol-gel transition at physiological
temperatures, poloxamers are suited for mucosal adhesion following i.n delivery.
Additionally, poloxamers have also been shown to enhance permeation across the nasal
mucosa, possibly owing to a combination of the inhibition of efflux transporters,123
acceleration of solute diffusion within the lipid bilayer,127 and transient opening of the
cellular tight junctions.205 One recent study showed that IN administration of the antiretroviral drug zidovudine in adult rabbits resulted in nearly 4-fold greater CNS
concentrations from formulations containing poloxamer, presumably due to longer
retention in the nasal cavity and/or permeation enhancement of the drug.129
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Intranasal insufflation is less studied than instillation of droplets or inhalation of
atomized liquid sprays. As a result, optimization of solid particle formulations intended
for IN insufflation has received less attention in the literature. Formulation of very fine
drug particles adsorbed onto the surfaces of larger inert carriers, analogous to dry powder
inhalers, is unlikely to be successful for IN insufflation as the larger carrier particles
would be more likely to settle under gravity and provide little or no deposition in the
olfactory region. Physical mixtures of drug and polymer having comparable particle size
ranges may be possible in some cases, however, segregation of components upon
insufflation is undesirable. Consequently, in this study, formulation involved suspension
of ultrafine drug particles in molten carrier polymer, followed by co-solidification upon
cooling. Subsequent micronization allowed sizing of compositionally uniform particles
according to IN delivery-specific recommendations.
In the present work, preparation and characterization of binary composite solid
microparticles of RBVN in poloxamer allowed evaluation of their potential use in direct
CNS targeting using intranasal drug delivery. It was hypothesized that deposition of
these solid microparticles on the nasal mucosa would result in higher pemeation of
RBVN across epithelial cells relative to a RBVN solution.

Solid drug-in-polymer

microparticles were prepared, optimized, and characterized. Permeation of RBVN across
olfactory mucosal tissue was studied in vitro and compared with permeation from liquid
vehicle solutions of the drug.
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4.2. Experimental Section
Ribavirin was purchased from Jinan Jiaquan Chemicals Co. Ltd. (Jinan, China,
Lot number 02110330). Poloxamer 188 NF (POX188, also referred to as Pluronic F68)
was purchased from Spectrum Chemicals, New Brunswick, NJ (CAS Number 9003-116). All powders were stored in a desiccator over P2O5 (~0% RH) for at least one week
prior to experimentation, to remove environmental water.

4.2.1. Determination of RBVN solubility in POX188
Mixtures of RBVN and POX188 were manually prepared by geometric dilution at
10, 20, 30, 40, 50, 60, 70, 80 and 85 % w/w with respect to polymer. Each physical
mixture was analyzed using a differential scanning calorimeter (DSC), equipped with a
refrigerated cooling accessory (Model Q100, TA Instruments, New Castle, DE, USA).
Three replicate DSC samples (5.0 + 0.5 mg) were prepared at each composition placed in
an Al sample pan that was hermetically sealed. Samples were heated from ambient
temperature to 200 C at a constant heating rate of 2 °C/min. Dry N2 gas (50 mL/min)
was allowed to constantly purge the DSC cell during all experiments, and measurements
were subject to a three-point temperature and enthalpy calibration accomplished using
Sn (Tm 231.9 oC), In (Tm 156.6 oC), and o-terphenyl (Tm 55-56 oC) standards. The
endotherm attributable to melting of RBVN in the presence of varying amounts of
POX188 was carefully recorded, and the depression of its extrapolated onset of melting
(To), peak maximum (Tp) and enthalpy of melting (ΔHm) of RBVN were used to indicate
solubility in molten POX188 which in turn would influence maximum drug loading.
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4.2.2. Preparation of binary composite microparticles
Physical blends of RBVN and POX188 were prepared in 1:1 w/w ratio using a
laboratory scale blender, followed by equilibration at ~0% RH for 24 h. These blends
were assessed for content uniformity with a low variation (RSD <5%) chosen as the
criteria for subsequent use. Physical mixtures were transferred to a crucible, which was
immersed in a silicon oil bath maintained at 100 ºC which was higher than the melting
temperature of POX188 (Tm = 55–60 °C), but well below the melting temperature of
RBVN (Tm = 168–170 °C). Crystalline RBVN was suspended in molten POX188 and the
set temperature was maintained isothermally to allow homogeneous mixing.

To

minimize water vapor sorption, dry N2 gas was continuously streamed over the crucibles
during preparation. Following mixing, the 1:1 RBVN : POX188 suspensions were
quenched by immersion of the crucible in liquid nitrogen, resulting in formation of a cosolidified disc that was removed for further processing.
To ensure no thermal degradation of the RBVN during suspension preparation,
blends were held isothermally for 20-30 min in a thermogravimetric analyzer (TGA) at
100 ºC, and <1% weight loss was recorded. Additionally, physical blends were heated in
a DSC to 100 ºC and held isothermally for 30 min to assess time-dependent drug
solubility in polymer. Following these extended hold times samples were quenched in
situ in DSC, before reheating. Recorded values for the melting parameters (To, Tp and
ΔHm) between heating cycles remained consistent with pure component values, indicating
that the RBVN remained undissolved in POX188 during suspension preparation.
To make the co-solidified discs suitable for simulation of IN delivery, mechanical
sizing was accomplished using a cryogenic impact mill (SPEX Certiprep 6750 Freezer
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Mill, Metuchen, NJ). Approximately 1.0 g of RBVN : POX188 (1:1) solid suspension
was manually broken down into coarse particles (~3-4 mm), which were placed in a
cylindrical polycarbonate milling vessel. A stainless steel cylindrical milling rod was
placed in the vessel, and the sample temperature was allowed to equilibrate for 3 min
prior to milling, following immersion in the mill liquid nitrogen bath. The processing
temperature was continuously maintained during comminution by regular replenishment
of the liquid nitrogen bath. Similar to Crowley and Zografi,167 materials were ground for
2 min intervals at a frequency of 10 Hz, separated by 2 min cool-down periods, allowing
minimization of local sample temperature increases. Upon completion of 20 min total
milling, the ground sample was sieve fractionated (Performer III Model: SS-3, Gilson
Company, Lewis Center, OH) and the fines that passed through the 53 µm sieve (US
standard number 270) were collected and stored over P2O5. Subsequent characterization
of milled particles was performed to verify maintenance of RBVN phase purity during
manufacturing, sample potency, chemical stability, particle size, and morphology. All
characterization experiments were repeated in triplicate.

4.2.3. Characterization
4.2.3.1. Ribavirin solid phase purity
Binary microparticles obtained through cryogenic grinding were characterized to
ensure that processed RBVN maintained a single solid form, using powder X-ray
diffraction (PXRD) and differential scanning calorimetry (DSC). PXRD patterns were
obtained using an X’Pert Pro MPD system (PANalytical B.V., Almelo, the Netherlands),
equipped with a Cu anode (λ = 1.5406 Å), an auxiliary elliptical mirror, and an
X’CeleratorTM detector. Powder samples were loaded between two layers of Kapton®
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film (ChemPlex, Palm City, FL) and spun in a vertical sample stage. Consistent
irradiation times of 135 s per step with an angular step size of 0.017 °2 were used for all
diffraction experiments. PXRD data were collected over 5–50 °2θ, using a respective
voltage and amperage of 45.0 kV and 40.0 mA.
Conventional DSC measurements were made to determine the melting
temperatures (Tm) of ribavirin polymorphs. Accurately weighed samples of 5.0 + 0.5 mg
were hermetically sealed in Al sample pans and heated at either 2°C/min or 40°C/min to
200 ºC.163 All measurements were performed in triplicate and reported as mean values +
standard deviation.

4.2.3.2. Assessment of Particle properties
The particle size and size distribution of sieve cuts containing 20–53 μm
microparticles were analyzed at 10x magnification using an Olympus BX-51 optical
microscope equipped with a polarizing filter. Photomicrographs were obtained to
evaluate size and measure the Feret diameter for approximately 300 particles and
crystallinity was confirmed through notable birefringence. Additionally, scanning
electron microscopy (Hitachi S-3400N scanning electron microscope equipped with a
Bruker Quantax model 400 energy dispersive spectrometer using an XFlash® 5010 EDS
detector) was used to image particles and assess morphology. Samples were mounted on
double-sided carbon tape affixed to an aluminum specimen holder. Images were collected
using a working distance of 15 mm and an accelerating voltage of 2 kV.
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4.2.3.3. Microparticle drug content and Content uniformity
Drug content was measured by dissolving a mass of RBVN : POX188 (1:1)
composite microparticles equivalent to a dose of 20 mg RBVN in distilled water. The
resulting solutions were filtered through 0.45 m filter and diluted for HPLC analysis.
Particle content uniformity was determined by randomly choosing 12 samples from the
milled and sized powder. A low variation (RSD <5%) was chosen as the acceptance
criteria for drug uniformity.
Finally, to ensure RBVN chemical stability during temperature-intense
suspension preparation, and shear stress-intense particle sizing, the potency of RBVN
extracted from microparticles was compared with untreated raw material. All
measurements were reported as mean + SD. Precise RBVN concentration measurements
for all samples were made with a Waters Alliance 2690 HPLC system (Milliford, MA)
equipped with photo diode array (PDA) detector using a Hypersil C18 reverse phase
column (5 m, 250 mm x 4.6 mm i.d., Waters, MA, USA). Previously filtered and
degassed mobile phase comprising of 95:5 v/v mixture of 0.01 M potassium dihydrogen
phosphate solution and pure methanol (pH adjusted to 5) was used. The mobile phase
was pumped continuously at a flow rate of 1.0 mL/min with an injection volume of 20
L. Standard solutions and test samples were analyzed at the detector wavelength of 207
nm. All sample solutions were diluted in mobile phase.
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4.2.4. Evaluation of Microparticle Performance
4.2.4.1. in vitro Drug Release
The in vitro RBVN release studies were performed using Franz diffusion cells
(PermeGear, Hellertown, PA). Regenerated cellulose dialysis membrane (Spectrum
Laboratories Inc., Houston, TX) was mounted between the donor and receiver
compartments of the diffusion cell. The receiver compartment was filled with 5 mL of
simulated nasal electrolyte solution (SNES), thermostated at 37+1 ºC and gently agitated
(200 rpm) by means of a magnetic stirrer. SNES was prepared with 8.77 g NaCl, 2.98 g
KCl, 0.59 g CaCl2 anhydrous in 1000 mL distilled water with the final pH adjusted
between 6.0 and 6.5. Microparticles characterized in Section 4.2.3 containing no more
than 5.0 mg of free drug (dose adjusted accordingly) were evenly sprinkled on the prehydrated dialysis membrane. Only 20 µL SNES containing 2% w/v mucin was added to
the donor side in order to maintain a hydration environment similar to that in the nasal
cavity.142
At predetermined time intervals, 200 µL samples were withdrawn from the
sidearm of the receiver compartment and replaced with fresh, pre-warmed dissolution
medium. The amount of drug released was assessed spectrophotometrically (UV
Spectrophotometer 8453, Hewlett Packard, Germany) at λmax of 207 nm (Linearity range
= 5 μg/mL to 17.5 μg/mL, R2 = 0.9998). To ensure mass balance, the residual powder in
the donor compartment was dissolved in 200 µL of fresh, pre-warmed SNES and
assayed. Each release experiment was performed in triplicate.
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4.2.4.2. in vitro Nasal Cell Toxicity
RPMI 2650 human nasal septal carcinoma cells (ATCC cat. no. CCL 30) cells,
between passages 27 – 32, were grown in Eagle’s minimal essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS) 2 mM L-glutamine, 100 units/mL
penicillin and 100 mg/mL streptomycin, in collagen coated T-75 flasks (Novagen Inc.
Germany) humidified at 37 °C incubator with 5% CO2. The medium was changed every
48–36 hours. Cells were trypsinized with a 0.1% trypsin-EDTA solution upon reaching
80-90% confluency. Cytotoxicity assays were conducted using cells that were passaged at
a density of 3 x 104 cells per well in 200 µL culture medium to collagen-coated 96-well
plates (Novagen Inc. Germany), and incubated overnight for cell attachment.
Subsequently, 100 µL of culture medium was removed from all wells and changed with
appropriately diluted solutions of only RBVN, only POX188 or RBVN and POX188
mixture (1:1) in MEM to achieve final concentration spectrum of 0, 7.8, 15.6, 31.25,
62.5, 125, 250, 500, 1000 µg/mL of each ingredient and incubated for 24 h.
Cell viability was determined by adding the CellTiter-Glo reagent (Promega).
For this, 50 µL media containing treated cells was transferred to an opaque-walled
multiwell plate. About 25 µL of CellTiter-Glo® reagent was added to every well. The
contents were mixed for 15 minutes on an orbital shaker to induce cell lysis. The plate to
incubated at room temperature for 10 minutes to stabilize luminescent signal
andluminescence was measured using a microplate reader (Model 1420-051, Victor3,
Perkin Elmer, Shelton, CT). Control wells were prepared by mixing 50 µL of media
without cells and 25 µL of CellTiter-Glo® reagent to obtain a value for background
luminescence.
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4.2.4.3. in vitro Permeation Measurements
Bovine olfactory mucosa was used as a model tissue for permeation studies,
where L-DOPA permeability was measured by adapting the methods published by
Chemuturi et al.143 Briefly, cow heads were obtained from Bud’s Custom Meats
(Riverside, IA). The olfactory turbinates, which were covered by a pale yellow olfactory
mucosa, were removed within 15 min of decapitation. The excised tissues were
thoroughly rinsed with KRB and transported in fresh KRB maintained on ice; all studies
were conducted within 4 h of procurement to ensure tissue viability.
The permeability of RBVN molecules through the bovine olfactory mucosa was
measured during experiments that used Franz diffusion cells displaying a permeation area
of 0.64 cm2. Tissue was carefully removed from the underlying cartilage and affixed with
the mucosal side facing the donor compartment, between the opposing faces of the two
half-chambers (donor and receiver), using a series of pins that surrounded the opening.
Five mL of Krebs ringer buffer (KRB, pH 6.8), pre-warmed to 37 °C, was added to the
acceptor chamber. To ensure oxygenation and agitation, a mixture of 95% O2 and 5%
CO2 was bubbled through the system. The temperature within the chambers was
maintained at 37 °C. After 30 min equilibration, RBVN was loaded either as a 5 mg/mL
aqueous solution, 5 mg of solid particles, or 10 mg of 1:1 RBVN : POX188
microparticles. For the solid sample test groups, an additional 50 L of KRB was added
to the donor compartment to mimic the low hydration volume of a typical nasal cavity. At
predetermined time points over a 2 h interval, 250 L samples were withdrawn from the
acceptor compartment, and replaced with an equal volume of fresh, pre-warmed KRB.
The samples were appropriately diluted, filtered and used for quantification. The amount
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of permeated drug was determined using UV-visible spectrophotometry at λ = 207 nm
(Linearity range = 5 μg/mL to 17.5 μg/mL, R2 = 0.9998). The apparent permeability
coefficient (Papp) (cm/s) was calculated according to the following equation.

𝐏𝐚𝐩𝐩 =

(

𝐝𝐌 𝟏
. ).
𝐝𝐭 𝐀

𝐂𝐨

𝐱 𝟔𝟎

(4.1.)

where M is the cumulative amount of drug in the receiver cell at time t, dM/dt is the mass
transport rate obtained from linear regression of the initial steady-state portion (µg/min),
A is the diffusion area (0.64 cm2) and Co is the initial donor concentration (µg/mL).

4.3. Results and Discussion
4.3.1. Preparation of Binary composite microparticles
Composite microparticles were designed to contain phase-pure inclusions of
crystalline RBVN suspended by a POX188 matrix to enable intimate mixing between the
two components and alleviate segregation issue likely with a simple physical mixture of
RBVN and POX188. This was intended to be achieved by heating 1:1 RBVN : POX188
mixtures to 100 °C (Tm, polymer < 100 °C < Tm, API), allowing melting of the polymer and
distributive mixing of the fine solid drug particles. Rapid solidification of the polymer
would result in suspension of phase-pure API cyrstallites surrounded by a re-solidified
polymer matrix, as demonstrated previously.206 Prior to this, the decision of drug loading
was based on the DSC data taken for physical mixtures of RBVN and POX188 at various
compositions (Figure 4.1). Each DSC thermogram was observed to have two distinct
melting endotherms consistent with the values for POX188 (57.07 + 1.31 °C) and the low
Tm enantiotrope of RBVN, R-II (166.87 ± 2.03 °C) .163 Of note, neither the onset of
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melting (To) nor the peak maximum temperature (Tmax) deviated significantly relative to
either pure component, indicating that little to no drug dissolved in the molten polymer
during preparation, confirming preparation of the desired suspension. Avoiding partial or
complete dissolution of RBVN in molten polymer was deemed important to prevent
heterogeneous formation of molecularly dispersed drug-polymer solid solution
surrounded by variable degrees of suspended crystalline RBVN. It was thought that such
systems would likely have highly varied delivery rates, the potential for non-uniform
moisture uptake, and potentially issues with respect to insufflation, nasal deposition,
dissolution and permeation profiles.
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Figure 4.1. (a) DSC thermograms of physical mixtures of RBVN and POX188 in varying
proportions of polymer measured at the heating rate of 2 °C/min. (b) Extrapolated onset
of melting plotted as a function of polymer composition.
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These data also suggested that a relatively high fraction of RBVN could be suspended in
POX188, allowing the formulation to balance the need for reasonable dosing with the
presence of sufficient polymer to promote permeation enhancement. As such,
formulations containing 25% or 50% w/w RBVN were selected for subsequent
experimentation.
Figure 4.2 shows a schematic representation of the process by which 1:1 RBVN :
POX188 binary composite microparticles were prepared.

Solidified drug-polymer

mixtures had to be milled in order to achieve nasally administrable particle sizes. A
SPEX Certiprep freezer mill was chosen to micronize the samples, owing to cryogenic
temperature control throughout the comminution process. In Chapter 3, it was noted that
when RBVN was cryogenically milled for longer than 60 min, changes in solid form
were observed. In the present work, therefore, total milling exposure was limited to
shorter times (i.e. 10 or 20 min).

Figure 4.2. Schematic representation of RBVN : POX188 (1:1) binary composite
preparation.
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In this manner, a 2x2 full factorial design of experiments was created with drug
loading (as factor 1) and milling time (as factor 2). The effect of these factors on physical
transformation, particle size and size distribution and content uniformity was studied. The
results are summarized in Table 4.1 and detailed discussion on the chosen formulation is
provided in the later sections.

Table 4.1. Properties of BCM prepared using 2x2 full factorial design of experiments
(DoE) with % w/w drug loading (as factor 1) and milling time (as factor 2).
Formulation
F1

Drug
loading
(% w/w)
50

Milling
time
(min)
20

% Yield
(20 μm
sieve cut)
48 %

Evidence of
physical
transformation
No

Drug
content
RSD 9.8

F2

50

10

42 %

No

RSD 3.0

F3

25

20

42 %

No

RSD 4.6

F4

25

10

30 %

No

RSD 2.6

RSD – Relative standard deviation

As the data indicate, none of the four formulations showed evidence that milling
caused a physical transformation of the RBVN; however the yield from milling varied,
represented by the sieve fraction of interest, and the drug content. Based on these results,
F2 (50% w/w drug loaded product milled for 10 min), which demonstrated moderate
yield with very tight drug content and content uniformity, was used for subsequent
experiments.
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4.3.2. Characterization of Microparticles
4.3.2.1. Solid state properties
PXRD and DSC were used to characterize the microparticles following
preparation and processing. The PXRD patterns of pure component RBVN powder,
POX188 powder, and processed microparticles were compared as shown in Figure 4.3.
As shown, the reference diffractograms for the RBVN and POX188 show characteristic
Bragg peaks, respectively at 11.94, 18.15, 20.3, 20.6, 24.44, 27.1 °2θ and 19.1, 22.0,
23.2 °2θ, all of which were conserved in both physical mixtures as well as processed
microparticles. These data indicate that the crystal form of both components was
preserved throughout preparation.

Figure 4.3. PXRD patterns of 1 : 1 RBVN and POX188 product as it progresses through
the different stages of manufacturing scheme, PM – physical mixture, SS – solid
suspension post cooling in ice water, BCM – Binary composite microparticles after sieve
fractionation. PXRD patterns of pure components are provided for comparison.
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Figure 4.4 shows a comparison of DSC thermograms for pure components with
those of a 1:1 physical mixture and 1:1 RBVN : POX188 microparticles. The DSC
thermogram for pure RBVN showed only a single single sharp endothermic peak at
168.64 ± 0.21 °C, consistent with melting of the room-temperature stable polymorph,
Form R-II.163 POX188 thermograms had an endothermic peak at 54.32 ± 1.39 °C,
consistent with literature values for its melting.206 DSC data for the 1:1 composite
microparticles showed two distinct endothermic peaks, one at 55.9 ± 1.59 °C and
168.2 ± 0.48 °C, which were attributable to POX188 and RBVN, respectively, while the
thermograms for the microspheres, slow heating DSC curve (2 oC/min) was similar to
that for physical mixture with no reduction in the melting of POX188 and a 3 °C
depression in the onset of melting of RBVN. These differences could be the effect of
particle size reduction that the microparticles were subjected to during milling. None of
the microparticles showed any evidence of a solid form change, confirming that RBVN
and POX188 remained phase pure. It is noted that high heating rate (40 oC/min) was
applied for improving detectability of small quantities of amorphous RBVN/R-I, but no
discernable changes were observed.
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Figure 4.4. DSC thermograms of pure RBVN, pure POX188 and the milled + sieve
fractionated composite microparticle drug product at 2 °C/min heating rate.

4.3.2.2. Particle properties
In the present study, the selected sieve fraction of composite microparticles was
characterized for particle size distribution and bulk morphology (Figure 4.5a – 4.5b).
The median primary particle size (d50) was 20.6 µm, with d10 and d90 respectively
measuring 6.03 µm and 48.1 µm (See Fig. 4.5c). When observed under polarized light,
particles prominently exhibited birefringence suggesting that RBVN remains in
crystalline state (data not shown).
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Figure 4.5. (a and b) Micrograph depicting particle size distribution of 1:1 RBVN :
POX188 binary composite microparticles. The particles were not immersed in oil,
observed through a 10× objective. These micrographs were used to measure Feret
diameter (n = 300) particles; (c) particle size distribution of primary particles observed in
(a and b).
Scanning electron microscopy (SEM) technique was used to assess the bulk
morphology of final microparticles. Relative to the agglomerated needle-like morphology
of standalone RBVN and spherical shape of POX 188, the binary composite
microparticles demonstrated irregular surface morphology (figure 4.6). Although the
morphology of particles obtained from analytical samples may not be particularly
favorable for reproducibly emitted doses from nasal devices, it is expected that the size
reduction step necessary at larger scales will likely make the particle morphology more
regular; making it suitable for insufflation and nasal deposition.
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Figure 4.6. Scanning electron micrographs: (A) unprocessed ribavirin, (B) poloxamer
188 and (C) 1:1 (w/w) milled + sieved fractionated composite microparticles.

4.3.2.3. Drug content and uniformity
Samples were randomly withdrawn from the microparticles collected on the 20
μm sieve and assessed for drug content. Based on spectrophotometric analysis, the mean
RBVN content was measured to be 50.1 %w/w with a relative standard deviation RSD of
3.0. This suggests that the two components of the microparticle system were adhered
strong enough to overcome the mechanical stresses of milling and sieve fractionation. For
comparison, a control group comprised of a 1:1 physical mixture of RBVN and POX188
(both components individually milled to 20 – 53 μm particle sizes) was prepared in lab
scale V-blender. This mixture was exposed to mechanical sieve shaking similar to
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composite microparticles. Interestingly, segregation into individual components was
observed within 10 min of mechanical shaking, resulting in a mean RBVN content of
52.1 %w/w with poor RSD of 8.3, which worsened as shaking continued. Similar to this
observation, segregation of RBVN and POX188 is likely to occur during transport and/or
insufflation of a dry, solid, nasal drug product, potentially manifesting as inconsistent
performance. As a result, physical mixtures of RBVN and POX188 were felt unlikely to
be viable formulations; therefore only the binary composite microparticles were
evaluated for in vitro performance.

4.3.3. Evaluation of formulation
4.3.3.1. in vitro Drug Release
Drug release from microparticles was evaluated in vitro using a semi-permeable
regenerated cellulose membrane to separate donor and receiver compartments in a Franz
diffusion cell. A 3000-3500 Da MWCO (molecular weight cut off) was used to facilitate
selective permeation of dissolved RBVN molecules (molecular weight = 244.21 Da),
while retaining the POX188 molecules (average molecular weight = 8400 Da) on the
membrane surface. In contrast to typical diffusion experiments, the dissolution volume on
donor side of the Franz cell was purposely maintained at 20 µL to mimic the hydration
volume in a typical adult human nasal cavity. Consequently, in vitro release experiments
were considered to consist of three-steps: (1) drug dissolution within the hydrated
polymer matrix (2) drug diffusion through the polymer matrix into the donor fluid, and
(3) accumulation of drug in the receiver side of the diffusion cell, after passing through
the membrane.
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It is acknowledged that the chosen release model only allows for multiple
sampling from the receiver side which, in turn, provides information about the rate of
drug accumulation in the receiver side. It does not, however, directly assess the first two
processes i.e., drug dissolution and diffusion rates. Owing to the complexity associated
with this setup, a control group of pure component RBVN microparticles was added to
the experimental design to eliminate one of three abovementioned processes i.e., drug
diffusion from the polymer matrix. Furthermore, it is conservatively assumed that RBVN
permeation through the cellulose membrane is less likely to be rate-limiting as the pore
size of the membrane (~1-10 nm reported by manufacturers) is considerably larger than
the size of single drug molecule dissolved in water. By this argument, the observed
“apparent release” profile from standalone RBVN microparticles (see figure 4.7) is an
indirect estimation of drug dissolution in the donor side. It can be seen that dissolution
of RBVN in the donor side is not instantaneous but proceeds gradually over the course of
the experiment. Approximately 70% of the drug was released (or dissolved in this case)
in 45 min, which reaches completion (~97%) within 180 min.
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Figure 4.7. The apparent cumulative RBVN release from standalone solid drug particles
(black circles) and binary composite microparticles (grey circles).
When these data are compared with the RBVN release rate from binary composite
microparticles, the influence/effect of POX188 on drug release became clear. Although
the extent of cumulative RBVN release from polymer microparticles remained
comparable at 180 min, it is noteworthy that the initial release rate was slower relative to
the pure component drug particles. This result was not unexpected because the RBVN
particles have to not only undergo dissolution in the donor side but the dissolved RBVN
molecules have to diffuse through the polymer matrix prior to permeation, collectively
decreasing the rate at which drug molecules appear in the receiver compartment.
Poloxamers® are known to exhibit reversible thermal gelation and their effect on
drug release is extensively studied.207-210 Evidence suggests that in an aqueous solution,
the copolymer molecules aggregate as micelles when the temperature is increased. The
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micellization is likely due to the dehydration of the hydrophobic PPO blocks with
temperature. At sufficiently high concentrations and temperature, these micellar
structures entangle to form rigid gels, which in turn produces a decrease in the number
and size of water channels, leading to an increased path length for diffusion. A decrease
in RBVN release rate from binary composite microparticles is attributed to poloxamer
gelation in the donor compartment. As the release experiments progressed, rapid
conversion of solid RBVN : POX188 composite microparticles into a thin film was
observed; which supports this claim. According to the data, it took approximately 75
mins for 70% drug to release, which was 1.7 times longer than the control group. While it
can be argued that such a release rate is not reflective of the human nasal clearance time
(estimated at 10-20 min, and most drug may remain unabsorbed and lost, there is some
literature data to suggest that poloxamer containing gel formulations can be retained in
the nasal cavity for up to 100-110 min.128,129 This suggests that >90% drug release can be
assumed in the nasal cavity from the microparticles formulated in this study.

4.3.3.2. in vitro Cytotoxicity
During the development of drug-loaded formulations for IN administration,
preclinical studies assessing transmucosal drug transport or toxic effects of excipients can
be performed using excised tissue, primary cell cultures, or immortalized cell lines. 211
Excised human tissue is not only difficult to obtain, but also presents inter- and intraindividual differences. As a consequence, drug permeation studies are usually performed
in nasal mucosa excised from experimental or slaughtered animals, which introduce other
drawbacks, such as species differences in tissue composition, transporter expression and
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ethical concerns. Alternatively, in vitro human cell lines (primary and immortalized) can
be used to evaluate drug formulations.
Immortalized cell lines from human origin are of great interest owing to good
genetic homogeneity, data reproducibility and ease of culture maintenance.212 In
particular, RPMI 2650, an immortalized cell line derived from an anaplastic squamous
cell carcinoma of the human nasal septum, is the only commercially available cell line
having morphological and biochemical resemblance with normal human nasal
epithelium.211-214 These RPMI 2650 cells were investigated as a permeation model to
evaluate RBVN : POX188 (1:1) solid microparticle formulations prepared and
characterized in Section 4.3.1 and 4.3.2, respectively. Prior to the permeation
experiments, it was imperative to assess the safety of nasal epithelium in the presence of
the components of microparticles. For this reason, RPMI 2650 cell viability was studied
after 24 h of incubation with pure RBVN, pure POX188 and 1:1 mixture of RBVN and
POX188 over a spectrum of concentration and the results are captured in Figure 4.8.
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Figure 4.8. Cytotoxicity assay using CellTiter Glo® reagent (reported as mean ± SD,
n ≥ 3): RPMI 2650 cells were incubated with varying concentrations of POX188 only,
RBVN only and RBVN: POX188 (1:1) mixture for 24 h at 37 °C and 5% CO2 humidified
atmosphere. 2 mg/mL stock solutions prepared in high-grade sterile water was sterile
filtered and serially diluted with media to generate the spectrum of concentrations used
here. For 1:1 physical mixtures, appropriate dose adjustment was done (i.e. 4 mg/mL
stock) was prepared to obtain concentrations upon dilution that are comparable to the
other test groups. Statistical differences within the same group are denoted as; **P <
0.01; ***P < 0.001 and between groups are denoted as #P < 0.05.

The effect of increasing ribavirin concentration on the viability of RPMI 2650
cells is shown here. As expected, higher concentrations of RBVN resulted in a greater
reduction in cell viability. In the test group containing only RBVN, the measured cell
viability was reduced by 25.7 %, 30.1 % and 36.8 % respectively, at concentrations 250,
500 and 1000 μg/mL. RBVN is known to inhibit the synthesis of DNA within cells,
resulting in cell death and prevention of cell division.215, 216
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In contrast to the results above, pure component POX188 showed no significant
cytotoxic effect

over the entire concentration range studied, which was in close

agreement with observations in other cell lines.217, 218 Poloxamers® have been shown to
have cytoprotective effect in vitro and in vivo.219,220 The most well-documented
characteristic of POX188 is its ability to repair damaged cell membranes by mechanisms
that, while not entirely clear, may be attributable to helping increase the lipid packing
density by direct incorporation of POX188 into the phospholipid bilayer.221 In the present
study, when the cells were exposed to RBVN in the presence of POX188, the viability
was improved considerably, which was more prominent at higher concentration. At 1000
μg/ml, cells incubated with RBVN exhibited 63.2% viability, which was improved to
89.5% in the presence of POX188. It is plausible that poloxamer may have sequestered
RBVN from entering into the cells through the ability to incorporate in lipid bilayer.
It is acknowledged that the time of incubation used in these experiments is not
reflective of human nasal residence time; however, the extension of exposure time
guaranteed an observable and quantifiable change in viability that enabled a comparison
of the cytotoxicity between test groups. Based on these results, 1000 μg/mL initial RBVN
concentration was used for in vitro permeation experiments using a nasal cell line, with
an exposure period of only 4 h where no cytotoxicity was observed (data not shown).
Using the method laid out by Bai et. al.213 and Goncalves et. al.222 attempted growth of
RPMI 2650 monolayers (See figure 4.9a) at air-liquid interface was performed. The
RPMI 2650 cells were seeded (at a density of 4 × 105 /cm2) onto collagen-coated
permeable polytetrafluoroethylene inserts and grown at an air–liquid interface for 8-10
days. Unlike Bai et. al., however, our repeated trials failed to produce polarized
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monolayers with cells interconnected through tight junction proteins. Instead, clusters of
cells and distinct open regions resulting in a ‘leaky’ permeation membrane were
observed, as represented in figure 4.9b. Therefore, it was decided to incorporate freshly
excised olfactory tissue from bovine source as the model for permeation.

Figure 4.9. (a) A representation of permeation barrier produced with RPMI 2650 nasal
cell line uniformily grown at an air-liquid interface within the cell inserts. Reprinted from
International Journal of Pharmaceutics, 515, Vanessa S.S. Gonçalves, Ana A. Matias,
Joana Poejo, Ana T. Serra, Catarina M.M. Duarte, Application of RPMI 2650 as a cell
model to evaluate solid formulations for intranasal delivery of drugs, pp:1-10, Copyright
2016, with permission from Elsevier. (b) A microscopic image of RPMI 2650 cells
growing as clusters on the inserts, as observed on day 10 from the day of seeding. Media
was changed on the basolateral side every 48 hours. Reprinted from Journal of
Pharmaceutical Sciences, 97, Shuhua Bai, Tianzhi Yang, Thomas J. Abbruscato, Fakhrul
Ahsan, Evaluation of human nasal RPMI 2650 cells grown at an air–liquid interface as a
model for nasal drug transport studies, pp:1165-1178, Copyright 2008, with permission
from Elsevier.

4.3.3.3. in vitro Permeation
The present work was designed to evaluate RBVN permeation when deposited as
solid microparticles directly on nasal mucosal tissues. As such, a control group involving
loading of RBVN in aqueous solution was introduced to compare how the permeation of
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drug might be affected. It should be noted that the configuration of permeation cells used
here was different from Chapter 2. In using the vertical tissue diffusion cells for the LDOPA work, it was realized that solid microparticles may have drifted away from the
diffusion area during the course of the experiment, which would manifest itself as a
premature plateau in the drug transport profile. To avoid this potentially confounding
variable and ensure that the solid RBVN microparticles remained deposited on the tissue
throughout experiments, diffusion chambers allowing horizontal tissue mounting were
used.

Figure 4.10. in vitro permeation profile of RBVN across bovine olfactory tissue, when
loaded as aqueous solution. Data are expressed as mean + SD, n=3. The dashed line
denoted steady state region.
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A 0.2 mL aliquot of a 5 mg/mL aqueous solution of RBVN was added to the
donor compartment to expose (theoretically) 1 mg of RBVN to the mounted tissue. After
120 min of contact with the nasal mucosa, the cumulative amount of RBVN that
permeated from solution, per unit tissue area, was 742.20 ± 16.92 µg cm-2 (n = 3, see
figure 4.10.). The linearity of the profile (r2 > 0.99), without significant lag-time,
suggested that drug permeation occurred at a constant rate. The average flux in the
steady-state region (Jss), calculated based on Equation 4.1, was 4.02 + 0.51 µg/cm2∙min,
while the apparent permeability coefficient (Papp) was estimated to be (1.34 + 0.17) x 10-5
cm/s based on Equation 4.1. This agreed closely with a previously reported value of Papp
of RBVN across rabbit nasal mucosa (1.92 + 0.18) x 10-5 cm/s).22 These preliminary
experiments confirmed high permeability of RBVN across bovine olfactory tissue in
vitro; however, considering the rapid mucociliary clearance of the nasal cavity, it is likely
that aqueous solutions containing RBVN would not remain in residence for more than
10-20 min.
For a direct comparison with aqueous RBVN solution, direct deposition of 1.0-1.5
mg RBVN solid microparticles on the excised tissue was planned. Owing to the
impalpable nature of the solid RBVN microparticles, it was difficult to manually load
such small quantities of powder and maintain a dose precisely consistent with the
solution group. Therefore, 5 mg of RBVN solid microparticles was directly deposited on
the donor side of the tissue, while the dose of RBVN : POX188 (1:1) microparticles was
adjusted to provide comparable drug exposure (i.e., 10 mg of 1:1 binary microparticles).
The permeation profile for the two test groups of solid particles is shown in figure 4.11.
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Figure 4.11. in vitro permeation profiles of RBVN across bovine olfactory tissue when
loaded as pure component drug particles (open diamonds) and 1:1 RBVN : POX188
composite microparticles (closed diamonds). Data are expressed as mean + SD, n = 3.
As shown, the cumulative amount of RBVN permeated from polymer
microparticles (4332.95 + 460.11 µg/cm2) was about 3.3 fold greater than that which
permeated from pure component RBVN microparticles (1330.79 + 182.83 µg/cm2). This
was also reflected in the flux values, which were 18.72 + 3.4 µg/cm2∙min (r2 >0.92) and
47.81 + 22.42 µg/cm2∙min (r2 >0.99) respectively for RBVN particles and RBVN :
POX188 (1:1) composite microparticles.
A comparison of the permeation profiles exhibited by each test group notes
striking differences. The mass transport profile for RBVN loaded as standalone drug
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microparticles reaches a plateau after approximately 45 min, unlike the 1:1 RBVN :
POX188 composite microparticles. Given the horizontal setup, loss of microparticles
from the site of diffusion due to gravity was not expected. Additionally, under the
parameters maintained during these experiments, the receiver volume was >10 times the
saturation volume for RBVN (Cs = 149 mg/mL at 25 ºC) (Chapter 3, Section 3.3.2),
suggesting that it was reasonable to expect that sink conditions were maintained
throughout permeation measurements.
Careful examination of the literature offered some logical explanation of these
data in relation to the mucosal uptake mechanism of ribavirin molecules. Briefly, it is
known that ribavirin is absorbed into biological compartments (including intestinal cells,
erythrocytes, striated muscles and neurons) by transporter-mediated uptake, particularly
nucleoside transporters, CNT 2/3 and ENT 1/2.113,114,223 Owing to the high expression and
localization of these transporters in the olfactory epithelium, as reported by AlGhabeish,224 it is safe assume that RBVN molecules predominantly underwent active
uptake in these permeation measurements. Furthermore, the hydrophilic nature of
ribavirin makes molecular RBVN unlikely to undergo significant passive transport.
It is well-known that transporter-mediated uptake mechanisms can be saturated if
the substrate (drug) levels are sufficiently high. Once specific transporters are saturated,
no additional drug can be absorbed, irrespective of the concentration available in the
donor side. Reports indicate that ribavirin transport by human ENT1 in the erythrocytes is
saturable at 420 µM (~100 μg/mL),225 and in intestinal lumen at 44.5 µM (~11 μg/mL).114
In the absence of direct measurements on olfactory epithelium, it can only be
hypothesized that at 45 min almost all RBVN powder dissolved in the small volume of
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donor fluid and saturated the transporters, which in turn would be consistent with the
observed plateau beyond 45 min in the permeation profile of RBVN solid microparticles.
Alternatively, it can be speculated that the influx of RBVN molecules in the
olfactory tissue was counteracted by efflux transporters, resulting in reduced overall mass
transport. Evidence suggests that P-gp and BCRP efflux transporters are highly expressed
in the olfactory tissues, which show affinity towards nucleoside analogs structurally
related to RBVN.226 In contrast to the pure RBVN data, formulation of RBVN : POX188
(1:1) binary microparticles enabled unrestricted unidirectional transport of RBVN, as
shown in figure 4.11. Poloxamers® have been widely studied for efflux pump
inhibition123,124 in the areas of drug delivery beyond the blood brain barrier (BBB) and
cancer therapy. Additionally, these polymers are known to have an effect on membrane
fluidization and transient opening of tight junctions. It is speculated that a combination of
these physiological changes enabled higher flux and greater RBVN mass transport in the
presence of POX188. A schematic representation of the proposed mechanism is shown in
figure 4.12.
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Figure 4.12. Schematic representation of RBVN (blue closed circles) transport across the
olfactory epithelium.
As depicted in the figure, the presence of POX188 enables greater RBVN
permeation presumably via a combination of opening of tight junctions and inhibition of
efflux transporters. This is supported by our experimental observations. These data
confirm the superiority of the 1:1 binary composite microparticles in that it does not
compromise the cumulative extent of RBVN release, potentially reduces the cytotoxic
effect of RBVN and improves epithelial flux and overall mass transport. In contrast, the
usability of aqueous RBVN solutions is likely restricted by long term chemical ingetrity
of RBVN in dissolved state and rapid clearance from the site of deposition. Standalone
RBVN microparticles surely circumvent the issue of chemical instability but their full
potential may not be utilized due to saturable RBVN mucosal uptake.

135

4.4. Conclusion
In this work, solid microparticles comprised of a 1:1 suspension of fine crystalline
RBVN in POX188 matrix were developed. Particles were milled to an average size of 20
μm to make them suitable for intranasal delivery. The final microparticles were
physically and chemically stable, with a narrow particle size distribution and precise
content uniformity. The extent of RBVN release from microparticles was comparable to
standalone drug particles. Preliminary cytotoxicity tests indicated the effects of RBVN
and POX188 on the viability of nasal cell lines when exposed individually and as a 1:1
combination. This helped establish dosing for tissue experiments. Permeation of excised
bovine nasal tissue was evaluated in vitro, showing that 1:1 RBVN : POX188 composite
microparticles allowed the highest mass transport of ribavirin relative to RBVN solid
particles or RBVN solution. This was expected to be the result of transient opening of
tight junction proteins along with inhibition of efflux transporters. These data suggest that
formulation of a poorly permeating drug, such as RBVN with a permeation enhancer,
such as POX188, can be advantageous to ultimate mass transport of drug. The effect of
chronic dosing of permeation enhancer on the integrity of nasal epithelium, however,
remains to be tested.
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Chapter 5: Summary
Intranasal drug delivery has shown tremendous potential for direct entry of
permeation rate limited molecules into the CNS, by allowing drugs to bypass the BBB.
Research on nose-to-CNS uptake has revealed that deposition of formulation in the
olfactory region of the nasal cavity, allows opportunity for drug to be directly absorbed to
the CNS, providing the opportunity for treatment of various neurological conditions.
Research has suggested that deposition of solid particles resists mucocilliary
clearance, and can allow for greater retention time in the nasal cavity. Additional time at
the deposition site results in increased absorption from the nasal cavity when compared
with drug solutions or other liquid vehicle dosage forms. This was tested in the present
work, first by measuring epithelial flux and permeability across bovine olfactory tissue
for L-DOPA when loaded as either an aqueous solution or as dry, crystalline particles. As
hypothesized, the average steady-state flux (Jss) of L-DOPA from the solid microparticles
directly deposited on nasal epithelial tissue was 3 times greater than the Jss measured for
L-DOPA from solution. This was attributed to rapid dissolution of L-DOPA from the
microparticles that ultimately saturated the mucus layer. Consequently, a high driving
force was established across the nasal membrane, which enabled improved mass
transport. These findings suggested that intranasal delivery of small molecule organic
substances (SMOs) by the administration of solid microparticles might not only benefit
from improved chemical and microbiological stability but do so without compromising
the cumulative mass transport of drug across the olfactory membrane.
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The antiviral compound RBVN has been investigated in the treatment of several
diseases affecting the CNS, however, bioavailability to this compartment is extremely
limited, owing to the poor lipid permeation of this molecule. To improve the cumulative
extent of tissue transport in cases such as these, literature reports suggest the use of
permeation-enhacing polymers. The present work explored the IN delivery of solid
binary composite microparticles consisting of ultrafine crystalline RBVN suspended in a
surrounding solid matrix of Poloxamer F-188 (POX188). Prior to the preparation of
composite microparticles, it was crucial to investigate the effect of standard micronizing
techniques on the physical and chemical stability of RBVN. Little has been done
concerning susceptibility of this material to solid form changes during processing. In the
present work, solid-state transformations of RBVN were examined under different
thermal and mechanical stress conditions. Although the Ttr for RBVN enantiotropes
wasmeasured at ~70 °C, unprocessed R-II did not transform into high melting
enantiotrope R-I, at T > Ttr, even after 7 days. However, following grinding, the same
isothermal storage conditions resulted in rapid R-II  R-I conversion. This suggested
decrease in the energy barrier required to produce the high Tm enantiotrope during
pulverization; potentially by creating crystal defects during milling. Further, a
comparison of two milling equipments revealed that extensive grinding led to complete
R-II  R-I when the mill temperature was not controlled. In contrast, high shear
cryogenic grinding of R-II, conducted at T << Tg resulted in complete transformation to
persistent amorphous ribavirin. Ultimately, the findings in this work facilitated intelligent
selection of manufacturing equipment and process conditions for reproducibly generating
composite microparticles of RBVN and POX188.
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Co-solidified mixtures of 1:1 drug and polymer were micronized to dimensions
between 10-45 µm to promote maximum nasal deposition. Consistent with the RBVN
characterization work, it was confirmed that the final drug product demonstrated a
consistent solid form, acceptable chemical stability, and drug content uniformity, even
following comminution. Additionally, in vitro drug release studies revealed that the
cumulative RBVN release from the polymeric microparticles was comparable with
standalone drug microparticles. Although the initial release rate was slower in the
presence of polymer, it was argued that the mucoadhesive property of POX188 will retain
the drug product at the deposition site longer and not compromise the extent of RBVN
release. Further, the presence of POX188 appeared to counteract the observed cytotoxic
effect of RBVN in vitro by sequestering the latter. Lastly, a 3.3 fold higher amount of
RBVN cumulatively permeated through excised olfactory tissue when deposited as 1:1
RBVN : POX188 solid microparticles relative to standalone RBVN solid particles. This
was attributed to a combination of effects (1) transient opening of tight junctions between
olfactory epithelial cells and (2) bloackage of efflux transporters.
Ultimately, these data suggested a potential avenue for pharmaceutical
formulation research and development that could be particularly important in the
treatment of other neurological disorders. Indeed, drug molecules having limited CNS
bioavailability may be subject to greater nasal retention and permeation when introduced
as solid microparticles, providing the possibility of straightforward, non-invasive therapy
for current clinical practice. Nonetheless, it will be crucial to investigate the effect of
multiple dosing of microparticles on the integrity of nasal tissue – a compromised state of
which

may

inadvertently

provide

CNS
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entry

to

toxins

and

allergens.

Appendix A: Physical characterization of drug and
polymer dispersion behavior in PEG 4000 solid
dispersions using a suite of complementary analytical
techniques
A.1. Introduction
As poorly soluble new chemical entities enter drug development pipelines,
different approaches for solubility enhancement may be attempted as they are considered
for adoption as candidate molecules. Among these, preparation of solid amorphous
dispersions has received considerable attention.32, 227-230 Solid dispersions are prepared
by rapid co-solidfication of an active pharmaceutical ingredient (API) and a carrier
excipient (frequently a water soluble polymer), by one of several methods, including
spray drying,231 super-critical fluid processing,232 lyophilization,233 hot-melt extrusion,234
and high shear co-trituration.235, 236 Solid dispersions can increase the apparent solubility
of a material by allowing the drug to persist as an amorphous solid.237 Spontaneous
recrystallization of the drug is inhibited by its physical intercalation within interstices
formed by entanglement of the polymeric host.230, 238-240
Since both formation and physical stability of solid dispersions relies on
solidification from a mutually miscible API and polymer mixture, research in this area
has focused on predicting how the interactions between API and carrier enable
dispersability.241-244 Despite predictive advances, dispersion formulation still relies on
analytical techniques to confirm that a true dispersion has been formed. Several different
characterization approaches are reported throughout the literature, and include single-
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instrument,239, 245, 246 two-instrument242, 247 and multi-instrument methods,248 each aimed
at demonstrating that the physical properties and microstructure of the binary solid,
established by intimate, mutual dispersion of the components, are distinct from physical
mixtures of the two solids. Moreover, as solid dispersions become viable formulation
strategies for poorly soluble API, regulatory agencies will see an increased number of
filings for these materials. At present, no standard guidance directs characterization of
solid dispersions, leaving it to the literature to report best practices.
In this study solid dispersions were attempted using a modest library of 15 model
API in polyethylene glycol 4000 (PEG4000). PEG4000 is a hydrophilic, semicrystalline
polymer potentially useful as a solid dispersion carrier227, 228, 249 which has been shown to
increase the dissolution rate of poorly water soluble drugs such as carbamezapine.250
Despite historical use, the phase behavior of API in PEG remains challenging to
characterize. Upon co-solidification, PEG4000 has been shown to disperse API as pure
amorphous solid,251 a combination of amorphous and crystalline phases,252 only
crystalline solid,250 and form eutectic mixtures with API.253, 254 PEG4000 was, therefore,
chosen for this study as illustrative of resulting in very complex solid mixtures with API,
providing analytically challenging signals for interpretation using individual techniques
commonly employed in solid dispersion characterization. In this work, API:PEG4000
combinations will be classified in one of three categories, 1) Fully dispersed: quenching
of a completely miscible molten mixture results in a single amorphous phase; 2) Partially
dispersed: quenching results in a detectable amorphous phase, and recrystallized drug
and/or polymer; 3) Fully phase separated: quenching results in complete recrystallization
of the drug and polymer. A fourth potential outcome might be expected in some cases,
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where both components are in the amorphous state, but they are not dispersed in one
another. This possibility is unlikely with the polymer used here, and was not observed,
most likely due to the propensity of PEG4000 to rapidly crystallize.
The key objective of this work was to demonstrate that comprehensive
characterization is needed for PEG-based dispersions in order to properly classify
API:polymer behavior. Each sample in the library was characterized using a suite of
techniques including powder X-ray diffraction (PXRD), pair distribution function (PDF)
analysis,242,

247

hot-stage polarized-light microscopy (HSM), and differential scanning

calorimetry (DSC). The dispersion behavior of each API in PEG4000 was inferred using
this suite of techniques. In some instances, inferences drawn from single techniques
resulted in inconsistent classifications, while complementary characterization allowed for
better informed classification of the binary materials.

A.2. Materials and Methods
A.2.1. Materials
Chlorpropamide, indomethacin, tolbutamide, cimetidine, and griseofulvin were all
purchased from MP Biomedicals (Solon, OH).
purchased from Spectrum (Gardena, CA).

Ketoconazole and ibuprofen were

Quinidine and cloperastine·HCl were

purchased from Sigma-Aldrich (St. Louis, MO). Terfenadine and sulfanilamide were
purchased from Acros Organics (Geel, Belgium). Propranolol·HCl, nifedipine, and
itraconazole were purchased from TCI Chemicals (Portland, OH).

Melatonin and

polyethylene glycol 4000 were purchased from Alfa-Aesar (Ward Hill, MA).
structures for all model drugs and PEG4000 are shown in Table A.1.
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The

Table A.1. Molecular structures for model drugs and polymer used in this study.
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Griseofulvin

NH2

A.2.2. Co-solidification of API:PEG4000 Mixtures
Physical mixtures of each API and PEG4000 were manually prepared in a 3:1
(%w/w) API:polymer ratio, and equilibrated at 10%RH for 24 h. Physical mixtures
were transferred to a crucible immersed in silicone oil maintained at Tm,API +10°C. The
molten mixture was stirred for 20-30 min to ensure that all solid had disappeared.
Mixing times were determined based durations at Tm,API +10oC at which insignificant
thermal degradation was observed.

Each material was held isothermally in a

thermogravimetric analyzer (TGA) at Tm,API +10oC, and <2% w/w weight loss was set
as a criterion for thermal stability at this temperature. Additionally each API was heated
in a DSC to Tm +15°C, and held isothermally for 30 min. After the extended isothermal
hold, samples were quenched in the DSC, before reheating. The Tg values all
corresponded well with reported literature values, and the baseline heat flows following
melting of these samples were steady, suggesting that each API was stable under the
conditions used to make the dispersions. Additionally, the literature suggests that no
significant chemical degradation should be expected at temperatures equal to or greater
than those used in the present experiments for chlorpropamide,255 griseofulvin,256
indomethacin,257 itraconazole,258 ketoconazole,259 nifedipine,260 terfenedine,261 and
tolbutamide.257
Nitrogen gas was continuously streamed over the crucibles during preparation, to
prevent moisture sorption. Molten mixtures were quenched by immersion of the crucible
in liquid nitrogen. Pure component amorphous samples were prepared using the same
method as the API:PEG4000 mixtures. All preparations were repeated in triplicate.
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A.2.3. Differential Scanning Calorimetry (DSC)
Glass transition temperatures (Tg), melting temperatures (Tm) and recrystallization
temperatures (Tc) were measured in triplicate for all samples using a Model Q100 DSC
(TA Instruments, New Castle, DE), operated under a three-point temperature/enthalpy
calibration using o-terphenyl, indium, and tin standards, and a cell constant calibration
using indium. All experiments were conducted using 50 mL/min nitrogen purge to the
cell. Sample “chips” of co-solidified mixtures (4-8 mg) were hermetically sealed in
aluminum pans, and initially cooled at 20°C/min to -80°C.

Following in situ

equilibration at -80oC, each sample was heated at either 2°C/min or 20°C/min to Tm,API
+10°C. All pure component drug and polymer samples (3-5 mg) were heated at 20°C/min
from room temperature to Tm +10°C, held isothermally for 5 min, and then rapidly cooled
to -80°C in situ.

Quenched samples were then re-heated at 20°C/min to

Tm +10°C.
The expected Tg for drug:polymer mixtures (assuming intimate mixing of the two
liquid phases) was calculated using the Couchman-Karasz equation:262

𝑻𝒈 =

𝒘𝑨𝑷𝑰 𝑻𝒈,𝑨𝑷𝑰 + 𝑲𝒘𝒑 𝑻𝒈,𝒑

(A.1)

𝒘𝑨𝑷𝑰 + 𝑲𝒘𝒑

where wAPI and wp were the weight fractions of API and polymer, respectively, Tg,API and
Tg,p are the glass transition temperatures of amorphous API and polymer, respectively,
and K= ΔCp,p/ΔCp,API, where ΔCp,p and ΔCp,API are the changes in heat capacity through
the glass transitions of the polymer and API, respectively. Calculated Tg values were
compared with observed Tg values for mixtures, interpolated from the DSC heat flow
signal, measured as the midpoint of the step change in heat capacity. It is important to
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note that Tg,p measured in these experiments was very low (-67.92°C),263-265 and
PEG4000 rapidly recrystallized at room temperature.

As such, pure amorphous

PEG4000 could not be prepared as a pure component reference for use with any of the
other characterization experiments.

A.2.4. Optical Hot Stage Microscopy (HSM)
Small, intact chips of each co-solidified API:PEG4000 mixture were placed on a
microscope slide and heated/cooled using an Instec HCS 302 Pelletier heating stage with
an STC 200 temperature controller (Instec, Boulder, CO). Samples were heated at
10°C/min from ambient temperature to Tm,API +10°C, held isothermally for 5 min, and
then cooled back to ambient temperature at 10°C/min. Observations were made using an
Olympus BX-51 optical microscope equipped with a polarizing filter, under 10X
magnification. Photomicrographs were obtained throughout the heating/cooling profile to
observe phase changes in the solids as a result of heating, or to distinguish between
crystalline polymer and crystalline API.

A.2.5. Powder X-ray Diffraction (PXRD)
PXRD data were collected in transmission geometry, by placing intact samples
between two layers of Kapton® film (ChemPlex, Palm City, FL), spun (16 rpm) in a
vertical sample stage. Sample positioning, rotation and transmission geometry allowed
complete volume interrogation of all samples, therefore, diffraction data were collected
from each solid, in its entirety. An X’Pert Pro MPD system (PANalytical B.V., Almelo,
the Netherlands), equipped with a copper anode (λ = 1.5406 Å), an auxiliary elliptical
mirror, and X’CeleratorTM detector was used to collect diffraction data at an operational
voltage/amperage of 45.0 kV/40.0 mA.

To maintain consistent counting statistics
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between experiments, consistent irradiation times of 51.04 s per step (0.017° 2θ steps)
were used to collect data over 2-100 °2θ.

A.2.6. Pair Distribution Function (PDF) analyses of PXRD data
The pair distribution function (PDF) is a total scattering method utilizing the
Fourier relationship between reciprocal and real space.266,
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The PDF reports the

probability of finding two atoms separated by a distance r, and is obtained using
Equation A.2:
𝑮(𝒓) =

𝟐
𝝅

𝑸𝒎𝒂𝒙

∫𝟎

𝑸[𝑺(𝑸) − 𝟏] 𝐬𝐢𝐧 𝑸(𝒓) 𝒅𝑸

(A.2)
S(Q) is the structure function obtained from a normalized PXRD pattern, and Q is the
magnitude of the scattering vector. To enable correct calculation of S(Q), corrections
were made to measured diffraction data, according to those outlined in Egami and
Billinge.259 The integration limit, Qmax, is the momentum transfer resolution of the
diffraction experiment, which depends on both the maximum diffraction angle (100 ˚2θ)
and the X-ray wavelength (λ = 1.5406 Å) used in PXRD data acquisition. Intensity
corrections (e.g., background due to Kapton® film, absorption, etc.) and PDF calculations
were performed in the MATLAB environment (v2012b, MathWorks, Natick, MA) using
a graphical user interface programmed in-house.268
PDF-transformed PXRD data from co-solidified samples has been shown to be
useful in differentiating between phase-separated and completely dispersed samples.242,
246, 247

In the present work, PDF-transformed PXRD data for co-solidified samples

(observed PDF) were compared to calculated PDFs generated by weighted linear
combination of the PDF transforms for individual amorphous components (theoretical
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PDF). Dispersion behavior was inferred using the following criteria: 1. Sum-of-squares
difference between theoretical and observed PDFs (R-value); 2. agreement or deviation
of scaling coefficients relative to known 3:1 experimental compositions of API:polymer;
and, 3. observation of regions in the PDF difference plot that did not contain zero in the
3σ confidence interval (CI).269
Cases in which the theoretical and observed PDFs were superimposable were
concluded to be at least partially phase-separated. That is, the short-range order of the cosolidified product was adequately described by the interatomic distances of physical
mixtures

of

API

and

polymer.

Conversely,

significant

deviations

between

theoretical/observed PDFs were used to suggest that short-range order unique to intimate
API/polymer mixing was present, suggesting complete dispersion following solidification
from a miscible mixture.242, 247
It was noted above that, owing to rapid recrystallization of PEG4000, PXRD for
pure amorphous polymer could not be obtained, but was required for calculation of
theoretical PDFs. As an alternative, PXRD patterns of liquid PEGs (PEG 200, PEG 300,
and PEG 400) were collected. The PXRD and PDF data for the three liquid PEGs were
indistinguishable, suggesting that although the polymers differed in their degree of
substitution, their disorder and aperiodicity were sufficiently similar that they could be
reasonably substituted for higher molecular weight PEGs, such as amorphous PEG4000
in the PDF routine.
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A.3. Results and Discussion
A.3.1. API:PEG4000 library
15 separate API:PEG4000 binary solids (n=3) were made. Following quenching,
each sample was characterized using PXRD (with PDF-transformation, where
appropriate), HSM, and DSC in order to classify co-solidified mixtures as either fully
dispersed, partially dispersed or fully phase separated.

Inferences made using each

technique independent of the others are detailed below, followed by a summary that
considers collective inferences made using complementary characterization.

A.3.2. Inferences from PXRD data
Pure PEG4000 recrystallized rapidly on solidification, consistent with literature
reports for high molecular weight PEGs.251,

252, 270

PXRD patterns for PEG4000 were

collected for both untreated solid, and polymer subjected to the same melt-quench cycle
described for API:PEG4000 mixtures.

Both PEG4000 diffraction patterns were

superimposable, suggesting that polymer recrystallization following melt-quenching
resulted in the same solid as received from the vendor. PXRD patterns for API:PEG4000
mixtures were, therefore, easily separated based on characteristic PEG4000 diffraction
relative to peaks unique to the API.
PXRD data are summarized in Table A.2.

Of the 15 API solidified with

PEG4000, 10 mixtures showed evidence of some crystallinity.

In most cases,

characteristic peaks attributable to both drug and polymer were detectable, however,
tolbutamide:PEG4000 was unique in that it only diffracted at angles consistent with the
API,

but

not

the

polymer.

In

contrast,
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cloperastine·HCl:PEG4000,

itraconazole:PEG4000, and propranolol·HCl:PEG4000 solid mixtures all diffracted at
angles consistent with only the polymer.
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Table A.2. Summary of PXRD analyses. Cambridge Structural Database (CSD) reference codes for each API are indicated
parenthetically below the compound name.271, 272 CSD structures were used to identify diffraction peaks for crystalline API in
API:polymer mixtures.
API component
(CSD Reference code)
Chlorpropamide
(BEDMIG02)
Cimetidine (CIMETD)
Cloperastine HCl
(QAWNAD)

Diffraction attributable to
API (°2θ)
Minute peaks at 11.7, 19.5,
21.6
Not observed

Diffraction attributable to
PEG4000 (°2θ)

X-ray scattering attributable
to some amorphous content

Minute peaks at 15.0, 19.1

Yes

Not observed

Yes

Not observed

Minute peaks at 18.6, 22.7

Yes

Griseofulvin (GRISFL01)

Minute peaks at 10.8, 26.7

Minute peak at 23.9

Yes

Definite peaks at 22.7, 23.5

No

Not observed

Yes

PXRD
Inference
Partially
dispersed
Fully dispersed
Partially
dispersed
Partially
dispersed
Fully phase
separated
Fully dispersed
Partially
dispersed

Indomethacin (INDMET03)

Definite peaks at 6.1, 16.6,
17.7
Not observed

Itraconazole (TEHZIP)

Not observed

Definite peaks at 18.6, 22.7

Yes

Ketoconazole (KCONAZ)

Not observed

Not observed

Yes

Fully dispersed

Minute peak at 23.6

Yes

Partially
dispersed

Not observed

Yes

Minute peaks at 18.6, 22.7

Yes

Ibuprofen (IBPRAC01)
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Nifedipine (BICCIZ)

Minute peak at 10.6,
unidentified peaks* at 18.6,
25.4
Not observed

Propranolol HCl (FIDGAB)

Not observed

Melatonin (MELATN01)

Minute peaks at 8.0, 18.5,
Minute peaks at 19.1, 23.3
33.0
Minute peaks at 15.7, 19.7,
Sulfanilamide (SULAMD06)
Minute peaks at 22.7, 33.0
35.5
Terfenadine (XUHTID)
Not observed
Not observed
Minute peaks at 11.9, 19.1.
Tolbutamide Form I
Some peaks attributable to
Not observed
(ZZZPUS02)
Form II**
*Peaks not consistent with MELATN01 structure; may be metastable form
**Peaks consistent with ZZZPUS03 structure; metastable to Tolbutamide (Form I)
Quinidine (BOMDUC)

Yes
Barely
Yes
Yes

Fully dispersed
Partially
dispersed
Partially
dispersed
Partially
dispersed
Fully dispersed
Partially
dispersed

Recrystallization of both drug and polymer during solidification was easily
observed in all three ibuprofen:PEG4000 samples. Characteristic diffraction from both
drug and polymer were detected in co-solidified mixtures (Figure A.1a), and significant
X-ray scattering was not detectable in any of the diffraction patterns, suggesting absence
of amorphous drug.

Figure A.1. Overlay of PXRD patterns. (a) Pure ibuprofen (IBPRAC01) is indicated in
blue; co-solidified 3:1 w/w ibuprofen:PEG4000 is shown in black; pure PEG4000 is
shown in red. Select characteristic diffraction peaks attributable to API and polymer are
indicated as blue stars and red closed circles, respectively. (b) Pure cimetidine
(CIMETD) is indicated in blue; co-solidified 3:1 w/w cimetidine:PEG4000 is shown in
black; pure PEG4000 is shown in red. Characteristic diffraction from neither drug nor
polymer was observed, suggesting no crystalline content.
Taken in isolation, the PXRD data indicate that ibuprofen and PEG4000 were
completely phase separated, suggesting that ibuprofen did not form a stable dispersion
with PEG4000 under these conditions. Of the 15 API tested, ibuprofen was the only API
whose PXRD characterization demonstrated this phase behavior (Table A.2).
Each of the 6 solid mixtures (other than ibuprofen) whose PXRD patterns
contained at least some diffraction attributable to the API also contained evidence of
persistent amorphous content.

These samples were largely X-ray amorphous, with

diffuse scattering over all angles 2θ, which obscured all but the most intense Bragg
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diffraction peaks, detectable for both the API and polymer (Table A.2). As such, PXRD
could not determine whether the amorphous content was from the API, polymer, or both.
Since PEG4000 was expected to rapidly recrystallize in all samples, and the drug was
present in 3:1 w/w ratio, the inclination might have been to assume that only drug was
present as amorphous solid. This would be inconsistent with the semicrystalline nature of
PEG4000, which even when recrystallized, contributes minor diffuse scatter from the
amorphous regions of the polymer. More strikingly, however, were the PXRD patterns
for 5 of the mixtures (cimetidine, indomethacin, ketoconazole, nifedipine, and
terfenadine) all of which were completely X-ray amorphous following solidification
(Figure A.1b, Table A.2). This suggested that the high concentration of drug in these
preparations inhibited PEG4000 recrystallization, contrary to its expected behavior. As
such, it is likely that amorphous scattering observed in PXRD for other solids contained
contributions from both drug and polymer.

Had the PXRD data been interpreted

independent of the other characterization data, these 5 materials would have been
classified as fully dispersed, having solidified from fully miscible mixtures of API and
PEG4000. The remaining 9 materials would have been classified as partially dispersed in
PEG4000 (Table A.2), where the combination of API and polymer at this composition
allows some amorphous solid to persist at room temperature, following quenching.
Using PXRD data in this way ignores some important limitations of the
technique. X-ray scattering by most mixtures in these experiments suggested significant
amorphous content.

In highly amorphous samples, diffraction from very small

crystallites of API or polymer may not be detectable, potentially leading to the
assumption that samples contained no crystalline content. A study conducted by
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Rumondor et al., demonstrated a 1.9-2.2% limit of detection for crystalline felodipine in
a substantially amorphous

background that included poly(vinylpyrrolidone).273

Assuming no crystalline content in X-ray amorphous patterns might lead to incorrect
classification of systems such as cimetidine, indomethacin, ketoconazole, nifedipine, and
terfenadine, since the presence of even small quantities of crystalline API suggests only
partially dispersed samples at this composition. Mixtures solidified from PEG4000 and
chlorpropamide, cloperastine, griseofulvin, itraconazole, melatonin, propranolol·HCl,
quinidine, sulfanilamide and tolbutamide, were classified as partially dispersed, which
did not change when data from complementary techniques were ultimately considered,
however, the PXRD data alone were incapable of distinguishing whether persistent
amorphous phase was due to API, PEG4000, or both. Identifying this particular phase
behavior is important to suggest whether or not a different ratio of API and polymer
might result in a fully dispersed solid, which might be useful to a formulator attempting
to use PEG4000 as a carrier. Finally, scattering from a very small fraction of amorphous
content may be undetected in highly crystalline PXRD patterns. This could potentially
lead to an improper inference for systems such as ibuprofen:PEG4000, where the PXRD
data suggested complete recrystallization of the drug. Even if undetected persistent
amorphous ibuprofen was present, the results suggest insignificant ability to disperse it in
PEG4000.

A.3.3. Inferences from PDF-transformed PXRD data
Of the 15 API:PEG4000 combinations in this study, 5 mixtures, cimetidine,
indomethacin, ketoconazole, nifedipine, and terfenadine, resulted in completely X-ray
amorphous diffraction patterns, which, based on previous research involving analysis of
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PDF analysis17 were the only data suited to interpretation in this manner. Despite X-ray
amorphous PXRD patterns, PDF analysis was not done for ketoconazole:PEG4000,
owing to the inability to prepare a fully amorphous sample of pure ketoconazole for
theoretical PDF calculation. A summary of the PDF data for the remaining 4 solids is
shown in Table A.3.
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Table A.3. Summary of PDF analyses. R-values were minimized by artificially scaling API:polymer w/w concentrations
used to generate theoretical PDF.
R-valuea

Theoretical Drug
Concentration (%)

Theoretical PEG4000
Concentration (%)

Observed regions in r where
0 was not contained in the CI

PDF inference

Cimetidine:PEG4000

0.259 (0.022)

54 (1)

46 (1)

Yes

Fully dispersed

Terfenadine:PEG 4000

0.198 (0.007)

76 (2)

24 (2)

Yes

Fully dispersed

Indomethacin:PEG 4000

0.184 (0.039)

64 (3)

36 (3)

Yes

Fully dispersed

Nifedipine:PEG 4000

0.126 (0.010)

77 (2)

23 (2)

Yes

Fully dispersed
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Solid Mixtures

a

Reported values represent the average and standard deviation of three replicate preparations

PDF interpretation for cimetidine:PEG4000 suggests complete dispersion at this
composition, resulting from solidification of a completely miscible mixture of molten
drug and polymer.

In this case, the observed and calculated PDFs were not

superimposable (Figure A.2a), reflected in R=0.259, which was only minimized when
the theoretical PDF drug:polymer concentration weightings were artificially adjusted to
54% and 46% (w/w), respectively (Table A.3). Additionally, the difference plot (ΔG(r)
between predicted and observed data) for cimetidine:PEG4000 contained regions
in r where the confidence intervals did not contain zero (Figure A.2b). Taken together,
this suggests that the PDF-transformed data for solidified cimetidine:PEG4000 contained
new interatomic distances not explained by a physical mixture of the two amorphous
solids, supporting its complete dispersion in PEG4000. Similar interpretations of the PDF
patterns for indomethacin:PEG4000, nifedipine:PEG4000, and terfenadine:PEG4000
solids are also shown in Table A.3.

Figure A.2a and A.2b PDF analysis of 3:1 w/w co-solidified cimetidine:PEG4000
sample (as labeled).
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This particular characterization approach, while useful, is the most ambiguous
when interpreted without complementary techniques. Its inclusion in a characterization
routine can provide additional information for PXRD data, but should not be done in lieu
of other complementary techniques. To reinforce this, consider that the PXRD data
suggested that cimetidine, indomethacin, nifedipine, and terfenadine had all formed
completely amorphous binary dispersions, which was subsequently confirmed by the
PDF analyses. PDF interpretations suggested that each of these systems formed intimate
drug/polymer interactions unique to a dispersion.

This interpretation required

comparison between an observed and calculated PDF generated from PXRD data from
amorphous pure components. Since amorphous PEG4000 could not be prepared, PXRD
data from liquid PEG400 were used to generate the calculated PDF. It is easy to imagine
that differences between liquid PEG400 and solid amorphous PEG4000 at the scale of
drug/polymer interactions may be substantial enough that the unique separation distances
interpreted in the data were manifestations of the theoretical PDF and not indicative of
the actual dispersion. Ultimately, classifications of dispersion behavior made using the
other techniques are much more compelling, suggesting that PDF analysis is
inappropriate for PEG-based dispersions.

A.3.4. Inferences from HSM data
The use of polarized light microscopy in dispersion characterization is
widespread, where observed birefringence indicates the presence of crystallinity in a
sample.

This technique is analytically challenging when characterizing systems

comprised of a rapidly recrystallizing carrier polymer, such as PEG4000, as
differentiating between birefringence from the polymer and API is required.
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All samples were observed initially at room temperature, immediately following
preparation, and the photomicrographs for each API:PEG4000 mixture are shown in
Figure A.3. Observed birefringence was interpreted as recrystallization of either drug or
polymer during quenching. Samples were heated and cooled, as described above, while
observed using both polarized and un-polarized light to differentiate between crystalline
polymer and API.

Figure A.3. Initial room temperature polarized light microscopy images of co-solidified
3:1 w/w samples containing PEG4000 and (a) chlorpropamide (b) cimetidine (c)
cloperastine·HCl (d) griseofulvin (e) ibuprofen (f) indomethacin (g) itraconazole (h)
ketoconazole (i) melatonin (j) nifedipine (k) propranolol·HCl (l) quinidine (m)
sulfanilamide (n) terfenadine (o) tolbutamide. Image (p) represents only PEG4000 at
room temperature. All scale bars (in yellow) correspond to 50 µm.
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Extensive birefringence was observed throughout the ibuprofen:PEG4000
samples, from small crystallites not easily distinguished as either drug or polymer
(Figure A.3e). As the solid was heated, the polymer began melting at ~45oC, resulting in
disappearance of some of the birefringent crystallites, while the remainder persisted as
crystalline ibuprofen, which melted beginning at ~70oC. Interpretation of HSM data
alone indicated no detectable amorphous ibuprofen, suggesting complete phase
separation when quenched in the presence of PEG4000.
The photomicrographs for mixtures containing cimetidine, indomethacin, ketoconazole,
nifedipine, and terfenadine (all of which resulted in completely X-ray amorphous
diffraction patterns), showed that only cimetidine:PEG4000 resulted in a dispersion
having no birefringence when observed under polarized light. Moreover, this image
showed a single, homogeneous sample, resembling a solidified glass (Figure A.3b),
having no observed grains that might indicate trace phase separation.

When the

cimetidine:PEG4000 was heated to Tm,API +10oC, minor recrystallization of trace
cimetidine was observed at 80oC (in 1/3 preparations), which then melted at 160oC. In
the other 2 cimetidine:PEG4000 solids, neither recrystallization nor melting of either
polymer or drug was observed.

Taken alone, HSM suggests that cimetidine and

PEG4000 were fully dispersed, having solidified from a completely miscible molten
mixture at this composition.

Without the complementary techniques, however, the

question could certainly be raised whether or not the photomicrographs were
representative of the entire sample, as the experiments focused on a single area during
heating, making it possible to have missed subtle phase behavior outside the field of
view.

Here, the HSM inference for cimetidine:PEG4000 miscibility is made more
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compelling when complemented with the PXRD data, which involved complete sample
interrogation with X-rays.
Room temperature photomicrographs for the mixtures containing indomethacin,
ketoconazole, nifedipine, and terfenadine clearly showed small, birefringent grains,
representing a small fraction of the total sample, some of which melted at ~60oC
(identifying them as PEG4000).

The other grains melted at the respective Tm,API,

suggesting that a small amount of the drug had recrystallized during quenching of each
sample. These HSM data suggested that these 4 drugs were only partially dispersed with
PEG4000, but that extensive recrystallization did not occur during quenching. It is
important to note that this inference was potentially complicated by observed
recrystallization of API from molten PEG at ~80oC in each of these samples. Since
recrystallization began immediately following melting of the PEG4000, distinguishing
between persistent API grains and those formed during the experiment was difficult, and
could potentially vary from one field of view to another.

Nonetheless, at room

temperature most of the API and polymer was initially amorphous, and the solid that
recrystallized during quenching likely fell below the detection limit of PXRD. This
reinforces that classifying solids of indomethacin, ketoconazole, nifedipine, and
terfenadine with PEG4000 as fully dispersed, made using only PXRD data were
incorrect.

A.3.5. Inferences from DSC data
Of the various techniques employed in the characterization of solid dispersions,
DSC is among the most frequently used.274 Fully dispersed systems should, in theory,
result in thermograms containing a single Tg intermediate to the Tg of either pure
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component amorphous phase, predictably weighted according to relationships such as the
Couchman-Karasz Equation262 or the Gordon-Taylor Equation.275 Partially dispersed
mixtures characteristically show two distinct Tg values, plasticized or anti-plasticized
relative to their pure component values, and typically crystalline API formed during
solidification. While classifications of dispersion behavior can be straightforward for
some API:polymer combinations, PEG4000 proved to be much more complicated.
DSC data for API:PEG4000 mixtures are summarized in Table A.4.
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Table A.4. Summary of DSC analyses.
Solid Mixture

Pure
component
Tg (°C)

Chlorpropamide

15.39

-1.29

-4.97 (0.78)

Not observed

105.21ⱡ (3.21)

Fully dispersed

Cimetidine
Cloperastine
HCl

57.38

39.87

30.24 (2.54)

58.38; n=1

Not observed

Fully dispersed

41.47

11.05

-4.11 (0.07); n=2

50.76 (4.95)

144.40ⱡ (1.15)

Partially dispersed

ⱡ

Calculated
Tg (°C) from Eq 1

Observed Tga
(°C) (20°C/min)

Observed
PEG4000 Tma (°C)
(20°C/min)

Observed API
Tma (°C) (20°C/min)

DSC Inference
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Griseofulvin

98.68

67.75

30.65 (0.18)

Not observed

213.92 (3.53)

Ibuprofen

-35.35

-39.36

Not observed

44.86ᵼ (2.36)

69.95 (1.11)

Fully dispersed
Fully phase
separated

Indomethacin

54.14

34.66

1.00 (0.70)

Not observed

144.12ⱡ (1.17)

Fully dispersed

Itraconazole

66.17

45.35

-22.09; n=1

54.90ᵼ (3.82)

161.88ⱡ (0.47)

Fully dispersed

Ketoconazole

53.97

27.62

-52.28 (0.12); n=2
1.24; n=1

55.47 (1.03);
n=2

149.18ⱡ (0.31)

Partially dispersed

Melatonin

20.12

7.2

1.35 (0.34)

52.76 (1.30)

105.63ⱡ (0.67)

Partially dispersed

ⱡ

Nifedipine
Propranolol
HCl

53.35

30.83

-0.63 (5.96)

Not observed

151.06 (8.13)

Fully dispersed

43.45

24.15

11.79 (1.31)

Not observed

157.43ⱡ (0.52)

Fully dispersed

ⱡ

Quinidine

68.35

51.57

10.43 (8.75)

Not observed

166.40 (1.79)

Fully dispersed

Sulfanilamide

N/A*

N/A*

-0.74 (0.9); n=2

56.00 (0.98)

153.97 (4.27)

Partially dispersed

Terfenadine

69.05

39.65

-30.79 (3.72); n=2
Two Tg's: 7.95 &
61.32*** (n=1)

TC,API = 86.14
(1.35)** n=2

140.15ⱡ (0.59)

Partially dispersed

Tolbutamide

13.16

-4.10

Not observed

42.21 (0.62)

113.91 (0.57)

Fully phase
separated

aReported

values represent the average and standard deviation of three replicate preparations unless otherwise mentioned

*Sulfanilamide pure component Tg unable to be determined by DSC; rapid recrystallization during in situ quench
ᵼT
ⱡT
m,PEG4000 preceded by PEG4000 recrystallization
m,API preceded by API recrystallization
**API recrystallization over expected Tm,PEG range. PEG melting confirmed in Hot Stage Microscopy
***Two Tg's, one attributable to PEG4000 and the other to API

Classification of ibuprofen:PEG4000 was very straightforward using PXRD and
HSM. This continued with DSC, although the data suggested potential eutectic behavior
between this drug and polymer with complete recrystallization upon cooling the
preparation (Figure A.4).

Figure A.4. Overlay of DSC thermograms. Pure ibuprofen is indicated in blue, cosolidified 3:1 w/w ibuprofen:PEG4000 is shown in black; pure PEG4000 is shown in red.
No Tg was observed; only melt endotherms consistent with Tm,p and Tm,API.
This interpretation is supported by observations made by Law et al..255 No Tg was
observed in these thermograms, however, distinct melting endotherms, having onsets at
44.86oC and 69.95oC were observed, corresponding with slightly depressed values for the
respective Tm for PEG4000 and ibuprofen.

Neither Tm were preceded by

recrystallization, suggesting that both drug and polymer fully crystallized during
quenching. Taken alone, the DSC data suggest that ibuprofen and PEG4000 completely
phase separated during solidification.

A similar inference could be made for
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tolbutamide:PEG4000. No Tg was observed for these solids, suggesting no amorphous
content (Table A.4).

Melting of the PEG4000 was clearly observed for

tolbutamide:PEG4000, which was not preceded by recrystallization, suggesting that the
polymer had recrystallized during solidification. Following Tm,p however, the baseline in
these thermograms did not re-establish, prior to the signal that was clearly interpreted as
melting of the tolbutamide. In this case, the signals suggested that the API crystallized
during solidification, and then dissolved/recrystallized in the molten PEG as the
temperature

was

increased.

The

Tg

region

of

the

DSC

thermogram

for

cimetidine:PEG4000 is shown in Figure A.5, relative to pure component thermograms
obtained, respectively from melt/quenched samples of cimetidine and PEG4000.

Figure A.5. Overlay of Tg regions in DSC thermograms from top to bottom: Pure
cimetidine (in blue), co-solidified 3:1 w/w cimetidine:PEG4000 (in black) and pure
PEG4000 (in red). A single Tg was measured for the mixture, which fell intermediate to
Tg,p and Tg,API.
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A single Tg was observed at 30.24oC for cimetidine:PEG4000, which was
comparable with the theoretical Tg of the mixture (39.87oC) predicted by Equation A.1
(Table A.4). In 1/3 replicates for cimetidine:PEG4000, a small endotherm at 58.38oC
was observed, corresponding to Tm,p. None of the 3 cimetidine:PEG4000 replicates
showed evidence of API recrystallization/melting during the temperature ramp. These
data suggest that 1/3 cimetidine:PEG4000 solid mixtures had slight recrystallization of
the polymer, although all three allowed persistence of amorphous cimetidine.
Independent of the other techniques, the DSC data strongly suggest that a fully dispersed
binary amorphous solid can form by solidification of a fully miscible 3:1 mixture of
cimetidine and PEG4000. These data potentially illustrate a limitation to characterizing
dispersions using only DSC. Given the limited sample size used in these experiments,
sub-sampling from the co-solidified mixtures was unavoidable. It could be argued that
DSC might miss recrystallized drug or polymer, if the “chips” taken from the overall
glass were selected from a persistent homogeneous region, rather than a phase separated
region. This reinforces the necessity of complementary techniques having greater (if not
complete) sample interrogation for confirmation that sub-sampling doesn’t bias the
inferences made from DSC alone.
Table A.4 also illustrates the complexity of the DSC data used to characterize
solid mixtures with PEG4000, the behavior of which clustered into four generalized
groups. In DSC patterns for itraconazole:PEG4000, a distinct Tg was not observed,
however, the predicted Tg value was expected commensurate with PEG recrystallization
and melting.. As samples were heated, distinct crystallization/melting of the PEG4000,
followed by distinct crystallization/melting of the itraconazole was clearly observed. This
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suggested that solidification resulted in at least some dispersed amorphous itraconazole
and polymer. In particular, the enthalpies of recrystallization/melting for the drug were
comparable, suggesting that the drug was predominantly amorphous following
quenching. Considered in isolation, the DSC data for itraconazole:PEG4000 appear to be
consistent with a fully dispersed drug in polymer, however, ambiguity remains as to
whether the entire API content was amorphous.
In

the

second

ketoconazole:PEG4000,

grouping

of

thermal

melatonin:PEG4000,

and

data,

cloperastine:PEG4000,

sulfaniliamide:PEG4000,

were

observed to have a single Tg indicating persistent amorphous content of the quenched
solids. Clear endotherms unambiguously attributable to PEG4000 melting were also
observed for each of these solids, none of which were preceded by clear recrystallization,
suggesting that the polymer recrystallized during solidification.

Following Tm,p,

recrystallization/melting of the API occurred for each solid, likely because the molten
PEG allowed for increased mobility of the API molecules, enabling their crystallization
during the temperature ramp. The presence of crystalline API following solidification
was more difficult to interpret from the DSC data alone.

Ketoconazole:PEG4000

thermograms had only a single Tg observed per solid, however, these occurred at
inconsistent values from sample to sample (Table A.4). Ultimately, they were all skewed
towards the Tg,p, suggesting that ketoconazole was partially dispersed in PEG4000,
resulting in anti-plasticization of Tg,p. Additionally, in the melatonin:PEG4000 mixtures,
the recrystallization exotherm for the API integrated to a much lower enthalpy relative to
the respective melt endotherm, potentially suggesting some crystallization of API during
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co-solidification. Taken together, these APIs were classified as partially dispersed in
PEG4000.
In the third grouping, solid mixtures that included chlorpropamide, indomethacin,
nifedipine, propranolol·HCl, griseofulvin, and quinidine, were observed to have a single
Tg. As the temperature was increased for these solids, neither crystallization nor melting
of the PEG4000 was observed, suggesting that the polymer remained amorphous during
solidification, and was inhibited from recrystallization by the very high drug
concentration present. Each thermogram also had a distinct recrystallization exotherm
prior to the respective melting endotherms for the API. This suggested that these drugs
solidified as amorphous solids and only recrystallized as a consequence of heating in the
DSC experiments.

It should be noted that the API recrystallization observed for

chlorpropamide:PEG4000 overlapped with the region where Tm,p would normally be
observed. Since the DSC signal reports net heat flow, it is entirely possible that melting
of polymer that recrystallized during solidification was obscured by the recrystallization
of the chlorpropamide. Using only the DSC data, all of the API in this grouping were,
therefore, classified as fully dispersed in PEG4000, having no clear evidence of
recrystallization during quenching. In the case of chlorpropamide, the ambiguity
associated with the overlap exothermic/endothermic signals could easily result in a
misclassification of drug:polymer dispersion behavior, highlighting a limitation of DSC
interpretation in systems such as these.
Finally, using only the DSC data, terfenedine:PEG4000 was classified as only
partially dispersed. These thermograms showed two Tg events at 7.95oC and 61.32oC in
1/3 of the solids, and a single Tg (average value of -30.79oC) in the other two replicate
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solids (Figure A.6). Although PEG4000 melting was not observed in these samples, the
recrystallization of the API overlapped with the temperature range where PEG melting
was expected, potentially obscuring that signal.

Figure A.6. Overlay of Tg regions in DSC thermograms from top to bottom: Pure
terfenadine (in blue), co-solidified 3:1 w/w terfenadine:PEG4000 (in black) and pure
PEG4000 (in red). Panel a) a single Tg was measured for the mixture (-28.16oC in this
replicate; mean -30.79oC; n=2), which fell intermediate to Tg,p and Tg,API. Panel b) two Tg
values were measured (7.96oC and 61.32oC) indicating plasticization and
antiplasticization, respectively for Tg,API and Tg,p.

A.3.6. Combined inferences from physicochemical characterization suite
A summary of the classifications of dispersion behavior based on each technique in
isolation is found in Table A.5, and compared with classifications made by collectively
considering all of the characterization data. Of the 15 API:PEG4000 combinations, only
6 resulted in samples whose dispersion behavior was consistently categorized using each
of the four methods.

That said, owing to limitations described for each individual

technique, inferences in isolation of the other techniques were not made with the same
confidence relative to those made using all of the pooled data.
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Table A.5. Summary of inferences from individual techniques compared with inferences
made by collective consideration of all techniques (Combined Inference).
Solid Mixture

PXRD

PDF

HSM

DSC

Chlorpropamide

Partially
dispersed

N/A

Partially
dispersed

Fully dispersed

Cimetidine

Fully dispersed

Fully dispersed

Fully dispersed

Fully dispersed

Fully dispersed

Cloperastine·HCl

Partially
dispersed

N/A

Partially
dispersed

Partially
dispersed

Partially
dispersed

Griseofulvin

Partially
dispersed
Fully phase
separated

N/A

Partially
dispersed
Fully phase
separated

Fully dispersed

Partially
dispersed
Fully phase
separated

Indomethacin

Fully dispersed

Fully dispersed

Fully dispersed

Itraconazole

Partially
dispersed
Fully dispersed

N/A

Partially
dispersed
Partially
dispersed
Partially
dispersed

Partially
dispersed

Partially
dispersed
Partially
dispersed
Partially
dispersed

Melatonin

Partially
dispersed

N/A

Partially
dispersed

Partially
dispersed

Partially
dispersed

Nifedipine

Fully dispersed

Fully dispersed

Fully dispersed

Propranolol·HCl

Partially
dispersed
Partially
dispersed
Partially
dispersed

N/A

Partially
dispersed
Partially
dispersed
Partially
dispersed
Partially
dispersed

Partially
dispersed

Partially
dispersed
Partially
dispersed
Partially
dispersed
Partially
dispersed

Terfenadine

Fully dispersed

Fully dispersed

Partially
dispersed

Partially
dispersed

Partially
dispersed

Tolbutamide

Partially
dispersed

N/A

Partially
dispersed

Fully phase
separated

Partially
dispersed

Ibuprofen

Ketoconazole

Quinidine
Sulfanilamide

N/A

N/A

N/A
N/A
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Fully phase
separated

Fully dispersed

Fully dispersed
Fully dispersed

Combined
Inference
Partially
dispersed

Consider the case of cimetidine, which was classified as fully dispersed in
PEG4000 at this composition. The PXRD data suggested a completely amorphous solid
(Table A.2), while the PDF analysis suggested that the amorphous phases were
intimately dispersed, allowing for interatomic distances unique to a dispersion (Figure
A.2). These data were made considerably more compelling, however, by the absence of
detectable crystallinity by polarized light microscopy (Figure A.3b), and the presence of
a single Tg value comparable to the theoretical Tg and the absence of crystallinity having
resulted from solidification cimetidine and PEG4000 (Table A.4, Figure A.5).
Similarly, ibuprofen:PEG4000 was unambiguously classified fully phase separated based
on complete recrystallization prior to analysis. The PXRD data confirmed that the
ibuprofen was entirely crystalline (Figure A.1). The absence of a Tg in the DSC data
(Figure A.5), and no observation of any recrystallization in both DSC and HSM further
reinforced that no amorphous material was present in any of these samples.
The necessity of using complementary characterization techniques on quenched
API:PEG400 mixtures was best illustrated with samples for which inferences based on a
single technique were inconsistent (Table A.5).

For example, the PXRD data for

nifedipine:PEG4000 suggested a completely amorphous solid (Table A.2), supported by
PDF analysis, which suggested intimate dispersion of amorphous drug and polymer to
form a single phase (Table A.3). The DSC data appeared to also support formation of a
fully dispersed solid, evidenced by a single Tg, and no detectable crystallinity from either
component, formed during co-solidification (Table A.4). Had the microscopy not been
performed, these three analyses would have suggested that nifedipine was fully dispersed
in PEG4000 at this composition. As shown in Figure A.3j, however, tiny, birefringent
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crystalline grains were visible in the polarized light photomicrograph, which comprised a
small fraction of the overall sample.

This indicated some recrystallization during

solidification. Furthermore, the HSM routine showed that some of these crystallites did
not melt until Tm,API, clearly indicating that the nifedipine had recrystallized to some
extent. Although this classified the 3:1 solid as partially dispersed, the presence of
substantial, persistent amorphous phase suggests that at a lower drug loading a fully
dispersed solid may be possible.
Also of note in Table A.5 is the fact that all of the classifications made
exclusively using HSM are identical to the final inferences from collective consideration
of the data. This could appear to suggest that HSM was superior to the other methods,
and potentially the only technique needed to characterize API:PEG4000 solid mixtures.
Indeed, polarized light microscopy appears to be able to visualize sample crystallinity too
small to be observed in either the PXRD or DSC signals. Like DSC, however, samples
subjected to microscopy were limited by the necessity of sub-sampling. Not only are
“chips” taken from larger, co-solidified samples for visualization, the field of view at any
given time is only a fraction of the chip.

While the presence of crystallinity is

unambiguous, and the identity of the crystals (API or PEG) can be determined from the
observations through the heating cycle, the absence of crystallinity in a microscopy
experiment likely needs to be confirmed in many samples to confidently assume that the
entire sample contains no crystals.
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A.4. Conclusion
A library of 15 API was co-solidified with PEG4000. Characterization of the
resulting solids was done using PXRD, PDF analysis, DSC and HSM, and API were
classified as either fully dispersed, partially dispersed or fully phase separated in the
polymer at a 3:1 weight ratio. The dispersion behavior of only 6/15 of the mixtures was
consistently classified using data from each of the techniques independent of the others,
reflecting the limits of each method in individually characterizing potential dispersions
involving PEG as a carrier. PXRD was limited by the ability to detect diffraction from
very small crystallites in an almost entirely amorphous sample.

HSM was able to

confirm the presence of crystalline API in 4/5 X-ray amorphous patterns, more correctly
identifying those API as partially dispersed in PEG4000. The significant amorphous
content interpreted from PXRD data complemented by the limited crystallinity observed
using HSM suggested that indomethacin, ketoconazole, nifedipine, and terfenedine may
be fully dispersable in PEG4000 at a lower concentration. DSC in isolation was limited
by potentially overlapping signals from the API and PEG, which made it difficult to
distinguish crystallinity formed during solidification vs. recrystallization that occurs
exclusively because of the temperature program imposed on the samples by the
experiment. Again, HSM was able to confirm the presence of initial drug and polymer
crystallites that formed during solidification of the molten mixtures, as well as distinguish
events that occurred at experimental temperatures.

Overall, the complexity of

drug/polymer dispersion behavior, especially in mixtures involving PEG4000, combined
with data subtleties that likely need to be interpreted to distinguish between partially and

173

fully dispersed mixtures, reinforces the need to use complementary techniques in order to
ensure thorough characterization.
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